date generated: 2022-05-10
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## x
## 5_8S_rRNA 12.9204273
## 7SK 1.4582210
## A1BG 2.1192797
## A1BG-AS1 6.5771976
## A1CF -0.2475616
## A2M -10.7739590
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 2512 |
num_genes_in_profile | 26741 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 9101 |
num_profile_genes_not_in_sets | 17640 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Gene sets metrics | |
---|---|
num_genesets | 2512 |
num_genesets_excluded | 1029 |
num_genesets_included | 1483 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
CLEC7A (Dectin-1) induces NFAT activation | 11 | 1.73e-06 | -0.833 | 8.11e-06 |
Establishment of Sister Chromatid Cohesion | 11 | 2.26e-06 | -0.823 | 1.02e-05 |
Cohesin Loading onto Chromatin | 10 | 7.27e-06 | -0.819 | 2.94e-05 |
ERKs are inactivated | 13 | 4.28e-07 | -0.810 | 2.27e-06 |
S33 mutants of beta-catenin aren’t phosphorylated | 15 | 5.89e-08 | -0.808 | 3.91e-07 |
S37 mutants of beta-catenin aren’t phosphorylated | 15 | 5.89e-08 | -0.808 | 3.91e-07 |
S45 mutants of beta-catenin aren’t phosphorylated | 15 | 5.89e-08 | -0.808 | 3.91e-07 |
Signaling by CTNNB1 phospho-site mutants | 15 | 5.89e-08 | -0.808 | 3.91e-07 |
Signaling by GSK3beta mutants | 15 | 5.89e-08 | -0.808 | 3.91e-07 |
T41 mutants of beta-catenin aren’t phosphorylated | 15 | 5.89e-08 | -0.808 | 3.91e-07 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 1.76e-07 | -0.806 | 1.07e-06 |
APC truncation mutants have impaired AXIN binding | 14 | 2.29e-07 | -0.798 | 1.33e-06 |
AXIN missense mutants destabilize the destruction complex | 14 | 2.29e-07 | -0.798 | 1.33e-06 |
Signaling by AMER1 mutants | 14 | 2.29e-07 | -0.798 | 1.33e-06 |
Signaling by APC mutants | 14 | 2.29e-07 | -0.798 | 1.33e-06 |
Signaling by AXIN mutants | 14 | 2.29e-07 | -0.798 | 1.33e-06 |
Truncations of AMER1 destabilize the destruction complex | 14 | 2.29e-07 | -0.798 | 1.33e-06 |
Signaling by Hippo | 20 | 7.94e-10 | -0.794 | 7.32e-09 |
MET activates RAP1 and RAC1 | 11 | 5.41e-06 | -0.792 | 2.27e-05 |
MAPK3 (ERK1) activation | 10 | 2.78e-05 | -0.765 | 1.00e-04 |
RAF-independent MAPK1/3 activation | 23 | 2.16e-10 | -0.764 | 2.17e-09 |
Interleukin-6 signaling | 11 | 1.18e-05 | -0.763 | 4.54e-05 |
Beta-catenin phosphorylation cascade | 17 | 5.52e-08 | -0.761 | 3.83e-07 |
Mitotic Telophase/Cytokinesis | 13 | 2.05e-06 | -0.760 | 9.40e-06 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 5.85e-11 | -0.756 | 6.52e-10 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 7.20e-06 | -0.719 | 2.92e-05 |
Defective EXT2 causes exostoses 2 | 13 | 7.20e-06 | -0.719 | 2.92e-05 |
Synthesis of PIPs at the early endosome membrane | 16 | 1.38e-06 | -0.697 | 6.58e-06 |
Signaling by PDGFRA extracellular domain mutants | 12 | 3.55e-05 | -0.689 | 1.24e-04 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 3.55e-05 | -0.689 | 1.24e-04 |
Activation of RAC1 | 13 | 1.72e-05 | -0.688 | 6.43e-05 |
Synthesis of PIPs at the late endosome membrane | 11 | 8.35e-05 | -0.685 | 2.69e-04 |
Signal transduction by L1 | 21 | 5.62e-08 | -0.684 | 3.86e-07 |
ALK mutants bind TKIs | 12 | 4.26e-05 | -0.682 | 1.46e-04 |
FOXO-mediated transcription of cell cycle genes | 16 | 5.18e-06 | -0.658 | 2.18e-05 |
Syndecan interactions | 20 | 5.15e-07 | -0.648 | 2.70e-06 |
Prolonged ERK activation events | 14 | 2.87e-05 | -0.646 | 1.03e-04 |
CTLA4 inhibitory signaling | 17 | 4.47e-06 | -0.643 | 1.92e-05 |
Gastrin-CREB signalling pathway via PKC and MAPK | 17 | 4.75e-06 | -0.641 | 2.02e-05 |
Cell-extracellular matrix interactions | 16 | 9.64e-06 | -0.639 | 3.82e-05 |
Regulation of gene expression by Hypoxia-inducible Factor | 11 | 2.44e-04 | -0.639 | 7.14e-04 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 3.95e-16 | -0.634 | 9.46e-15 |
Signaling by WNT in cancer | 32 | 5.49e-10 | -0.633 | 5.19e-09 |
Processing and activation of SUMO | 10 | 5.34e-04 | -0.632 | 1.43e-03 |
ERK/MAPK targets | 22 | 2.85e-07 | -0.632 | 1.59e-06 |
Frs2-mediated activation | 12 | 1.60e-04 | -0.629 | 4.86e-04 |
STAT5 activation downstream of FLT3 ITD mutants | 10 | 5.78e-04 | -0.628 | 1.53e-03 |
Signaling by PDGFR in disease | 20 | 1.17e-06 | -0.628 | 5.65e-06 |
Citric acid cycle (TCA cycle) | 22 | 3.63e-07 | -0.626 | 1.96e-06 |
Signaling by Activin | 15 | 2.67e-05 | -0.626 | 9.65e-05 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
CLEC7A (Dectin-1) induces NFAT activation | 11 | 1.73e-06 | -0.833000 | 8.11e-06 |
Establishment of Sister Chromatid Cohesion | 11 | 2.26e-06 | -0.823000 | 1.02e-05 |
Cohesin Loading onto Chromatin | 10 | 7.27e-06 | -0.819000 | 2.94e-05 |
ERKs are inactivated | 13 | 4.28e-07 | -0.810000 | 2.27e-06 |
S33 mutants of beta-catenin aren’t phosphorylated | 15 | 5.89e-08 | -0.808000 | 3.91e-07 |
S37 mutants of beta-catenin aren’t phosphorylated | 15 | 5.89e-08 | -0.808000 | 3.91e-07 |
S45 mutants of beta-catenin aren’t phosphorylated | 15 | 5.89e-08 | -0.808000 | 3.91e-07 |
Signaling by CTNNB1 phospho-site mutants | 15 | 5.89e-08 | -0.808000 | 3.91e-07 |
Signaling by GSK3beta mutants | 15 | 5.89e-08 | -0.808000 | 3.91e-07 |
T41 mutants of beta-catenin aren’t phosphorylated | 15 | 5.89e-08 | -0.808000 | 3.91e-07 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 1.76e-07 | -0.806000 | 1.07e-06 |
APC truncation mutants have impaired AXIN binding | 14 | 2.29e-07 | -0.798000 | 1.33e-06 |
AXIN missense mutants destabilize the destruction complex | 14 | 2.29e-07 | -0.798000 | 1.33e-06 |
Signaling by AMER1 mutants | 14 | 2.29e-07 | -0.798000 | 1.33e-06 |
Signaling by APC mutants | 14 | 2.29e-07 | -0.798000 | 1.33e-06 |
Signaling by AXIN mutants | 14 | 2.29e-07 | -0.798000 | 1.33e-06 |
Truncations of AMER1 destabilize the destruction complex | 14 | 2.29e-07 | -0.798000 | 1.33e-06 |
Signaling by Hippo | 20 | 7.94e-10 | -0.794000 | 7.32e-09 |
MET activates RAP1 and RAC1 | 11 | 5.41e-06 | -0.792000 | 2.27e-05 |
MAPK3 (ERK1) activation | 10 | 2.78e-05 | -0.765000 | 1.00e-04 |
RAF-independent MAPK1/3 activation | 23 | 2.16e-10 | -0.764000 | 2.17e-09 |
Interleukin-6 signaling | 11 | 1.18e-05 | -0.763000 | 4.54e-05 |
Beta-catenin phosphorylation cascade | 17 | 5.52e-08 | -0.761000 | 3.83e-07 |
Mitotic Telophase/Cytokinesis | 13 | 2.05e-06 | -0.760000 | 9.40e-06 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 5.85e-11 | -0.756000 | 6.52e-10 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 7.20e-06 | -0.719000 | 2.92e-05 |
Defective EXT2 causes exostoses 2 | 13 | 7.20e-06 | -0.719000 | 2.92e-05 |
Synthesis of PIPs at the early endosome membrane | 16 | 1.38e-06 | -0.697000 | 6.58e-06 |
Signaling by PDGFRA extracellular domain mutants | 12 | 3.55e-05 | -0.689000 | 1.24e-04 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 3.55e-05 | -0.689000 | 1.24e-04 |
Activation of RAC1 | 13 | 1.72e-05 | -0.688000 | 6.43e-05 |
Synthesis of PIPs at the late endosome membrane | 11 | 8.35e-05 | -0.685000 | 2.69e-04 |
Signal transduction by L1 | 21 | 5.62e-08 | -0.684000 | 3.86e-07 |
ALK mutants bind TKIs | 12 | 4.26e-05 | -0.682000 | 1.46e-04 |
FOXO-mediated transcription of cell cycle genes | 16 | 5.18e-06 | -0.658000 | 2.18e-05 |
Syndecan interactions | 20 | 5.15e-07 | -0.648000 | 2.70e-06 |
Prolonged ERK activation events | 14 | 2.87e-05 | -0.646000 | 1.03e-04 |
CTLA4 inhibitory signaling | 17 | 4.47e-06 | -0.643000 | 1.92e-05 |
Gastrin-CREB signalling pathway via PKC and MAPK | 17 | 4.75e-06 | -0.641000 | 2.02e-05 |
Cell-extracellular matrix interactions | 16 | 9.64e-06 | -0.639000 | 3.82e-05 |
Regulation of gene expression by Hypoxia-inducible Factor | 11 | 2.44e-04 | -0.639000 | 7.14e-04 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 3.95e-16 | -0.634000 | 9.46e-15 |
Signaling by WNT in cancer | 32 | 5.49e-10 | -0.633000 | 5.19e-09 |
Processing and activation of SUMO | 10 | 5.34e-04 | -0.632000 | 1.43e-03 |
ERK/MAPK targets | 22 | 2.85e-07 | -0.632000 | 1.59e-06 |
Frs2-mediated activation | 12 | 1.60e-04 | -0.629000 | 4.86e-04 |
STAT5 activation downstream of FLT3 ITD mutants | 10 | 5.78e-04 | -0.628000 | 1.53e-03 |
Signaling by PDGFR in disease | 20 | 1.17e-06 | -0.628000 | 5.65e-06 |
Citric acid cycle (TCA cycle) | 22 | 3.63e-07 | -0.626000 | 1.96e-06 |
Signaling by Activin | 15 | 2.67e-05 | -0.626000 | 9.65e-05 |
Signaling by FGFR3 fusions in cancer | 10 | 6.17e-04 | -0.625000 | 1.62e-03 |
Postmitotic nuclear pore complex (NPC) reformation | 27 | 2.73e-08 | -0.618000 | 1.96e-07 |
tRNA processing in the mitochondrion | 20 | 1.84e-06 | 0.616000 | 8.56e-06 |
Adenylate cyclase inhibitory pathway | 12 | 2.21e-04 | -0.616000 | 6.52e-04 |
RHO GTPases Activate WASPs and WAVEs | 36 | 1.67e-10 | -0.615000 | 1.73e-09 |
Uptake and function of anthrax toxins | 11 | 4.20e-04 | -0.614000 | 1.17e-03 |
Ephrin signaling | 19 | 3.78e-06 | -0.612000 | 1.65e-05 |
Spry regulation of FGF signaling | 16 | 2.23e-05 | -0.612000 | 8.18e-05 |
Deadenylation of mRNA | 22 | 7.75e-07 | -0.608000 | 3.92e-06 |
Platelet sensitization by LDL | 16 | 2.53e-05 | -0.608000 | 9.21e-05 |
GAB1 signalosome | 17 | 1.42e-05 | -0.608000 | 5.42e-05 |
Signaling by KIT in disease | 19 | 4.46e-06 | -0.608000 | 1.92e-05 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 19 | 4.46e-06 | -0.608000 | 1.92e-05 |
ER Quality Control Compartment (ERQC) | 21 | 1.53e-06 | -0.606000 | 7.20e-06 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 37 | 1.91e-10 | -0.605000 | 1.96e-09 |
HS-GAG biosynthesis | 28 | 3.40e-08 | -0.602000 | 2.42e-07 |
Endosomal/Vacuolar pathway | 12 | 3.46e-04 | -0.596000 | 9.82e-04 |
Calnexin/calreticulin cycle | 26 | 1.40e-07 | -0.596000 | 8.75e-07 |
Recycling pathway of L1 | 27 | 9.07e-08 | -0.594000 | 5.87e-07 |
DCC mediated attractive signaling | 14 | 1.26e-04 | -0.592000 | 3.89e-04 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 1.72e-09 | -0.588000 | 1.43e-08 |
RHOF GTPase cycle | 42 | 4.42e-11 | -0.587000 | 5.16e-10 |
Activation of BAD and translocation to mitochondria | 15 | 8.33e-05 | -0.587000 | 2.69e-04 |
Signaling by FLT3 ITD and TKD mutants | 16 | 4.90e-05 | -0.586000 | 1.65e-04 |
CD209 (DC-SIGN) signaling | 19 | 9.95e-06 | -0.585000 | 3.92e-05 |
RORA activates gene expression | 18 | 1.76e-05 | -0.584000 | 6.56e-05 |
CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 1.47e-03 | -0.581000 | 3.50e-03 |
Cholesterol biosynthesis | 24 | 9.00e-07 | -0.579000 | 4.45e-06 |
Activation of gene expression by SREBF (SREBP) | 42 | 9.33e-11 | -0.577000 | 1.00e-09 |
Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 11 | 9.79e-04 | -0.574000 | 2.46e-03 |
COPI-independent Golgi-to-ER retrograde traffic | 33 | 1.20e-08 | -0.573000 | 8.82e-08 |
Nephrin family interactions | 21 | 6.02e-06 | -0.570000 | 2.51e-05 |
HDMs demethylate histones | 23 | 2.21e-06 | -0.570000 | 1.00e-05 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 29 | 1.13e-07 | -0.569000 | 7.18e-07 |
PKA-mediated phosphorylation of CREB | 18 | 3.50e-05 | -0.563000 | 1.24e-04 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 50 | 5.58e-12 | -0.563000 | 7.52e-11 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 17 | 6.36e-05 | -0.560000 | 2.08e-04 |
Downstream signal transduction | 29 | 1.83e-07 | -0.559000 | 1.10e-06 |
Depolymerisation of the Nuclear Lamina | 15 | 1.80e-04 | -0.558000 | 5.46e-04 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 12 | 8.25e-04 | -0.557000 | 2.11e-03 |
STAT3 nuclear events downstream of ALK signaling | 10 | 2.27e-03 | -0.557000 | 5.05e-03 |
Regulation of signaling by CBL | 18 | 4.35e-05 | -0.556000 | 1.49e-04 |
PKA activation | 16 | 1.23e-04 | -0.554000 | 3.83e-04 |
MECP2 regulates neuronal receptors and channels | 17 | 7.66e-05 | -0.554000 | 2.48e-04 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 25 | 1.95e-06 | -0.550000 | 8.99e-06 |
GRB2:SOS provides linkage to MAPK signaling for Integrins | 13 | 6.07e-04 | -0.549000 | 1.60e-03 |
Signaling by TGF-beta Receptor Complex | 74 | 3.43e-16 | -0.548000 | 8.35e-15 |
IRAK2 mediated activation of TAK1 complex | 10 | 2.72e-03 | -0.547000 | 5.91e-03 |
RHO GTPases activate KTN1 | 11 | 1.66e-03 | -0.547000 | 3.90e-03 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 24 | 3.43e-06 | -0.547000 | 1.51e-05 |
TGF-beta receptor signaling activates SMADs | 32 | 8.37e-08 | -0.547000 | 5.47e-07 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 2.54e-07 | -0.544000 | 1.44e-06 |
Miscellaneous transport and binding events | 23 | 6.84e-06 | -0.542000 | 2.81e-05 |
Interleukin-27 signaling | 10 | 3.02e-03 | -0.542000 | 6.49e-03 |
FCGR3A-mediated phagocytosis | 57 | 1.50e-12 | -0.541000 | 2.12e-11 |
Leishmania phagocytosis | 57 | 1.50e-12 | -0.541000 | 2.12e-11 |
Parasite infection | 57 | 1.50e-12 | -0.541000 | 2.12e-11 |
Defective B4GALT7 causes EDS, progeroid type | 19 | 4.50e-05 | -0.541000 | 1.54e-04 |
Synthesis of PIPs at the Golgi membrane | 16 | 1.81e-04 | -0.540000 | 5.48e-04 |
Negative regulation of MET activity | 21 | 1.85e-05 | -0.540000 | 6.89e-05 |
Attenuation phase | 23 | 7.45e-06 | -0.540000 | 2.99e-05 |
Role of LAT2/NTAL/LAB on calcium mobilization | 13 | 7.63e-04 | -0.539000 | 1.96e-03 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 18 | 7.58e-05 | -0.539000 | 2.46e-04 |
Signal regulatory protein family interactions | 11 | 1.99e-03 | -0.538000 | 4.47e-03 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 1.97e-04 | -0.537000 | 5.89e-04 |
VEGFR2 mediated cell proliferation | 19 | 4.98e-05 | -0.537000 | 1.67e-04 |
COPI-mediated anterograde transport | 79 | 1.41e-16 | -0.537000 | 3.68e-15 |
Insulin processing | 25 | 3.98e-06 | -0.533000 | 1.72e-05 |
EPHA-mediated growth cone collapse | 15 | 3.55e-04 | -0.533000 | 1.00e-03 |
Cargo concentration in the ER | 31 | 2.90e-07 | -0.532000 | 1.61e-06 |
IRE1alpha activates chaperones | 50 | 7.93e-11 | -0.531000 | 8.78e-10 |
Golgi Associated Vesicle Biogenesis | 55 | 9.55e-12 | -0.531000 | 1.28e-10 |
Interleukin-15 signaling | 14 | 6.01e-04 | -0.530000 | 1.59e-03 |
SUMOylation of SUMOylation proteins | 35 | 5.87e-08 | -0.529000 | 3.91e-07 |
Downregulation of TGF-beta receptor signaling | 26 | 2.96e-06 | -0.529000 | 1.31e-05 |
Signaling by ALK fusions and activated point mutants | 55 | 1.15e-11 | -0.529000 | 1.49e-10 |
Signaling by ALK in cancer | 55 | 1.15e-11 | -0.529000 | 1.49e-10 |
Non-integrin membrane-ECM interactions | 42 | 3.14e-09 | -0.528000 | 2.53e-08 |
Transport of Ribonucleoproteins into the Host Nucleus | 32 | 2.53e-07 | -0.526000 | 1.44e-06 |
MET promotes cell motility | 29 | 9.43e-07 | -0.526000 | 4.64e-06 |
p130Cas linkage to MAPK signaling for integrins | 13 | 1.03e-03 | -0.526000 | 2.56e-03 |
RHOV GTPase cycle | 37 | 3.12e-08 | -0.526000 | 2.23e-07 |
MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 4.13e-07 | -0.525000 | 2.19e-06 |
Golgi-to-ER retrograde transport | 113 | 5.19e-22 | -0.524000 | 2.20e-20 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 1.10e-03 | -0.523000 | 2.70e-03 |
CaMK IV-mediated phosphorylation of CREB | 10 | 4.30e-03 | -0.521000 | 8.81e-03 |
Zinc transporters | 14 | 7.31e-04 | -0.521000 | 1.89e-03 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 28 | 1.84e-06 | -0.521000 | 8.56e-06 |
The role of Nef in HIV-1 replication and disease pathogenesis | 23 | 1.54e-05 | -0.520000 | 5.83e-05 |
Export of Viral Ribonucleoproteins from Nucleus | 33 | 2.31e-07 | -0.520000 | 1.33e-06 |
Circadian Clock | 67 | 1.89e-13 | -0.519000 | 3.29e-12 |
MAP kinase activation | 63 | 9.78e-13 | -0.519000 | 1.45e-11 |
NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 3.68e-07 | -0.519000 | 1.98e-06 |
Nuclear import of Rev protein | 34 | 1.66e-07 | -0.518000 | 1.01e-06 |
VEGFR2 mediated vascular permeability | 26 | 4.70e-06 | -0.518000 | 2.00e-05 |
VLDLR internalisation and degradation | 11 | 2.91e-03 | -0.518000 | 6.27e-03 |
RAF activation | 34 | 1.78e-07 | -0.517000 | 1.07e-06 |
Signaling by TGFB family members | 98 | 9.14e-19 | -0.516000 | 3.01e-17 |
Receptor Mediated Mitophagy | 11 | 3.03e-03 | -0.516000 | 6.49e-03 |
Transport of the SLBP Dependant Mature mRNA | 36 | 8.58e-08 | -0.515000 | 5.58e-07 |
RAC2 GTPase cycle | 86 | 1.56e-16 | -0.514000 | 3.92e-15 |
XBP1(S) activates chaperone genes | 48 | 6.95e-10 | -0.514000 | 6.53e-09 |
N-Glycan antennae elongation | 14 | 8.75e-04 | -0.514000 | 2.23e-03 |
Glutamate and glutamine metabolism | 13 | 1.36e-03 | -0.513000 | 3.29e-03 |
Caspase activation via Dependence Receptors in the absence of ligand | 10 | 5.12e-03 | -0.511000 | 1.03e-02 |
Interactions of Vpr with host cellular proteins | 37 | 7.83e-08 | -0.510000 | 5.14e-07 |
Signaling by FLT3 fusion proteins | 19 | 1.20e-04 | -0.509000 | 3.76e-04 |
Signaling by EGFR | 50 | 4.80e-10 | -0.509000 | 4.60e-09 |
Interactions of Rev with host cellular proteins | 37 | 9.21e-08 | -0.507000 | 5.94e-07 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 45 | 3.95e-09 | -0.507000 | 3.11e-08 |
Transport of the SLBP independent Mature mRNA | 35 | 2.10e-07 | -0.507000 | 1.25e-06 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 1.61e-03 | -0.505000 | 3.79e-03 |
Folding of actin by CCT/TriC | 10 | 5.70e-03 | -0.505000 | 1.13e-02 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 181 | 8.03e-32 | -0.505000 | 6.27e-30 |
COPI-dependent Golgi-to-ER retrograde traffic | 80 | 6.87e-15 | -0.503000 | 1.50e-13 |
RHOH GTPase cycle | 35 | 2.56e-07 | -0.503000 | 1.44e-06 |
Negative regulation of MAPK pathway | 43 | 1.15e-08 | -0.503000 | 8.58e-08 |
RHOU GTPase cycle | 40 | 3.75e-08 | -0.503000 | 2.65e-07 |
TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 3.90e-03 | -0.503000 | 8.07e-03 |
Josephin domain DUBs | 10 | 6.02e-03 | -0.502000 | 1.18e-02 |
Signaling by Leptin | 10 | 6.05e-03 | -0.501000 | 1.19e-02 |
Complex I biogenesis | 57 | 5.81e-11 | 0.501000 | 6.52e-10 |
Rev-mediated nuclear export of HIV RNA | 35 | 2.90e-07 | -0.501000 | 1.61e-06 |
MET activates PTK2 signaling | 18 | 2.36e-04 | -0.500000 | 6.94e-04 |
VEGFA-VEGFR2 Pathway | 91 | 1.51e-16 | -0.500000 | 3.85e-15 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 26 | 1.01e-05 | -0.500000 | 3.98e-05 |
Pentose phosphate pathway | 13 | 1.83e-03 | -0.499000 | 4.19e-03 |
Protein ubiquitination | 73 | 1.74e-13 | -0.498000 | 3.08e-12 |
Signaling by VEGF | 100 | 6.79e-18 | -0.498000 | 2.01e-16 |
Growth hormone receptor signaling | 20 | 1.16e-04 | -0.498000 | 3.65e-04 |
Nucleotide biosynthesis | 12 | 2.86e-03 | -0.497000 | 6.18e-03 |
Nuclear Pore Complex (NPC) Disassembly | 36 | 2.55e-07 | -0.496000 | 1.44e-06 |
Extra-nuclear estrogen signaling | 70 | 6.86e-13 | -0.496000 | 1.05e-11 |
Listeria monocytogenes entry into host cells | 20 | 1.24e-04 | -0.496000 | 3.85e-04 |
RHO GTPases activate IQGAPs | 11 | 4.43e-03 | -0.495000 | 9.07e-03 |
RHOD GTPase cycle | 53 | 4.65e-10 | -0.494000 | 4.48e-09 |
Regulation of actin dynamics for phagocytic cup formation | 59 | 5.68e-11 | -0.493000 | 6.43e-10 |
Regulation of localization of FOXO transcription factors | 12 | 3.18e-03 | -0.492000 | 6.78e-03 |
Ovarian tumor domain proteases | 38 | 1.56e-07 | -0.492000 | 9.64e-07 |
Glycogen synthesis | 15 | 9.85e-04 | -0.491000 | 2.47e-03 |
Vpr-mediated nuclear import of PICs | 34 | 7.45e-07 | -0.490000 | 3.80e-06 |
HSF1 activation | 26 | 1.50e-05 | -0.490000 | 5.69e-05 |
Regulation of IFNG signaling | 13 | 2.21e-03 | -0.490000 | 4.92e-03 |
Aflatoxin activation and detoxification | 14 | 1.55e-03 | 0.489000 | 3.68e-03 |
RHOG GTPase cycle | 74 | 3.55e-13 | -0.489000 | 5.85e-12 |
ISG15 antiviral mechanism | 73 | 5.63e-13 | -0.488000 | 8.70e-12 |
Tie2 Signaling | 17 | 5.02e-04 | -0.487000 | 1.36e-03 |
Oncogenic MAPK signaling | 78 | 1.01e-13 | -0.487000 | 1.92e-12 |
Interleukin-35 Signalling | 12 | 3.52e-03 | -0.486000 | 7.38e-03 |
SUMOylation of ubiquitinylation proteins | 39 | 1.62e-07 | -0.485000 | 9.90e-07 |
MET receptor recycling | 10 | 8.07e-03 | -0.484000 | 1.53e-02 |
Regulation of RUNX1 Expression and Activity | 18 | 3.80e-04 | -0.484000 | 1.06e-03 |
Transport to the Golgi and subsequent modification | 160 | 3.97e-26 | -0.484000 | 2.26e-24 |
Association of TriC/CCT with target proteins during biosynthesis | 37 | 3.55e-07 | -0.484000 | 1.93e-06 |
Signaling by FGFR4 in disease | 11 | 5.59e-03 | -0.482000 | 1.11e-02 |
Regulation of commissural axon pathfinding by SLIT and ROBO | 10 | 8.34e-03 | -0.482000 | 1.57e-02 |
InlB-mediated entry of Listeria monocytogenes into host cell | 15 | 1.25e-03 | -0.481000 | 3.04e-03 |
Defective B3GAT3 causes JDSSDHD | 19 | 2.82e-04 | -0.481000 | 8.18e-04 |
ER to Golgi Anterograde Transport | 131 | 2.45e-21 | -0.479000 | 9.58e-20 |
E3 ubiquitin ligases ubiquitinate target proteins | 53 | 1.63e-09 | -0.479000 | 1.37e-08 |
Nuclear Envelope Breakdown | 53 | 1.68e-09 | -0.478000 | 1.41e-08 |
RHOJ GTPase cycle | 54 | 1.19e-09 | -0.478000 | 1.01e-08 |
Antiviral mechanism by IFN-stimulated genes | 81 | 1.08e-13 | -0.477000 | 2.02e-12 |
Keratan sulfate biosynthesis | 24 | 5.25e-05 | -0.477000 | 1.75e-04 |
EPHB-mediated forward signaling | 34 | 1.73e-06 | -0.474000 | 8.10e-06 |
Regulation of HSF1-mediated heat shock response | 78 | 4.74e-13 | -0.473000 | 7.64e-12 |
activated TAK1 mediates p38 MAPK activation | 19 | 3.56e-04 | -0.473000 | 1.01e-03 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 3.79e-06 | -0.472000 | 1.65e-05 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 3.79e-06 | -0.472000 | 1.65e-05 |
MyD88 cascade initiated on plasma membrane | 81 | 2.15e-13 | -0.471000 | 3.62e-12 |
Toll Like Receptor 10 (TLR10) Cascade | 81 | 2.15e-13 | -0.471000 | 3.62e-12 |
Toll Like Receptor 5 (TLR5) Cascade | 81 | 2.15e-13 | -0.471000 | 3.62e-12 |
Erythropoietin activates RAS | 14 | 2.27e-03 | -0.471000 | 5.04e-03 |
Ca-dependent events | 34 | 2.02e-06 | -0.471000 | 9.27e-06 |
Regulation of KIT signaling | 15 | 1.60e-03 | -0.471000 | 3.77e-03 |
IRAK1 recruits IKK complex | 10 | 9.99e-03 | -0.470000 | 1.85e-02 |
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 9.99e-03 | -0.470000 | 1.85e-02 |
Heme signaling | 42 | 1.39e-07 | -0.469000 | 8.71e-07 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 19 | 4.05e-04 | -0.469000 | 1.13e-03 |
rRNA processing in the mitochondrion | 24 | 7.05e-05 | 0.469000 | 2.29e-04 |
Fcgamma receptor (FCGR) dependent phagocytosis | 84 | 1.23e-13 | -0.468000 | 2.26e-12 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 6.64e-06 | -0.467000 | 2.74e-05 |
NS1 Mediated Effects on Host Pathways | 41 | 2.24e-07 | -0.467000 | 1.33e-06 |
RUNX3 regulates NOTCH signaling | 14 | 2.52e-03 | -0.466000 | 5.52e-03 |
G-protein mediated events | 50 | 1.17e-08 | -0.466000 | 8.68e-08 |
Asparagine N-linked glycosylation | 276 | 1.13e-40 | -0.466000 | 1.40e-38 |
EGFR downregulation | 31 | 7.35e-06 | -0.465000 | 2.95e-05 |
SUMOylation of DNA replication proteins | 46 | 4.89e-08 | -0.465000 | 3.43e-07 |
p75NTR signals via NF-kB | 16 | 1.31e-03 | -0.464000 | 3.16e-03 |
GPVI-mediated activation cascade | 30 | 1.08e-05 | -0.464000 | 4.21e-05 |
CD28 co-stimulation | 29 | 1.56e-05 | -0.463000 | 5.86e-05 |
Glycolysis | 67 | 5.29e-11 | -0.463000 | 6.04e-10 |
RHOQ GTPase cycle | 58 | 1.06e-09 | -0.463000 | 9.50e-09 |
mRNA decay by 5’ to 3’ exoribonuclease | 15 | 1.92e-03 | -0.463000 | 4.35e-03 |
Toll Like Receptor 3 (TLR3) Cascade | 90 | 3.35e-14 | -0.462000 | 6.72e-13 |
SHC1 events in EGFR signaling | 14 | 2.77e-03 | -0.462000 | 6.01e-03 |
Cellular response to heat stress | 96 | 5.10e-15 | -0.462000 | 1.13e-13 |
Signaling by SCF-KIT | 41 | 3.60e-07 | -0.459000 | 1.95e-06 |
Diseases associated with glycosaminoglycan metabolism | 36 | 1.89e-06 | -0.459000 | 8.74e-06 |
Sodium/Calcium exchangers | 11 | 8.54e-03 | -0.458000 | 1.60e-02 |
TICAM1, RIP1-mediated IKK complex recruitment | 18 | 7.72e-04 | -0.458000 | 1.98e-03 |
Keratan sulfate/keratin metabolism | 29 | 1.99e-05 | -0.458000 | 7.35e-05 |
Formation of tubulin folding intermediates by CCT/TriC | 23 | 1.48e-04 | -0.457000 | 4.54e-04 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 3.10e-03 | -0.456000 | 6.64e-03 |
Nuclear Events (kinase and transcription factor activation) | 60 | 9.86e-10 | -0.456000 | 8.91e-09 |
Signaling by Erythropoietin | 25 | 7.92e-05 | -0.456000 | 2.56e-04 |
RAC3 GTPase cycle | 91 | 5.65e-14 | -0.455000 | 1.10e-12 |
DAG and IP3 signaling | 38 | 1.17e-06 | -0.455000 | 5.67e-06 |
Interleukin-17 signaling | 68 | 8.11e-11 | -0.455000 | 8.90e-10 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 20 | 4.25e-04 | -0.455000 | 1.17e-03 |
Neurodegenerative Diseases | 20 | 4.25e-04 | -0.455000 | 1.17e-03 |
FCERI mediated Ca+2 mobilization | 28 | 3.08e-05 | -0.455000 | 1.10e-04 |
Gap junction degradation | 10 | 1.28e-02 | -0.455000 | 2.28e-02 |
Signaling by NTRK1 (TRKA) | 113 | 6.72e-17 | -0.454000 | 1.78e-15 |
RHO GTPases activate CIT | 19 | 6.36e-04 | -0.453000 | 1.67e-03 |
GRB2 events in EGFR signaling | 13 | 4.86e-03 | -0.451000 | 9.86e-03 |
Transcriptional activation of mitochondrial biogenesis | 53 | 1.43e-08 | -0.450000 | 1.04e-07 |
Constitutive Signaling by Overexpressed ERBB2 | 11 | 9.81e-03 | -0.450000 | 1.83e-02 |
Metal ion SLC transporters | 23 | 1.89e-04 | -0.450000 | 5.68e-04 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 1.85e-03 | -0.450000 | 4.23e-03 |
Mitophagy | 28 | 3.87e-05 | -0.449000 | 1.35e-04 |
DARPP-32 events | 23 | 1.92e-04 | -0.449000 | 5.78e-04 |
Membrane Trafficking | 583 | 1.95e-77 | -0.449000 | 7.21e-75 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression | 13 | 5.23e-03 | -0.447000 | 1.05e-02 |
N-glycan antennae elongation in the medial/trans-Golgi | 24 | 1.49e-04 | -0.447000 | 4.54e-04 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 27 | 5.87e-05 | -0.447000 | 1.94e-04 |
Signaling by cytosolic FGFR1 fusion mutants | 18 | 1.05e-03 | -0.446000 | 2.62e-03 |
Signaling by NODAL | 20 | 5.61e-04 | -0.446000 | 1.50e-03 |
Signal amplification | 29 | 3.27e-05 | -0.445000 | 1.17e-04 |
FLT3 Signaling | 37 | 2.77e-06 | -0.445000 | 1.23e-05 |
Cyclin A/B1/B2 associated events during G2/M transition | 25 | 1.18e-04 | -0.445000 | 3.71e-04 |
PLC beta mediated events | 46 | 1.91e-07 | -0.444000 | 1.14e-06 |
Signaling by MET | 66 | 4.61e-10 | -0.443000 | 4.46e-09 |
PINK1-PRKN Mediated Mitophagy | 21 | 4.44e-04 | -0.443000 | 1.21e-03 |
ATF6 (ATF6-alpha) activates chaperones | 12 | 7.95e-03 | -0.442000 | 1.51e-02 |
CaM pathway | 32 | 1.50e-05 | -0.442000 | 5.69e-05 |
Calmodulin induced events | 32 | 1.50e-05 | -0.442000 | 5.69e-05 |
Selective autophagy | 58 | 5.75e-09 | -0.442000 | 4.46e-08 |
Pexophagy | 11 | 1.14e-02 | -0.440000 | 2.07e-02 |
FLT3 signaling in disease | 28 | 5.49e-05 | -0.440000 | 1.82e-04 |
RND1 GTPase cycle | 42 | 7.86e-07 | -0.440000 | 3.95e-06 |
SARS-CoV-2 Infection | 71 | 1.49e-10 | -0.439000 | 1.56e-09 |
Regulated proteolysis of p75NTR | 11 | 1.16e-02 | -0.439000 | 2.10e-02 |
PECAM1 interactions | 11 | 1.19e-02 | -0.438000 | 2.14e-02 |
Nuclear events stimulated by ALK signaling in cancer | 19 | 9.49e-04 | -0.438000 | 2.40e-03 |
Signaling by BRAF and RAF1 fusions | 61 | 3.35e-09 | -0.437000 | 2.69e-08 |
Cargo recognition for clathrin-mediated endocytosis | 101 | 3.06e-14 | -0.437000 | 6.22e-13 |
Intra-Golgi traffic | 43 | 7.34e-07 | -0.436000 | 3.75e-06 |
Clathrin-mediated endocytosis | 139 | 6.16e-19 | -0.436000 | 2.09e-17 |
Toll Like Receptor 9 (TLR9) Cascade | 91 | 6.97e-13 | -0.435000 | 1.06e-11 |
HSF1-dependent transactivation | 33 | 1.56e-05 | -0.434000 | 5.86e-05 |
HuR (ELAVL1) binds and stabilizes mRNA | 10 | 1.75e-02 | -0.434000 | 3.00e-02 |
COPII-mediated vesicle transport | 66 | 1.07e-09 | -0.434000 | 9.52e-09 |
Apoptotic cleavage of cell adhesion proteins | 10 | 1.77e-02 | -0.433000 | 3.04e-02 |
Interleukin-6 family signaling | 23 | 3.29e-04 | -0.433000 | 9.39e-04 |
Signaling by CSF3 (G-CSF) | 30 | 4.22e-05 | -0.432000 | 1.45e-04 |
EPH-Ephrin signaling | 91 | 1.05e-12 | -0.432000 | 1.54e-11 |
Integrin signaling | 25 | 1.88e-04 | -0.431000 | 5.65e-04 |
MyD88-independent TLR4 cascade | 94 | 5.43e-13 | -0.430000 | 8.48e-12 |
TRIF(TICAM1)-mediated TLR4 signaling | 94 | 5.43e-13 | -0.430000 | 8.48e-12 |
Constitutive Signaling by EGFRvIII | 15 | 4.01e-03 | -0.429000 | 8.27e-03 |
Signaling by EGFRvIII in Cancer | 15 | 4.01e-03 | -0.429000 | 8.27e-03 |
MHC class II antigen presentation | 98 | 2.23e-13 | -0.428000 | 3.72e-12 |
Signaling by NTRKs | 131 | 2.42e-17 | -0.428000 | 7.03e-16 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 1.18e-06 | -0.428000 | 5.69e-06 |
Vesicle-mediated transport | 614 | 5.47e-74 | -0.428000 | 1.35e-71 |
Dissolution of Fibrin Clot | 12 | 1.03e-02 | -0.427000 | 1.89e-02 |
RET signaling | 37 | 6.89e-06 | -0.427000 | 2.81e-05 |
Regulation of FOXO transcriptional activity by acetylation | 10 | 1.99e-02 | -0.425000 | 3.37e-02 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 93 | 1.37e-12 | -0.425000 | 1.99e-11 |
Apoptotic cleavage of cellular proteins | 36 | 1.03e-05 | -0.425000 | 4.04e-05 |
Retrograde neurotrophin signalling | 14 | 5.94e-03 | -0.425000 | 1.17e-02 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 1.49e-02 | -0.424000 | 2.63e-02 |
PKA activation in glucagon signalling | 15 | 4.50e-03 | -0.424000 | 9.19e-03 |
Regulation of TP53 Expression and Degradation | 36 | 1.11e-05 | -0.423000 | 4.29e-05 |
Translesion Synthesis by POLH | 18 | 1.88e-03 | -0.423000 | 4.29e-03 |
Signalling to ERKs | 33 | 2.60e-05 | -0.423000 | 9.44e-05 |
Sphingolipid de novo biosynthesis | 42 | 2.17e-06 | -0.422000 | 9.86e-06 |
Signaling by BMP | 23 | 4.64e-04 | -0.422000 | 1.26e-03 |
RND3 GTPase cycle | 41 | 3.40e-06 | -0.419000 | 1.50e-05 |
SHC1 events in ERBB2 signaling | 22 | 6.68e-04 | -0.419000 | 1.74e-03 |
Interleukin-7 signaling | 23 | 5.05e-04 | -0.419000 | 1.36e-03 |
PI3K events in ERBB2 signaling | 16 | 3.72e-03 | -0.419000 | 7.77e-03 |
Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 2.64e-06 | -0.419000 | 1.18e-05 |
Signaling by ERBB2 ECD mutants | 16 | 3.75e-03 | -0.418000 | 7.83e-03 |
Regulation of TP53 Degradation | 35 | 1.94e-05 | -0.417000 | 7.18e-05 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 86 | 2.34e-11 | -0.417000 | 2.84e-10 |
MyD88 dependent cascade initiated on endosome | 87 | 1.82e-11 | -0.416000 | 2.27e-10 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 87 | 1.82e-11 | -0.416000 | 2.27e-10 |
Nuclear Envelope (NE) Reassembly | 73 | 7.64e-10 | -0.416000 | 7.09e-09 |
PPARA activates gene expression | 112 | 3.04e-14 | -0.415000 | 6.22e-13 |
Alpha-protein kinase 1 signaling pathway | 11 | 1.71e-02 | -0.415000 | 2.95e-02 |
EPH-ephrin mediated repulsion of cells | 48 | 6.50e-07 | -0.415000 | 3.36e-06 |
Condensation of Prometaphase Chromosomes | 11 | 1.73e-02 | -0.415000 | 2.97e-02 |
Initiation of Nuclear Envelope (NE) Reformation | 19 | 1.80e-03 | -0.414000 | 4.13e-03 |
Translation of Replicase and Assembly of the Replication Transcription Complex | 13 | 9.87e-03 | -0.413000 | 1.83e-02 |
Negative regulation of the PI3K/AKT network | 100 | 9.14e-13 | -0.413000 | 1.37e-11 |
MASTL Facilitates Mitotic Progression | 10 | 2.40e-02 | -0.412000 | 3.95e-02 |
Kinesins | 41 | 4.91e-06 | -0.412000 | 2.07e-05 |
trans-Golgi Network Vesicle Budding | 71 | 1.88e-09 | -0.412000 | 1.55e-08 |
Autophagy | 125 | 1.68e-15 | -0.412000 | 3.77e-14 |
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 11 | 1.83e-02 | -0.411000 | 3.13e-02 |
Netrin-1 signaling | 46 | 1.63e-06 | -0.408000 | 7.69e-06 |
Macroautophagy | 112 | 8.16e-14 | -0.408000 | 1.57e-12 |
Retrograde transport at the Trans-Golgi-Network | 49 | 7.68e-07 | -0.408000 | 3.90e-06 |
RHOC GTPase cycle | 72 | 2.12e-09 | -0.408000 | 1.73e-08 |
Synthesis of PIPs at the plasma membrane | 50 | 6.17e-07 | -0.407000 | 3.20e-06 |
Diseases associated with glycosylation precursor biosynthesis | 18 | 2.78e-03 | -0.407000 | 6.01e-03 |
Regulation of lipid metabolism by PPARalpha | 114 | 5.58e-14 | -0.407000 | 1.10e-12 |
Constitutive Signaling by AKT1 E17K in Cancer | 26 | 3.39e-04 | -0.406000 | 9.65e-04 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 2.50e-05 | -0.406000 | 9.13e-05 |
Opioid Signalling | 82 | 2.17e-10 | -0.405000 | 2.17e-09 |
Gap junction trafficking and regulation | 20 | 1.71e-03 | -0.405000 | 3.98e-03 |
DAP12 interactions | 33 | 5.80e-05 | -0.404000 | 1.92e-04 |
Signaling by ALK | 26 | 3.64e-04 | -0.404000 | 1.03e-03 |
TBC/RABGAPs | 43 | 4.79e-06 | -0.403000 | 2.03e-05 |
Signaling by NTRK3 (TRKC) | 16 | 5.39e-03 | -0.402000 | 1.08e-02 |
Diseases of signal transduction by growth factor receptors and second messengers | 412 | 1.26e-44 | -0.401000 | 1.87e-42 |
Defective Intrinsic Pathway for Apoptosis | 22 | 1.14e-03 | -0.401000 | 2.81e-03 |
Cell-Cell communication | 110 | 4.19e-13 | -0.400000 | 6.83e-12 |
Pre-NOTCH Processing in Golgi | 18 | 3.41e-03 | -0.399000 | 7.19e-03 |
ERBB2 Regulates Cell Motility | 15 | 7.52e-03 | -0.399000 | 1.44e-02 |
A tetrasaccharide linker sequence is required for GAG synthesis | 25 | 5.75e-04 | -0.398000 | 1.53e-03 |
Laminin interactions | 23 | 9.81e-04 | -0.397000 | 2.46e-03 |
Response of Mtb to phagocytosis | 22 | 1.29e-03 | -0.396000 | 3.13e-03 |
SARS-CoV Infections | 152 | 3.24e-17 | -0.396000 | 9.23e-16 |
Membrane binding and targetting of GAG proteins | 14 | 1.03e-02 | -0.396000 | 1.89e-02 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 1.03e-02 | -0.396000 | 1.89e-02 |
Signaling by RAF1 mutants | 37 | 3.15e-05 | -0.395000 | 1.13e-04 |
L1CAM interactions | 94 | 4.20e-11 | -0.393000 | 4.95e-10 |
ESR-mediated signaling | 177 | 1.60e-19 | -0.393000 | 5.79e-18 |
Signaling by ERBB2 | 50 | 1.51e-06 | -0.393000 | 7.15e-06 |
RHOBTB GTPase Cycle | 35 | 5.99e-05 | -0.392000 | 1.97e-04 |
VxPx cargo-targeting to cilium | 19 | 3.12e-03 | -0.392000 | 6.67e-03 |
WNT5A-dependent internalization of FZD4 | 15 | 8.64e-03 | -0.392000 | 1.62e-02 |
RAB geranylgeranylation | 62 | 9.59e-08 | -0.391000 | 6.16e-07 |
Peptide chain elongation | 87 | 2.83e-10 | 0.391000 | 2.79e-09 |
Resolution of Sister Chromatid Cohesion | 105 | 4.36e-12 | -0.391000 | 5.97e-11 |
LDL clearance | 17 | 5.28e-03 | -0.391000 | 1.06e-02 |
Sialic acid metabolism | 30 | 2.13e-04 | -0.391000 | 6.29e-04 |
Fatty acyl-CoA biosynthesis | 35 | 6.71e-05 | -0.389000 | 2.19e-04 |
PI Metabolism | 78 | 2.74e-09 | -0.389000 | 2.23e-08 |
NOTCH3 Intracellular Domain Regulates Transcription | 23 | 1.25e-03 | -0.389000 | 3.04e-03 |
NF-kB is activated and signals survival | 13 | 1.53e-02 | -0.389000 | 2.68e-02 |
Acetylcholine regulates insulin secretion | 10 | 3.35e-02 | -0.388000 | 5.33e-02 |
Reduction of cytosolic Ca++ levels | 12 | 2.00e-02 | -0.388000 | 3.39e-02 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 19 | 3.52e-03 | -0.387000 | 7.38e-03 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 19 | 3.52e-03 | -0.387000 | 7.38e-03 |
Viral mRNA Translation | 87 | 4.49e-10 | 0.387000 | 4.38e-09 |
Signaling by Non-Receptor Tyrosine Kinases | 54 | 8.98e-07 | -0.386000 | 4.45e-06 |
Signaling by PTK6 | 54 | 8.98e-07 | -0.386000 | 4.45e-06 |
Regulation of PTEN mRNA translation | 12 | 2.05e-02 | -0.386000 | 3.46e-02 |
Signaling by EGFR in Cancer | 25 | 8.38e-04 | -0.386000 | 2.13e-03 |
Transcriptional regulation of white adipocyte differentiation | 82 | 1.53e-09 | -0.386000 | 1.30e-08 |
ATF6 (ATF6-alpha) activates chaperone genes | 10 | 3.50e-02 | -0.385000 | 5.51e-02 |
SUMOylation of RNA binding proteins | 47 | 5.41e-06 | -0.383000 | 2.27e-05 |
Post NMDA receptor activation events | 58 | 4.44e-07 | -0.383000 | 2.33e-06 |
Selenocysteine synthesis | 91 | 2.68e-10 | 0.383000 | 2.66e-09 |
Costimulation by the CD28 family | 59 | 3.91e-07 | -0.382000 | 2.09e-06 |
RHOBTB1 GTPase cycle | 23 | 1.62e-03 | -0.380000 | 3.80e-03 |
RHO GTPases activate PAKs | 21 | 2.63e-03 | -0.379000 | 5.74e-03 |
RHO GTPases Activate ROCKs | 19 | 4.28e-03 | -0.379000 | 8.79e-03 |
Glycosaminoglycan metabolism | 112 | 4.39e-12 | -0.378000 | 5.97e-11 |
Negative regulation of FLT3 | 15 | 1.12e-02 | -0.378000 | 2.04e-02 |
CD28 dependent PI3K/Akt signaling | 18 | 5.58e-03 | -0.377000 | 1.11e-02 |
TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 26 | 8.78e-04 | -0.377000 | 2.23e-03 |
RAB GEFs exchange GTP for GDP on RABs | 88 | 1.04e-09 | -0.376000 | 9.33e-09 |
Infection with Mycobacterium tuberculosis | 24 | 1.42e-03 | -0.376000 | 3.42e-03 |
TP53 Regulates Transcription of Cell Cycle Genes | 48 | 6.64e-06 | -0.376000 | 2.74e-05 |
Physiological factors | 11 | 3.12e-02 | -0.375000 | 4.98e-02 |
Diseases associated with N-glycosylation of proteins | 17 | 7.50e-03 | -0.375000 | 1.44e-02 |
Formation of RNA Pol II elongation complex | 57 | 9.98e-07 | -0.374000 | 4.88e-06 |
RNA Polymerase II Transcription Elongation | 57 | 9.98e-07 | -0.374000 | 4.88e-06 |
ADP signalling through P2Y purinoceptor 1 | 23 | 1.91e-03 | -0.374000 | 4.34e-03 |
RND2 GTPase cycle | 41 | 3.46e-05 | -0.374000 | 1.23e-04 |
Phase 2 - plateau phase | 15 | 1.22e-02 | 0.374000 | 2.19e-02 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 39 | 5.47e-05 | -0.373000 | 1.82e-04 |
HS-GAG degradation | 20 | 3.87e-03 | -0.373000 | 8.03e-03 |
AKT phosphorylates targets in the cytosol | 14 | 1.57e-02 | -0.373000 | 2.72e-02 |
Eukaryotic Translation Termination | 91 | 7.58e-10 | 0.373000 | 7.07e-09 |
Mitotic Prophase | 104 | 4.85e-11 | -0.373000 | 5.62e-10 |
Regulation of IFNA signaling | 13 | 2.00e-02 | -0.373000 | 3.39e-02 |
p75NTR recruits signalling complexes | 13 | 2.01e-02 | -0.372000 | 3.40e-02 |
Telomere C-strand synthesis initiation | 13 | 2.02e-02 | -0.372000 | 3.41e-02 |
FCGR3A-mediated IL10 synthesis | 34 | 1.74e-04 | -0.372000 | 5.29e-04 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 53 | 2.86e-06 | -0.371000 | 1.27e-05 |
GRB2 events in ERBB2 signaling | 16 | 1.02e-02 | -0.371000 | 1.87e-02 |
Sema3A PAK dependent Axon repulsion | 16 | 1.04e-02 | -0.370000 | 1.90e-02 |
Viral Messenger RNA Synthesis | 44 | 2.23e-05 | -0.369000 | 8.17e-05 |
mTORC1-mediated signalling | 24 | 1.77e-03 | -0.369000 | 4.10e-03 |
Suppression of phagosomal maturation | 13 | 2.17e-02 | -0.368000 | 3.63e-02 |
Late Phase of HIV Life Cycle | 135 | 1.75e-13 | -0.367000 | 3.08e-12 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 41 | 4.90e-05 | -0.366000 | 1.65e-04 |
Signaling by RAS mutants | 41 | 4.90e-05 | -0.366000 | 1.65e-04 |
Signaling by moderate kinase activity BRAF mutants | 41 | 4.90e-05 | -0.366000 | 1.65e-04 |
Signaling downstream of RAS mutants | 41 | 4.90e-05 | -0.366000 | 1.65e-04 |
WNT ligand biogenesis and trafficking | 23 | 2.39e-03 | -0.366000 | 5.29e-03 |
Activation of NMDA receptors and postsynaptic events | 71 | 1.00e-07 | -0.365000 | 6.37e-07 |
PI3K/AKT Signaling in Cancer | 93 | 1.11e-09 | -0.365000 | 9.78e-09 |
MET activates RAS signaling | 11 | 3.60e-02 | -0.365000 | 5.65e-02 |
Intracellular signaling by second messengers | 292 | 5.67e-27 | -0.365000 | 3.66e-25 |
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 10 | 4.61e-02 | -0.364000 | 7.02e-02 |
Heparan sulfate/heparin (HS-GAG) metabolism | 51 | 6.87e-06 | -0.364000 | 2.81e-05 |
Formation of ATP by chemiosmotic coupling | 18 | 7.57e-03 | 0.364000 | 1.45e-02 |
Gap junction trafficking | 18 | 7.60e-03 | -0.363000 | 1.45e-02 |
PI3K events in ERBB4 signaling | 10 | 4.77e-02 | -0.362000 | 7.16e-02 |
Host Interactions of HIV factors | 124 | 3.40e-12 | -0.362000 | 4.71e-11 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 5.25e-03 | -0.360000 | 1.05e-02 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 3.07e-02 | -0.360000 | 4.92e-02 |
alpha-linolenic acid (ALA) metabolism | 12 | 3.07e-02 | -0.360000 | 4.92e-02 |
Adherens junctions interactions | 29 | 7.91e-04 | -0.360000 | 2.03e-03 |
Glucose metabolism | 84 | 1.16e-08 | -0.360000 | 8.65e-08 |
DAP12 signaling | 26 | 1.52e-03 | -0.359000 | 3.61e-03 |
RHOB GTPase cycle | 69 | 2.47e-07 | -0.359000 | 1.41e-06 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 96 | 1.19e-09 | -0.359000 | 1.01e-08 |
Toll Like Receptor 2 (TLR2) Cascade | 96 | 1.19e-09 | -0.359000 | 1.01e-08 |
Toll Like Receptor TLR1:TLR2 Cascade | 96 | 1.19e-09 | -0.359000 | 1.01e-08 |
Toll Like Receptor TLR6:TLR2 Cascade | 96 | 1.19e-09 | -0.359000 | 1.01e-08 |
Inactivation of CSF3 (G-CSF) signaling | 25 | 1.90e-03 | -0.359000 | 4.33e-03 |
Prolactin receptor signaling | 11 | 3.99e-02 | -0.358000 | 6.21e-02 |
Thrombin signalling through proteinase activated receptors (PARs) | 30 | 6.97e-04 | -0.358000 | 1.81e-03 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 4.02e-02 | -0.357000 | 6.25e-02 |
Potential therapeutics for SARS | 83 | 1.92e-08 | -0.357000 | 1.40e-07 |
Signaling by high-kinase activity BRAF mutants | 32 | 4.82e-04 | -0.356000 | 1.31e-03 |
Free fatty acids regulate insulin secretion | 10 | 5.10e-02 | -0.356000 | 7.61e-02 |
NOTCH1 Intracellular Domain Regulates Transcription | 48 | 1.97e-05 | -0.356000 | 7.27e-05 |
Signaling by ERBB2 in Cancer | 26 | 1.69e-03 | -0.356000 | 3.94e-03 |
HIV Infection | 222 | 6.60e-20 | -0.355000 | 2.51e-18 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 92 | 3.85e-09 | -0.355000 | 3.06e-08 |
Amplification of signal from the kinetochores | 92 | 3.85e-09 | -0.355000 | 3.06e-08 |
HIV Life Cycle | 147 | 1.09e-13 | -0.355000 | 2.03e-12 |
FCERI mediated MAPK activation | 29 | 9.56e-04 | -0.354000 | 2.41e-03 |
EML4 and NUDC in mitotic spindle formation | 96 | 1.95e-09 | -0.354000 | 1.61e-08 |
Removal of the Flap Intermediate from the C-strand | 17 | 1.15e-02 | -0.354000 | 2.09e-02 |
Rab regulation of trafficking | 120 | 2.17e-11 | -0.353000 | 2.66e-10 |
NGF-stimulated transcription | 38 | 1.66e-04 | -0.353000 | 5.04e-04 |
Cyclin D associated events in G1 | 45 | 4.21e-05 | -0.353000 | 1.45e-04 |
G1 Phase | 45 | 4.21e-05 | -0.353000 | 1.45e-04 |
Transcriptional regulation by RUNX3 | 93 | 4.02e-09 | -0.353000 | 3.16e-08 |
Initial triggering of complement | 14 | 2.24e-02 | 0.352000 | 3.74e-02 |
PIP3 activates AKT signaling | 255 | 3.13e-22 | -0.352000 | 1.45e-20 |
SHC1 events in ERBB4 signaling | 14 | 2.29e-02 | -0.351000 | 3.81e-02 |
RHO GTPases Activate Formins | 119 | 3.57e-11 | -0.351000 | 4.27e-10 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 9.95e-03 | -0.351000 | 1.84e-02 |
SUMOylation of DNA damage response and repair proteins | 76 | 1.22e-07 | -0.351000 | 7.67e-07 |
Eukaryotic Translation Elongation | 92 | 5.98e-09 | 0.351000 | 4.60e-08 |
Assembly Of The HIV Virion | 16 | 1.52e-02 | -0.351000 | 2.67e-02 |
RHO GTPase Effectors | 258 | 3.57e-22 | -0.349000 | 1.58e-20 |
G alpha (z) signalling events | 42 | 8.99e-05 | -0.349000 | 2.88e-04 |
Toll Like Receptor 4 (TLR4) Cascade | 124 | 2.15e-11 | -0.348000 | 2.65e-10 |
Fc epsilon receptor (FCERI) signaling | 128 | 1.03e-11 | -0.348000 | 1.35e-10 |
Glucagon signaling in metabolic regulation | 29 | 1.31e-03 | -0.345000 | 3.16e-03 |
RNA Polymerase II Pre-transcription Events | 80 | 9.71e-08 | -0.345000 | 6.21e-07 |
Regulation of MECP2 expression and activity | 30 | 1.08e-03 | -0.345000 | 2.68e-03 |
Antigen processing: Ubiquitination & Proteasome degradation | 293 | 2.96e-24 | -0.344000 | 1.57e-22 |
Unfolded Protein Response (UPR) | 92 | 1.19e-08 | -0.344000 | 8.81e-08 |
Constitutive Signaling by Aberrant PI3K in Cancer | 66 | 1.39e-06 | -0.343000 | 6.63e-06 |
ADP signalling through P2Y purinoceptor 12 | 18 | 1.19e-02 | -0.342000 | 2.15e-02 |
Synthesis of substrates in N-glycan biosythesis | 60 | 4.53e-06 | -0.342000 | 1.94e-05 |
Translation of Structural Proteins | 29 | 1.43e-03 | -0.342000 | 3.43e-03 |
Cell junction organization | 79 | 1.53e-07 | -0.341000 | 9.50e-07 |
Platelet calcium homeostasis | 25 | 3.21e-03 | -0.340000 | 6.82e-03 |
Formation of Incision Complex in GG-NER | 43 | 1.17e-04 | -0.339000 | 3.69e-04 |
Class I MHC mediated antigen processing & presentation | 357 | 2.86e-28 | -0.339000 | 1.93e-26 |
TNFR1-induced proapoptotic signaling | 13 | 3.46e-02 | -0.338000 | 5.48e-02 |
Apoptotic execution phase | 49 | 4.22e-05 | -0.338000 | 1.45e-04 |
Signaling by WNT | 281 | 1.54e-22 | -0.338000 | 7.63e-21 |
Signaling by ERBB2 KD Mutants | 25 | 3.46e-03 | -0.338000 | 7.29e-03 |
Thromboxane signalling through TP receptor | 22 | 6.13e-03 | -0.338000 | 1.20e-02 |
Signaling by NOTCH1 | 74 | 5.17e-07 | -0.337000 | 2.70e-06 |
Signaling by FGFR3 | 38 | 3.22e-04 | -0.337000 | 9.23e-04 |
Interleukin-1 signaling | 97 | 9.47e-09 | -0.337000 | 7.17e-08 |
Cytochrome c-mediated apoptotic response | 13 | 3.54e-02 | -0.337000 | 5.57e-02 |
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 646 | 1.21e-48 | -0.336000 | 2.23e-46 |
Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 2.06e-03 | -0.336000 | 4.62e-03 |
CLEC7A (Dectin-1) signaling | 97 | 1.05e-08 | -0.336000 | 7.92e-08 |
Negative regulation of FGFR3 signaling | 27 | 2.54e-03 | -0.336000 | 5.55e-03 |
RAS processing | 19 | 1.14e-02 | -0.335000 | 2.06e-02 |
SUMOylation of chromatin organization proteins | 57 | 1.18e-05 | -0.335000 | 4.54e-05 |
Signaling by Rho GTPases | 630 | 3.43e-47 | -0.335000 | 5.66e-45 |
Budding and maturation of HIV virion | 28 | 2.17e-03 | -0.335000 | 4.84e-03 |
Deubiquitination | 249 | 8.67e-20 | -0.334000 | 3.21e-18 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 36 | 5.40e-04 | -0.333000 | 1.44e-03 |
Platelet activation, signaling and aggregation | 232 | 2.09e-18 | -0.333000 | 6.59e-17 |
Telomere Extension By Telomerase | 23 | 5.71e-03 | -0.333000 | 1.13e-02 |
Post-translational protein modification | 1276 | 2.61e-90 | -0.333000 | 1.94e-87 |
Mitochondrial tRNA aminoacylation | 21 | 8.39e-03 | -0.332000 | 1.57e-02 |
FOXO-mediated transcription of cell death genes | 15 | 2.59e-02 | -0.332000 | 4.24e-02 |
Activation of BH3-only proteins | 29 | 1.97e-03 | -0.332000 | 4.44e-03 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 75 | 6.62e-07 | -0.332000 | 3.41e-06 |
Interleukin-12 family signaling | 51 | 4.22e-05 | -0.331000 | 1.45e-04 |
PCP/CE pathway | 90 | 5.56e-08 | -0.331000 | 3.84e-07 |
Lysosphingolipid and LPA receptors | 12 | 4.72e-02 | -0.331000 | 7.12e-02 |
Advanced glycosylation endproduct receptor signaling | 11 | 5.75e-02 | -0.331000 | 8.50e-02 |
SARS-CoV-1 Infection | 50 | 5.20e-05 | -0.331000 | 1.74e-04 |
RHOBTB2 GTPase cycle | 23 | 6.06e-03 | -0.331000 | 1.19e-02 |
Interferon Signaling | 178 | 2.97e-14 | -0.330000 | 6.20e-13 |
Signaling by Receptor Tyrosine Kinases | 480 | 2.16e-35 | -0.330000 | 2.13e-33 |
Toll-like Receptor Cascades | 142 | 1.20e-11 | -0.329000 | 1.53e-10 |
G beta:gamma signalling through CDC42 | 18 | 1.56e-02 | -0.329000 | 2.71e-02 |
Metabolism of non-coding RNA | 53 | 3.52e-05 | -0.328000 | 1.24e-04 |
snRNP Assembly | 53 | 3.52e-05 | -0.328000 | 1.24e-04 |
O-linked glycosylation of mucins | 50 | 6.09e-05 | -0.328000 | 2.00e-04 |
Signaling by the B Cell Receptor (BCR) | 105 | 6.48e-09 | -0.328000 | 4.93e-08 |
Negative regulation of FGFR1 signaling | 30 | 1.92e-03 | -0.327000 | 4.35e-03 |
RNA polymerase II transcribes snRNA genes | 71 | 1.90e-06 | -0.327000 | 8.76e-06 |
RHO GTPase cycle | 437 | 7.51e-32 | -0.327000 | 6.18e-30 |
Caspase-mediated cleavage of cytoskeletal proteins | 12 | 5.01e-02 | -0.327000 | 7.49e-02 |
Intrinsic Pathway for Apoptosis | 53 | 3.91e-05 | -0.326000 | 1.36e-04 |
Ca2+ pathway | 60 | 1.23e-05 | -0.326000 | 4.71e-05 |
FOXO-mediated transcription | 59 | 1.50e-05 | -0.326000 | 5.69e-05 |
Regulation of FZD by ubiquitination | 20 | 1.17e-02 | -0.326000 | 2.11e-02 |
TRAF3-dependent IRF activation pathway | 14 | 3.49e-02 | -0.326000 | 5.51e-02 |
Dermatan sulfate biosynthesis | 11 | 6.17e-02 | -0.325000 | 9.08e-02 |
NOTCH2 intracellular domain regulates transcription | 12 | 5.10e-02 | -0.325000 | 7.61e-02 |
HCMV Early Events | 81 | 4.12e-07 | -0.325000 | 2.19e-06 |
Elastic fibre formation | 36 | 7.34e-04 | -0.325000 | 1.89e-03 |
Degradation of beta-catenin by the destruction complex | 83 | 3.02e-07 | -0.325000 | 1.65e-06 |
Class I peroxisomal membrane protein import | 19 | 1.42e-02 | -0.325000 | 2.51e-02 |
Activation of the TFAP2 (AP-2) family of transcription factors | 11 | 6.23e-02 | -0.325000 | 9.13e-02 |
Carnitine metabolism | 11 | 6.31e-02 | -0.324000 | 9.22e-02 |
Protein methylation | 15 | 3.00e-02 | -0.324000 | 4.83e-02 |
Downregulation of ERBB2:ERBB3 signaling | 13 | 4.37e-02 | -0.323000 | 6.72e-02 |
Defects in vitamin and cofactor metabolism | 21 | 1.05e-02 | -0.322000 | 1.91e-02 |
Mitotic Metaphase and Anaphase | 229 | 4.10e-17 | -0.322000 | 1.15e-15 |
Beta-catenin independent WNT signaling | 142 | 3.64e-11 | -0.321000 | 4.32e-10 |
Mitotic Anaphase | 228 | 6.44e-17 | -0.321000 | 1.74e-15 |
Regulation of BACH1 activity | 11 | 6.57e-02 | -0.320000 | 9.57e-02 |
Estrogen-dependent gene expression | 110 | 6.38e-09 | -0.320000 | 4.87e-08 |
RHOA GTPase cycle | 146 | 2.66e-11 | -0.319000 | 3.20e-10 |
MAPK family signaling cascades | 302 | 1.29e-21 | -0.319000 | 5.32e-20 |
Glutathione conjugation | 30 | 2.51e-03 | 0.319000 | 5.52e-03 |
MAPK6/MAPK4 signaling | 87 | 3.00e-07 | -0.318000 | 1.65e-06 |
Signaling by PDGF | 53 | 6.43e-05 | -0.317000 | 2.10e-04 |
Interleukin-20 family signaling | 19 | 1.67e-02 | -0.317000 | 2.87e-02 |
Metabolism of carbohydrates | 266 | 4.94e-19 | -0.317000 | 1.75e-17 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 5.02e-08 | 0.317000 | 3.49e-07 |
BBSome-mediated cargo-targeting to cilium | 21 | 1.23e-02 | -0.315000 | 2.21e-02 |
SUMOylation of intracellular receptors | 28 | 3.92e-03 | -0.315000 | 8.10e-03 |
Diseases associated with visual transduction | 10 | 8.48e-02 | 0.315000 | 1.19e-01 |
Diseases of the neuronal system | 10 | 8.48e-02 | 0.315000 | 1.19e-01 |
Retinoid cycle disease events | 10 | 8.48e-02 | 0.315000 | 1.19e-01 |
Uptake and actions of bacterial toxins | 29 | 3.36e-03 | -0.315000 | 7.11e-03 |
Adaptive Immune System | 657 | 3.14e-43 | -0.314000 | 4.24e-41 |
RAC1 GTPase cycle | 178 | 5.07e-13 | -0.313000 | 8.09e-12 |
MAP2K and MAPK activation | 36 | 1.15e-03 | -0.313000 | 2.82e-03 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 1.12e-02 | -0.312000 | 2.04e-02 |
Purine salvage | 12 | 6.13e-02 | -0.312000 | 9.03e-02 |
MTOR signalling | 40 | 6.53e-04 | -0.311000 | 1.71e-03 |
SUMOylation of transcription cofactors | 44 | 3.51e-04 | -0.311000 | 9.94e-04 |
Factors involved in megakaryocyte development and platelet production | 119 | 4.38e-09 | -0.311000 | 3.42e-08 |
Phospholipase C-mediated cascade; FGFR4 | 12 | 6.20e-02 | 0.311000 | 9.11e-02 |
Negative regulators of DDX58/IFIH1 signaling | 35 | 1.45e-03 | -0.311000 | 3.47e-03 |
Activated NOTCH1 Transmits Signal to the Nucleus | 31 | 2.79e-03 | -0.310000 | 6.03e-03 |
PKMTs methylate histone lysines | 45 | 3.27e-04 | -0.309000 | 9.35e-04 |
Translesion synthesis by POLK | 17 | 2.72e-02 | -0.309000 | 4.42e-02 |
Cargo trafficking to the periciliary membrane | 47 | 2.51e-04 | -0.309000 | 7.33e-04 |
Deactivation of the beta-catenin transactivating complex | 41 | 6.60e-04 | -0.307000 | 1.73e-03 |
Deadenylation-dependent mRNA decay | 53 | 1.08e-04 | -0.307000 | 3.45e-04 |
Common Pathway of Fibrin Clot Formation | 14 | 4.69e-02 | -0.307000 | 7.08e-02 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 3.14e-07 | 0.307000 | 1.71e-06 |
Metabolism of fat-soluble vitamins | 36 | 1.45e-03 | -0.307000 | 3.47e-03 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 125 | 3.14e-09 | 0.307000 | 2.53e-08 |
Hemostasis | 505 | 3.66e-32 | -0.306000 | 3.19e-30 |
Regulation of PTEN gene transcription | 61 | 3.90e-05 | -0.304000 | 1.36e-04 |
Vasopressin regulates renal water homeostasis via Aquaporins | 36 | 1.58e-03 | -0.304000 | 3.74e-03 |
HCMV Infection | 105 | 7.34e-08 | -0.304000 | 4.84e-07 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 28 | 5.41e-03 | -0.304000 | 1.08e-02 |
Interleukin-12 signaling | 43 | 5.72e-04 | -0.304000 | 1.52e-03 |
Formation of a pool of free 40S subunits | 99 | 1.78e-07 | 0.303000 | 1.07e-06 |
Metabolism of steroids | 138 | 9.30e-10 | -0.302000 | 8.47e-09 |
eNOS activation | 11 | 8.35e-02 | -0.301000 | 1.18e-01 |
C-type lectin receptors (CLRs) | 125 | 5.80e-09 | -0.301000 | 4.48e-08 |
The NLRP3 inflammasome | 15 | 4.34e-02 | -0.301000 | 6.68e-02 |
Synthesis of very long-chain fatty acyl-CoAs | 22 | 1.46e-02 | -0.301000 | 2.58e-02 |
RHOBTB3 ATPase cycle | 10 | 1.00e-01 | -0.300000 | 1.38e-01 |
Signaling by FGFR1 | 47 | 3.66e-04 | -0.300000 | 1.03e-03 |
Mitochondrial calcium ion transport | 22 | 1.47e-02 | -0.300000 | 2.61e-02 |
Mitotic Spindle Checkpoint | 109 | 5.95e-08 | -0.300000 | 3.94e-07 |
HDR through MMEJ (alt-NHEJ) | 10 | 1.00e-01 | -0.300000 | 1.39e-01 |
Interleukin receptor SHC signaling | 22 | 1.50e-02 | -0.300000 | 2.64e-02 |
MAPK1/MAPK3 signaling | 263 | 5.79e-17 | -0.299000 | 1.59e-15 |
SUMOylation | 171 | 1.55e-11 | -0.299000 | 1.96e-10 |
Platelet homeostasis | 76 | 6.93e-06 | -0.298000 | 2.82e-05 |
PTEN Regulation | 140 | 1.10e-09 | -0.298000 | 9.75e-09 |
Defective CFTR causes cystic fibrosis | 58 | 8.69e-05 | -0.298000 | 2.79e-04 |
Chaperonin-mediated protein folding | 85 | 2.07e-06 | -0.298000 | 9.47e-06 |
Chondroitin sulfate/dermatan sulfate metabolism | 49 | 3.12e-04 | -0.298000 | 8.97e-04 |
Signaling by Nuclear Receptors | 245 | 1.02e-15 | -0.297000 | 2.36e-14 |
Downstream TCR signaling | 89 | 1.24e-06 | -0.297000 | 5.96e-06 |
Myogenesis | 25 | 1.02e-02 | -0.297000 | 1.87e-02 |
Cellular response to hypoxia | 73 | 1.15e-05 | -0.297000 | 4.45e-05 |
FCERI mediated NF-kB activation | 76 | 7.65e-06 | -0.297000 | 3.06e-05 |
TCF dependent signaling in response to WNT | 187 | 2.49e-12 | -0.297000 | 3.48e-11 |
Molecules associated with elastic fibres | 27 | 7.64e-03 | -0.297000 | 1.46e-02 |
Elevation of cytosolic Ca2+ levels | 13 | 6.42e-02 | -0.296000 | 9.38e-02 |
Ub-specific processing proteases | 177 | 1.02e-11 | -0.296000 | 1.34e-10 |
Neddylation | 223 | 2.36e-14 | -0.296000 | 5.00e-13 |
Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 4.76e-02 | -0.295000 | 7.16e-02 |
Signaling by ERBB4 | 53 | 2.01e-04 | -0.295000 | 5.99e-04 |
Notch-HLH transcription pathway | 28 | 6.87e-03 | -0.295000 | 1.33e-02 |
Recognition of DNA damage by PCNA-containing replication complex | 30 | 5.21e-03 | -0.295000 | 1.05e-02 |
Downstream signaling events of B Cell Receptor (BCR) | 79 | 6.43e-06 | -0.293000 | 2.67e-05 |
Rap1 signalling | 15 | 4.99e-02 | -0.292000 | 7.48e-02 |
FGFR1 mutant receptor activation | 29 | 6.53e-03 | -0.292000 | 1.27e-02 |
IKK complex recruitment mediated by RIP1 | 22 | 1.79e-02 | -0.292000 | 3.06e-02 |
Aquaporin-mediated transport | 38 | 1.87e-03 | -0.291000 | 4.27e-03 |
Downregulation of ERBB2 signaling | 29 | 6.61e-03 | -0.291000 | 1.29e-02 |
Sphingolipid metabolism | 83 | 4.46e-06 | -0.291000 | 1.92e-05 |
Translesion synthesis by REV1 | 16 | 4.40e-02 | -0.291000 | 6.75e-02 |
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 11 | 9.49e-02 | -0.291000 | 1.32e-01 |
Receptor-type tyrosine-protein phosphatases | 19 | 2.89e-02 | -0.290000 | 4.67e-02 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 31 | 5.28e-03 | -0.289000 | 1.06e-02 |
Effects of PIP2 hydrolysis | 24 | 1.42e-02 | -0.289000 | 2.51e-02 |
RAF/MAP kinase cascade | 257 | 1.40e-15 | -0.289000 | 3.19e-14 |
Signaling by FGFR1 in disease | 36 | 2.71e-03 | -0.289000 | 5.90e-03 |
Separation of Sister Chromatids | 168 | 1.03e-10 | -0.289000 | 1.10e-09 |
Transcription of the HIV genome | 69 | 3.38e-05 | -0.289000 | 1.20e-04 |
Chaperone Mediated Autophagy | 17 | 3.98e-02 | -0.288000 | 6.20e-02 |
Regulation of TP53 Activity | 156 | 5.24e-10 | -0.288000 | 4.98e-09 |
Cell-cell junction organization | 54 | 2.52e-04 | -0.288000 | 7.34e-04 |
Integration of energy metabolism | 98 | 8.82e-07 | -0.287000 | 4.40e-06 |
SUMO E3 ligases SUMOylate target proteins | 165 | 1.98e-10 | -0.287000 | 2.01e-09 |
Semaphorin interactions | 61 | 1.08e-04 | -0.286000 | 3.45e-04 |
RHO GTPases Activate NADPH Oxidases | 22 | 2.02e-02 | -0.286000 | 3.41e-02 |
Nonhomologous End-Joining (NHEJ) | 43 | 1.18e-03 | -0.286000 | 2.88e-03 |
Ion homeostasis | 47 | 7.03e-04 | -0.286000 | 1.82e-03 |
TCR signaling | 110 | 2.34e-07 | -0.285000 | 1.34e-06 |
Signaling by Interleukins | 394 | 2.09e-22 | -0.285000 | 9.99e-21 |
Regulation of TP53 Activity through Acetylation | 29 | 8.04e-03 | -0.284000 | 1.53e-02 |
Transcriptional regulation by RUNX2 | 116 | 1.22e-07 | -0.284000 | 7.67e-07 |
Regulation of HMOX1 expression and activity | 63 | 9.63e-05 | -0.284000 | 3.08e-04 |
Signal Transduction | 2202 | 0.00e+00 | -0.284000 | 0.00e+00 |
Signaling by FGFR4 | 38 | 2.47e-03 | -0.284000 | 5.45e-03 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 5.76e-02 | -0.283000 | 8.50e-02 |
Cytokine Signaling in Immune system | 617 | 2.37e-33 | -0.283000 | 2.20e-31 |
Apoptosis | 171 | 1.80e-10 | -0.282000 | 1.85e-09 |
Platelet Aggregation (Plug Formation) | 33 | 4.98e-03 | -0.282000 | 1.01e-02 |
Negative regulation of FGFR4 signaling | 28 | 9.81e-03 | -0.282000 | 1.83e-02 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 36 | 3.42e-03 | -0.282000 | 7.21e-03 |
Activated NTRK2 signals through FRS2 and FRS3 | 11 | 1.06e-01 | -0.282000 | 1.45e-01 |
G beta:gamma signalling through PI3Kgamma | 23 | 1.94e-02 | -0.282000 | 3.31e-02 |
Apoptotic factor-mediated response | 19 | 3.37e-02 | -0.281000 | 5.34e-02 |
G-protein beta:gamma signalling | 30 | 7.69e-03 | -0.281000 | 1.47e-02 |
Respiratory electron transport | 103 | 8.33e-07 | 0.281000 | 4.17e-06 |
Metabolism of amine-derived hormones | 12 | 9.21e-02 | 0.281000 | 1.29e-01 |
Platelet degranulation | 112 | 2.93e-07 | -0.280000 | 1.62e-06 |
Interleukin-1 family signaling | 130 | 3.43e-08 | -0.280000 | 2.43e-07 |
AKT phosphorylates targets in the nucleus | 10 | 1.26e-01 | -0.279000 | 1.70e-01 |
Regulation of RUNX3 expression and activity | 54 | 3.85e-04 | -0.279000 | 1.07e-03 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 34 | 4.88e-03 | -0.279000 | 9.89e-03 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 5.36e-02 | -0.279000 | 7.98e-02 |
Digestion and absorption | 13 | 8.20e-02 | 0.279000 | 1.17e-01 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 1.80e-03 | -0.278000 | 4.13e-03 |
HIV Transcription Elongation | 42 | 1.80e-03 | -0.278000 | 4.13e-03 |
Tat-mediated elongation of the HIV-1 transcript | 42 | 1.80e-03 | -0.278000 | 4.13e-03 |
Pausing and recovery of Tat-mediated HIV elongation | 30 | 8.35e-03 | -0.278000 | 1.57e-02 |
Tat-mediated HIV elongation arrest and recovery | 30 | 8.35e-03 | -0.278000 | 1.57e-02 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 33 | 5.83e-03 | -0.277000 | 1.15e-02 |
Immune System | 1673 | 7.80e-81 | -0.277000 | 3.86e-78 |
RUNX2 regulates osteoblast differentiation | 23 | 2.18e-02 | -0.276000 | 3.64e-02 |
Signaling by ERBB2 TMD/JMD mutants | 22 | 2.48e-02 | -0.276000 | 4.08e-02 |
Signaling by NOTCH3 | 47 | 1.06e-03 | -0.276000 | 2.62e-03 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 2.20e-02 | -0.276000 | 3.68e-02 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 21 | 2.89e-02 | -0.275000 | 4.67e-02 |
IL-6-type cytokine receptor ligand interactions | 16 | 5.67e-02 | -0.275000 | 8.42e-02 |
Other semaphorin interactions | 16 | 5.71e-02 | -0.275000 | 8.45e-02 |
Glyoxylate metabolism and glycine degradation | 26 | 1.54e-02 | -0.274000 | 2.69e-02 |
Lewis blood group biosynthesis | 15 | 6.69e-02 | -0.273000 | 9.72e-02 |
Role of phospholipids in phagocytosis | 23 | 2.35e-02 | -0.273000 | 3.89e-02 |
Transport of vitamins, nucleosides, and related molecules | 37 | 4.07e-03 | -0.273000 | 8.38e-03 |
Regulation of PTEN stability and activity | 67 | 1.13e-04 | -0.273000 | 3.59e-04 |
Constitutive Signaling by NOTCH1 HD Domain Mutants | 15 | 6.76e-02 | -0.272000 | 9.79e-02 |
Signaling by NOTCH1 HD Domain Mutants in Cancer | 15 | 6.76e-02 | -0.272000 | 9.79e-02 |
Asymmetric localization of PCP proteins | 62 | 2.06e-04 | -0.272000 | 6.13e-04 |
Formation of HIV elongation complex in the absence of HIV Tat | 44 | 1.77e-03 | -0.272000 | 4.10e-03 |
Negative regulation of FGFR2 signaling | 30 | 9.86e-03 | -0.272000 | 1.83e-02 |
Programmed Cell Death | 197 | 4.98e-11 | -0.271000 | 5.73e-10 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 67 | 1.25e-04 | -0.271000 | 3.86e-04 |
HIV elongation arrest and recovery | 32 | 8.21e-03 | -0.270000 | 1.55e-02 |
Pausing and recovery of HIV elongation | 32 | 8.21e-03 | -0.270000 | 1.55e-02 |
Retinoid metabolism and transport | 32 | 8.53e-03 | -0.269000 | 1.60e-02 |
Disorders of Developmental Biology | 13 | 9.36e-02 | -0.269000 | 1.30e-01 |
Disorders of Nervous System Development | 13 | 9.36e-02 | -0.269000 | 1.30e-01 |
Loss of function of MECP2 in Rett syndrome | 13 | 9.36e-02 | -0.269000 | 1.30e-01 |
Pervasive developmental disorders | 13 | 9.36e-02 | -0.269000 | 1.30e-01 |
Neutrophil degranulation | 426 | 1.69e-21 | -0.268000 | 6.79e-20 |
Iron uptake and transport | 56 | 5.23e-04 | -0.268000 | 1.40e-03 |
Response to elevated platelet cytosolic Ca2+ | 117 | 5.57e-07 | -0.268000 | 2.90e-06 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 15 | 7.26e-02 | -0.268000 | 1.04e-01 |
Regulation of RUNX2 expression and activity | 70 | 1.09e-04 | -0.267000 | 3.45e-04 |
Leishmania infection | 194 | 1.31e-10 | -0.267000 | 1.38e-09 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 58 | 4.29e-04 | -0.267000 | 1.18e-03 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 58 | 4.29e-04 | -0.267000 | 1.18e-03 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 58 | 4.29e-04 | -0.267000 | 1.18e-03 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 58 | 4.29e-04 | -0.267000 | 1.18e-03 |
Signaling by NOTCH1 in Cancer | 58 | 4.29e-04 | -0.267000 | 1.18e-03 |
tRNA Aminoacylation | 42 | 2.75e-03 | -0.267000 | 5.97e-03 |
Vitamin D (calciferol) metabolism | 10 | 1.45e-01 | -0.266000 | 1.91e-01 |
Interleukin-4 and Interleukin-13 signaling | 95 | 7.29e-06 | -0.266000 | 2.94e-05 |
Cyclin A:Cdk2-associated events at S phase entry | 85 | 2.22e-05 | -0.266000 | 8.16e-05 |
Activation of NF-kappaB in B cells | 65 | 2.08e-04 | -0.266000 | 6.18e-04 |
M Phase | 371 | 1.50e-18 | -0.265000 | 4.83e-17 |
Regulation of RAS by GAPs | 64 | 2.46e-04 | -0.265000 | 7.19e-04 |
Transcriptional Regulation by MECP2 | 56 | 6.03e-04 | -0.265000 | 1.59e-03 |
DNA Double Strand Break Response | 52 | 9.55e-04 | -0.265000 | 2.41e-03 |
Neurotoxicity of clostridium toxins | 10 | 1.47e-01 | 0.265000 | 1.93e-01 |
Oncogene Induced Senescence | 31 | 1.09e-02 | -0.264000 | 1.97e-02 |
Phospholipid metabolism | 191 | 2.89e-10 | -0.264000 | 2.84e-09 |
Triglyceride metabolism | 27 | 1.78e-02 | -0.264000 | 3.04e-02 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 58 | 5.27e-04 | -0.263000 | 1.41e-03 |
NOD1/2 Signaling Pathway | 32 | 1.04e-02 | -0.262000 | 1.90e-02 |
Peroxisomal protein import | 60 | 4.55e-04 | -0.262000 | 1.24e-03 |
tRNA processing in the nucleus | 59 | 5.10e-04 | -0.262000 | 1.37e-03 |
Pyruvate metabolism | 29 | 1.48e-02 | -0.262000 | 2.61e-02 |
Cell surface interactions at the vascular wall | 105 | 3.71e-06 | -0.261000 | 1.63e-05 |
Chondroitin sulfate biosynthesis | 20 | 4.32e-02 | -0.261000 | 6.67e-02 |
SCF-beta-TrCP mediated degradation of Emi1 | 53 | 1.01e-03 | -0.261000 | 2.53e-03 |
Mitotic Prometaphase | 186 | 8.40e-10 | -0.261000 | 7.69e-09 |
Selenoamino acid metabolism | 115 | 1.39e-06 | 0.260000 | 6.63e-06 |
Protein folding | 91 | 1.79e-05 | -0.260000 | 6.67e-05 |
GLI3 is processed to GLI3R by the proteasome | 57 | 6.87e-04 | -0.260000 | 1.79e-03 |
Late endosomal microautophagy | 29 | 1.55e-02 | -0.260000 | 2.70e-02 |
Interferon gamma signaling | 82 | 4.78e-05 | -0.260000 | 1.62e-04 |
Assembly of active LPL and LIPC lipase complexes | 15 | 8.20e-02 | -0.259000 | 1.17e-01 |
Metabolism of proteins | 1754 | 2.75e-74 | -0.259000 | 8.15e-72 |
SLC transporter disorders | 82 | 4.99e-05 | -0.259000 | 1.67e-04 |
Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 8.27e-02 | -0.259000 | 1.17e-01 |
Insulin receptor signalling cascade | 49 | 1.74e-03 | -0.259000 | 4.03e-03 |
Cyclin E associated events during G1/S transition | 83 | 4.72e-05 | -0.258000 | 1.61e-04 |
RHO GTPases activate PKNs | 53 | 1.17e-03 | -0.258000 | 2.88e-03 |
Hh mutants are degraded by ERAD | 54 | 1.06e-03 | -0.257000 | 2.63e-03 |
G-protein activation | 20 | 4.62e-02 | -0.257000 | 7.03e-02 |
Activation of GABAB receptors | 37 | 6.85e-03 | -0.257000 | 1.33e-02 |
GABA B receptor activation | 37 | 6.85e-03 | -0.257000 | 1.33e-02 |
Nuclear Receptor transcription pathway | 47 | 2.32e-03 | -0.257000 | 5.14e-03 |
NOTCH4 Intracellular Domain Regulates Transcription | 20 | 4.73e-02 | -0.256000 | 7.14e-02 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 51 | 1.56e-03 | -0.256000 | 3.70e-03 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 20 | 4.76e-02 | -0.256000 | 7.16e-02 |
CDC42 GTPase cycle | 153 | 4.93e-08 | -0.255000 | 3.45e-07 |
Signaling by NTRK2 (TRKB) | 24 | 3.05e-02 | -0.255000 | 4.89e-02 |
Prefoldin mediated transfer of substrate to CCT/TriC | 27 | 2.21e-02 | -0.254000 | 3.69e-02 |
Innate Immune System | 872 | 1.49e-37 | -0.254000 | 1.70e-35 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 51 | 1.70e-03 | -0.254000 | 3.96e-03 |
Formation of apoptosome | 11 | 1.45e-01 | -0.254000 | 1.90e-01 |
Regulation of the apoptosome activity | 11 | 1.45e-01 | -0.254000 | 1.90e-01 |
mRNA decay by 3’ to 5’ exoribonuclease | 16 | 7.91e-02 | 0.254000 | 1.13e-01 |
Triglyceride catabolism | 18 | 6.32e-02 | -0.253000 | 9.23e-02 |
Disease | 1469 | 3.79e-60 | -0.253000 | 8.03e-58 |
Transcriptional Regulation by TP53 | 357 | 2.06e-16 | -0.253000 | 5.09e-15 |
Dectin-1 mediated noncanonical NF-kB signaling | 59 | 7.93e-04 | -0.252000 | 2.03e-03 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 1.17e-01 | -0.251000 | 1.59e-01 |
Chromatin modifying enzymes | 225 | 8.22e-11 | -0.251000 | 8.90e-10 |
Chromatin organization | 225 | 8.22e-11 | -0.251000 | 8.90e-10 |
HCMV Late Events | 77 | 1.41e-04 | -0.251000 | 4.33e-04 |
E2F mediated regulation of DNA replication | 22 | 4.20e-02 | -0.250000 | 6.51e-02 |
NIK–>noncanonical NF-kB signaling | 57 | 1.08e-03 | -0.250000 | 2.67e-03 |
Defects in cobalamin (B12) metabolism | 13 | 1.18e-01 | -0.250000 | 1.60e-01 |
Regulation of APC/C activators between G1/S and early anaphase | 79 | 1.23e-04 | -0.250000 | 3.84e-04 |
Cytosolic tRNA aminoacylation | 24 | 3.44e-02 | -0.249000 | 5.45e-02 |
FGFR4 ligand binding and activation | 11 | 1.52e-01 | 0.249000 | 1.99e-01 |
Cell Cycle, Mitotic | 513 | 3.63e-22 | -0.249000 | 1.58e-20 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 64 | 5.70e-04 | -0.249000 | 1.52e-03 |
Lysosome Vesicle Biogenesis | 34 | 1.21e-02 | -0.249000 | 2.17e-02 |
ECM proteoglycans | 47 | 3.20e-03 | -0.248000 | 6.79e-03 |
Hedgehog ligand biogenesis | 63 | 6.77e-04 | -0.247000 | 1.77e-03 |
Synaptic adhesion-like molecules | 20 | 5.55e-02 | -0.247000 | 8.24e-02 |
Polymerase switching on the C-strand of the telomere | 26 | 2.90e-02 | -0.247000 | 4.69e-02 |
Phospholipase C-mediated cascade; FGFR2 | 14 | 1.09e-01 | 0.247000 | 1.49e-01 |
DNA Damage Bypass | 47 | 3.37e-03 | -0.247000 | 7.12e-03 |
Infectious disease | 745 | 1.00e-30 | -0.247000 | 7.45e-29 |
Unwinding of DNA | 12 | 1.41e-01 | 0.246000 | 1.86e-01 |
RUNX2 regulates bone development | 30 | 2.03e-02 | -0.245000 | 3.42e-02 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 2.85e-02 | -0.244000 | 4.62e-02 |
Metabolism of lipids | 660 | 9.17e-27 | -0.243000 | 5.67e-25 |
Formation of the Early Elongation Complex | 33 | 1.55e-02 | -0.243000 | 2.70e-02 |
Formation of the HIV-1 Early Elongation Complex | 33 | 1.55e-02 | -0.243000 | 2.70e-02 |
RNA Polymerase III Abortive And Retractive Initiation | 41 | 7.23e-03 | -0.242000 | 1.39e-02 |
RNA Polymerase III Transcription | 41 | 7.23e-03 | -0.242000 | 1.39e-02 |
ROS sensing by NFE2L2 | 55 | 1.91e-03 | -0.242000 | 4.34e-03 |
TP53 Regulates Metabolic Genes | 85 | 1.15e-04 | -0.242000 | 3.64e-04 |
Degradation of GLI1 by the proteasome | 57 | 1.65e-03 | -0.241000 | 3.87e-03 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 1.19e-01 | -0.240000 | 1.61e-01 |
Pyroptosis | 24 | 4.28e-02 | -0.239000 | 6.61e-02 |
APC/C-mediated degradation of cell cycle proteins | 86 | 1.30e-04 | -0.239000 | 4.01e-04 |
Regulation of mitotic cell cycle | 86 | 1.30e-04 | -0.239000 | 4.01e-04 |
CRMPs in Sema3A signaling | 16 | 9.86e-02 | -0.238000 | 1.36e-01 |
Synthesis of PA | 32 | 1.96e-02 | -0.238000 | 3.33e-02 |
Hh mutants abrogate ligand secretion | 57 | 1.85e-03 | -0.238000 | 4.23e-03 |
SUMOylation of transcription factors | 19 | 7.23e-02 | -0.238000 | 1.04e-01 |
Neurotransmitter receptors and postsynaptic signal transmission | 158 | 2.35e-07 | -0.238000 | 1.35e-06 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 29 | 2.68e-02 | -0.237000 | 4.37e-02 |
Degradation of GLI2 by the proteasome | 57 | 1.96e-03 | -0.237000 | 4.42e-03 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 3.06e-02 | -0.236000 | 4.91e-02 |
Acyl chain remodelling of PG | 12 | 1.58e-01 | -0.235000 | 2.06e-01 |
Sema4D in semaphorin signaling | 24 | 4.61e-02 | -0.235000 | 7.02e-02 |
ER-Phagosome pathway | 87 | 1.51e-04 | -0.235000 | 4.59e-04 |
Cytoprotection by HMOX1 | 118 | 1.08e-05 | -0.234000 | 4.20e-05 |
Regulation of TP53 Activity through Phosphorylation | 91 | 1.11e-04 | -0.234000 | 3.53e-04 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 3.19e-03 | -0.234000 | 6.78e-03 |
Phospholipase C-mediated cascade; FGFR3 | 11 | 1.80e-01 | 0.233000 | 2.32e-01 |
SCF(Skp2)-mediated degradation of p27/p21 | 60 | 1.79e-03 | -0.233000 | 4.13e-03 |
Caspase activation via extrinsic apoptotic signalling pathway | 25 | 4.38e-02 | -0.233000 | 6.74e-02 |
Cytosolic sensors of pathogen-associated DNA | 62 | 1.52e-03 | -0.233000 | 3.62e-03 |
Signaling by FGFR in disease | 59 | 2.00e-03 | -0.232000 | 4.49e-03 |
mRNA Capping | 29 | 3.05e-02 | -0.232000 | 4.89e-02 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 25 | 4.46e-02 | -0.232000 | 6.82e-02 |
Cell Cycle Checkpoints | 260 | 1.11e-10 | -0.232000 | 1.18e-09 |
Phase 0 - rapid depolarisation | 30 | 2.79e-02 | 0.232000 | 4.54e-02 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 4.49e-02 | -0.232000 | 6.86e-02 |
RNA Polymerase III Transcription Initiation | 36 | 1.61e-02 | -0.232000 | 2.79e-02 |
Signaling by NOTCH | 196 | 2.38e-08 | -0.231000 | 1.72e-07 |
Cytosolic iron-sulfur cluster assembly | 13 | 1.49e-01 | 0.231000 | 1.96e-01 |
Assembly and cell surface presentation of NMDA receptors | 25 | 4.61e-02 | -0.230000 | 7.02e-02 |
Cell Cycle | 637 | 2.35e-23 | -0.230000 | 1.20e-21 |
Ubiquitin-dependent degradation of Cyclin D | 50 | 4.84e-03 | -0.230000 | 9.83e-03 |
Regulated Necrosis | 51 | 4.52e-03 | -0.230000 | 9.21e-03 |
Aggrephagy | 21 | 6.84e-02 | -0.230000 | 9.89e-02 |
Glycogen metabolism | 26 | 4.27e-02 | -0.230000 | 6.61e-02 |
Formation of Fibrin Clot (Clotting Cascade) | 27 | 3.89e-02 | -0.230000 | 6.07e-02 |
Presynaptic depolarization and calcium channel opening | 11 | 1.87e-01 | 0.230000 | 2.40e-01 |
Signaling by FGFR | 82 | 3.36e-04 | -0.229000 | 9.57e-04 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 2.30e-04 | -0.228000 | 6.77e-04 |
Formation of the beta-catenin:TCF transactivating complex | 53 | 4.08e-03 | -0.228000 | 8.38e-03 |
Diseases of glycosylation | 131 | 6.64e-06 | -0.228000 | 2.74e-05 |
Regulation of beta-cell development | 31 | 2.86e-02 | -0.227000 | 4.63e-02 |
Regulation of ornithine decarboxylase (ODC) | 49 | 5.99e-03 | -0.227000 | 1.18e-02 |
Disorders of transmembrane transporters | 155 | 1.14e-06 | -0.226000 | 5.55e-06 |
TP53 Regulates Transcription of Caspase Activators and Caspases | 11 | 1.94e-01 | 0.226000 | 2.48e-01 |
Transcriptional regulation by small RNAs | 69 | 1.18e-03 | -0.226000 | 2.89e-03 |
STING mediated induction of host immune responses | 15 | 1.31e-01 | -0.225000 | 1.75e-01 |
Regulation of PLK1 Activity at G2/M Transition | 87 | 3.02e-04 | -0.224000 | 8.72e-04 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 30 | 3.37e-02 | -0.224000 | 5.34e-02 |
GABA receptor activation | 47 | 8.00e-03 | -0.224000 | 1.52e-02 |
Death Receptor Signalling | 138 | 6.00e-06 | -0.223000 | 2.51e-05 |
Vpu mediated degradation of CD4 | 50 | 6.58e-03 | -0.222000 | 1.28e-02 |
Regulation of Apoptosis | 51 | 6.17e-03 | -0.222000 | 1.21e-02 |
G2/M Transition | 181 | 2.69e-07 | -0.221000 | 1.50e-06 |
RIPK1-mediated regulated necrosis | 27 | 4.65e-02 | -0.221000 | 7.07e-02 |
Regulation of necroptotic cell death | 27 | 4.65e-02 | -0.221000 | 7.07e-02 |
Degradation of AXIN | 53 | 5.35e-03 | -0.221000 | 1.07e-02 |
Transcriptional regulation by RUNX1 | 189 | 1.58e-07 | -0.221000 | 9.72e-07 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 8.09e-03 | -0.221000 | 1.53e-02 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 28 | 4.33e-02 | -0.221000 | 6.67e-02 |
Trafficking of AMPA receptors | 28 | 4.33e-02 | -0.221000 | 6.67e-02 |
Mitochondrial biogenesis | 91 | 2.97e-04 | -0.219000 | 8.61e-04 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 1.30e-01 | -0.219000 | 1.74e-01 |
Processive synthesis on the C-strand of the telomere | 19 | 9.88e-02 | -0.219000 | 1.36e-01 |
Formation of TC-NER Pre-Incision Complex | 53 | 5.94e-03 | -0.218000 | 1.17e-02 |
Translesion synthesis by POLI | 17 | 1.20e-01 | -0.218000 | 1.62e-01 |
Signaling by Insulin receptor | 72 | 1.40e-03 | -0.218000 | 3.37e-03 |
PI-3K cascade:FGFR3 | 16 | 1.32e-01 | -0.217000 | 1.76e-01 |
Transport of bile salts and organic acids, metal ions and amine compounds | 62 | 3.18e-03 | -0.217000 | 6.78e-03 |
S Phase | 160 | 2.32e-06 | -0.216000 | 1.04e-05 |
Branched-chain amino acid catabolism | 21 | 8.64e-02 | -0.216000 | 1.21e-01 |
rRNA modification in the nucleus and cytosol | 60 | 3.79e-03 | -0.216000 | 7.89e-03 |
Collagen chain trimerization | 42 | 1.55e-02 | 0.216000 | 2.70e-02 |
Polo-like kinase mediated events | 16 | 1.37e-01 | -0.215000 | 1.82e-01 |
p75 NTR receptor-mediated signalling | 95 | 3.08e-04 | -0.214000 | 8.86e-04 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 1.26e-01 | -0.214000 | 1.70e-01 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 1.26e-01 | -0.214000 | 1.70e-01 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 7.10e-03 | -0.214000 | 1.37e-02 |
Ion transport by P-type ATPases | 49 | 9.79e-03 | -0.213000 | 1.83e-02 |
Cellular response to chemical stress | 148 | 7.82e-06 | -0.213000 | 3.12e-05 |
TRAF6 mediated IRF7 activation | 17 | 1.29e-01 | -0.213000 | 1.73e-01 |
Sensory processing of sound by outer hair cells of the cochlea | 43 | 1.62e-02 | -0.212000 | 2.80e-02 |
Cell recruitment (pro-inflammatory response) | 23 | 7.86e-02 | -0.212000 | 1.12e-01 |
Purinergic signaling in leishmaniasis infection | 23 | 7.86e-02 | -0.212000 | 1.12e-01 |
IRF3-mediated induction of type I IFN | 12 | 2.04e-01 | -0.212000 | 2.58e-01 |
Mitotic G1 phase and G1/S transition | 147 | 9.35e-06 | -0.212000 | 3.72e-05 |
Mitotic G2-G2/M phases | 183 | 7.78e-07 | -0.212000 | 3.93e-06 |
Antigen processing-Cross presentation | 100 | 2.57e-04 | -0.211000 | 7.48e-04 |
Signaling by NOTCH2 | 33 | 3.56e-02 | -0.211000 | 5.59e-02 |
Class C/3 (Metabotropic glutamate/pheromone receptors) | 15 | 1.57e-01 | 0.211000 | 2.05e-01 |
G beta:gamma signalling through BTK | 16 | 1.45e-01 | -0.211000 | 1.90e-01 |
Metalloprotease DUBs | 25 | 6.90e-02 | -0.210000 | 9.97e-02 |
CDT1 association with the CDC6:ORC:origin complex | 57 | 6.13e-03 | -0.210000 | 1.20e-02 |
Transcription of E2F targets under negative control by DREAM complex | 19 | 1.13e-01 | -0.210000 | 1.55e-01 |
The activation of arylsulfatases | 11 | 2.30e-01 | -0.209000 | 2.85e-01 |
Signaling by NOTCH4 | 82 | 1.07e-03 | -0.209000 | 2.65e-03 |
Signaling by FGFR2 | 68 | 2.91e-03 | -0.209000 | 6.27e-03 |
SUMOylation of immune response proteins | 11 | 2.32e-01 | -0.208000 | 2.87e-01 |
TRAF6 mediated NF-kB activation | 23 | 8.44e-02 | -0.208000 | 1.19e-01 |
IRS-mediated signalling | 44 | 1.71e-02 | -0.208000 | 2.94e-02 |
Blood group systems biosynthesis | 19 | 1.17e-01 | -0.208000 | 1.59e-01 |
Signalling to RAS | 20 | 1.08e-01 | -0.207000 | 1.49e-01 |
G0 and Early G1 | 27 | 6.24e-02 | -0.207000 | 9.14e-02 |
G2/M DNA damage checkpoint | 69 | 3.07e-03 | -0.206000 | 6.58e-03 |
Transcriptional regulation of testis differentiation | 11 | 2.37e-01 | -0.206000 | 2.91e-01 |
Developmental Biology | 876 | 2.93e-25 | -0.206000 | 1.61e-23 |
G beta:gamma signalling through PLC beta | 18 | 1.31e-01 | -0.206000 | 1.75e-01 |
Nervous system development | 529 | 5.20e-16 | -0.205000 | 1.22e-14 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 72 | 2.57e-03 | -0.205000 | 5.62e-03 |
PI-3K cascade:FGFR1 | 18 | 1.32e-01 | -0.205000 | 1.76e-01 |
Formation of the cornified envelope | 36 | 3.30e-02 | -0.205000 | 5.26e-02 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 2.12e-03 | -0.205000 | 4.74e-03 |
Nucleotide Excision Repair | 110 | 2.01e-04 | -0.205000 | 5.99e-04 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 1.75e-03 | -0.205000 | 4.07e-03 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 2.09e-04 | 0.204000 | 6.20e-04 |
ERBB2 Activates PTK6 Signaling | 13 | 2.02e-01 | -0.204000 | 2.56e-01 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 6.14e-02 | -0.204000 | 9.04e-02 |
Dual incision in TC-NER | 65 | 4.49e-03 | -0.204000 | 9.19e-03 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 50 | 1.30e-02 | -0.203000 | 2.32e-02 |
p53-Independent DNA Damage Response | 50 | 1.30e-02 | -0.203000 | 2.32e-02 |
p53-Independent G1/S DNA damage checkpoint | 50 | 1.30e-02 | -0.203000 | 2.32e-02 |
Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 1.30e-03 | -0.203000 | 3.16e-03 |
G1/S Transition | 131 | 6.23e-05 | -0.202000 | 2.04e-04 |
Activation of the AP-1 family of transcription factors | 10 | 2.68e-01 | -0.202000 | 3.25e-01 |
G alpha (q) signalling events | 160 | 9.84e-06 | -0.202000 | 3.89e-05 |
IGF1R signaling cascade | 48 | 1.53e-02 | -0.202000 | 2.69e-02 |
Butyrophilin (BTN) family interactions | 10 | 2.68e-01 | 0.202000 | 3.25e-01 |
Regulation of gene expression in beta cells | 14 | 1.91e-01 | -0.202000 | 2.44e-01 |
Inflammasomes | 20 | 1.18e-01 | -0.202000 | 1.60e-01 |
Inositol phosphate metabolism | 46 | 1.79e-02 | -0.202000 | 3.06e-02 |
TNFR1-induced NFkappaB signaling pathway | 26 | 7.72e-02 | -0.200000 | 1.10e-01 |
TNF signaling | 44 | 2.16e-02 | -0.200000 | 3.62e-02 |
Glutathione synthesis and recycling | 12 | 2.31e-01 | 0.200000 | 2.86e-01 |
Degradation of DVL | 55 | 1.05e-02 | -0.199000 | 1.91e-02 |
Cellular responses to stress | 679 | 6.20e-19 | -0.199000 | 2.09e-17 |
Interleukin-2 family signaling | 36 | 3.87e-02 | -0.199000 | 6.04e-02 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 71 | 3.86e-03 | -0.198000 | 8.03e-03 |
Gene Silencing by RNA | 98 | 7.25e-04 | -0.197000 | 1.88e-03 |
Gene expression (Transcription) | 1392 | 1.80e-35 | -0.197000 | 1.91e-33 |
Telomere C-strand (Lagging Strand) Synthesis | 34 | 4.66e-02 | -0.197000 | 7.07e-02 |
L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 3.75e-04 | 0.197000 | 1.05e-03 |
G1/S DNA Damage Checkpoints | 64 | 6.46e-03 | -0.197000 | 1.26e-02 |
Metabolism of polyamines | 57 | 1.04e-02 | -0.196000 | 1.91e-02 |
ABC transporters in lipid homeostasis | 16 | 1.76e-01 | 0.196000 | 2.27e-01 |
Extension of Telomeres | 51 | 1.57e-02 | -0.195000 | 2.73e-02 |
Synthesis of PC | 28 | 7.36e-02 | -0.195000 | 1.06e-01 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 74 | 3.68e-03 | -0.195000 | 7.70e-03 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 16 | 1.77e-01 | -0.195000 | 2.28e-01 |
Glycogen storage diseases | 14 | 2.07e-01 | -0.195000 | 2.61e-01 |
Regulation of insulin secretion | 69 | 5.22e-03 | -0.194000 | 1.05e-02 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 25 | 9.28e-02 | -0.194000 | 1.29e-01 |
IRS-related events triggered by IGF1R | 47 | 2.16e-02 | -0.194000 | 3.62e-02 |
CASP8 activity is inhibited | 10 | 2.90e-01 | -0.193000 | 3.47e-01 |
Dimerization of procaspase-8 | 10 | 2.90e-01 | -0.193000 | 3.47e-01 |
Regulation by c-FLIP | 10 | 2.90e-01 | -0.193000 | 3.47e-01 |
PI3K Cascade | 40 | 3.44e-02 | -0.193000 | 5.45e-02 |
Protein localization | 159 | 2.58e-05 | -0.193000 | 9.37e-05 |
Cellular responses to stimuli | 688 | 5.03e-18 | -0.193000 | 1.52e-16 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 13 | 2.30e-01 | -0.192000 | 2.85e-01 |
O-linked glycosylation | 98 | 1.00e-03 | -0.192000 | 2.50e-03 |
UCH proteinases | 91 | 1.56e-03 | -0.192000 | 3.70e-03 |
SRP-dependent cotranslational protein targeting to membrane | 110 | 5.12e-04 | 0.192000 | 1.38e-03 |
Mismatch Repair | 15 | 1.99e-01 | -0.192000 | 2.53e-01 |
Tight junction interactions | 23 | 1.12e-01 | -0.192000 | 1.53e-01 |
FGFRL1 modulation of FGFR1 signaling | 11 | 2.71e-01 | -0.192000 | 3.28e-01 |
Sensory perception of taste | 27 | 8.54e-02 | 0.191000 | 1.20e-01 |
Cristae formation | 31 | 6.57e-02 | 0.191000 | 9.57e-02 |
Axon guidance | 507 | 1.59e-13 | -0.191000 | 2.88e-12 |
HIV Transcription Initiation | 47 | 2.37e-02 | -0.191000 | 3.91e-02 |
RNA Polymerase II HIV Promoter Escape | 47 | 2.37e-02 | -0.191000 | 3.91e-02 |
RNA Polymerase II Promoter Escape | 47 | 2.37e-02 | -0.191000 | 3.91e-02 |
RNA Polymerase II Transcription Initiation | 47 | 2.37e-02 | -0.191000 | 3.91e-02 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 47 | 2.37e-02 | -0.191000 | 3.91e-02 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 47 | 2.37e-02 | -0.191000 | 3.91e-02 |
Presynaptic function of Kainate receptors | 19 | 1.51e-01 | -0.190000 | 1.97e-01 |
Activated point mutants of FGFR2 | 13 | 2.36e-01 | 0.190000 | 2.90e-01 |
Peptide hormone metabolism | 69 | 6.47e-03 | -0.189000 | 1.26e-02 |
p53-Dependent G1 DNA Damage Response | 62 | 1.01e-02 | -0.189000 | 1.87e-02 |
p53-Dependent G1/S DNA damage checkpoint | 62 | 1.01e-02 | -0.189000 | 1.87e-02 |
Interleukin-10 signaling | 36 | 5.00e-02 | -0.189000 | 7.48e-02 |
ABC transporter disorders | 73 | 5.44e-03 | -0.188000 | 1.08e-02 |
RNA Pol II CTD phosphorylation and interaction with CE | 27 | 9.07e-02 | -0.188000 | 1.27e-01 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 9.07e-02 | -0.188000 | 1.27e-01 |
Long-term potentiation | 22 | 1.27e-01 | -0.188000 | 1.70e-01 |
Resolution of D-Loop Structures | 33 | 6.25e-02 | 0.187000 | 9.15e-02 |
Defective GALNT12 causes CRCS1 | 10 | 3.05e-01 | 0.187000 | 3.62e-01 |
DNA Damage Recognition in GG-NER | 38 | 4.68e-02 | -0.186000 | 7.08e-02 |
Cap-dependent Translation Initiation | 117 | 5.04e-04 | 0.186000 | 1.36e-03 |
Eukaryotic Translation Initiation | 117 | 5.04e-04 | 0.186000 | 1.36e-03 |
Generic Transcription Pathway | 1137 | 2.65e-26 | -0.185000 | 1.57e-24 |
Sensory perception of sweet, bitter, and umami (glutamate) taste | 22 | 1.32e-01 | 0.185000 | 1.76e-01 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 49 | 2.50e-02 | -0.185000 | 4.10e-02 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 22 | 1.34e-01 | -0.184000 | 1.79e-01 |
Transmission across Chemical Synapses | 220 | 2.42e-06 | -0.184000 | 1.09e-05 |
Orc1 removal from chromatin | 69 | 8.23e-03 | -0.184000 | 1.55e-02 |
RNA Polymerase II Transcription | 1256 | 2.75e-28 | -0.184000 | 1.93e-26 |
Hyaluronan metabolism | 14 | 2.34e-01 | -0.184000 | 2.89e-01 |
Processing of SMDT1 | 15 | 2.20e-01 | -0.183000 | 2.75e-01 |
FGFR2 ligand binding and activation | 15 | 2.20e-01 | 0.183000 | 2.75e-01 |
cGMP effects | 14 | 2.37e-01 | -0.183000 | 2.91e-01 |
Transcriptional regulation of granulopoiesis | 52 | 2.28e-02 | -0.182000 | 3.79e-02 |
Glycerophospholipid biosynthesis | 114 | 7.67e-04 | -0.182000 | 1.97e-03 |
Incretin synthesis, secretion, and inactivation | 19 | 1.69e-01 | -0.182000 | 2.19e-01 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 1.21e-02 | -0.181000 | 2.17e-02 |
RNA Polymerase III Transcription Termination | 23 | 1.33e-01 | -0.181000 | 1.77e-01 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 8.80e-04 | 0.181000 | 2.23e-03 |
Nonsense-Mediated Decay (NMD) | 113 | 8.80e-04 | 0.181000 | 2.23e-03 |
Phospholipase C-mediated cascade: FGFR1 | 13 | 2.59e-01 | 0.181000 | 3.15e-01 |
Tryptophan catabolism | 13 | 2.60e-01 | 0.180000 | 3.16e-01 |
G1/S-Specific Transcription | 29 | 9.31e-02 | -0.180000 | 1.30e-01 |
Transport of small molecules | 620 | 1.74e-14 | -0.180000 | 3.74e-13 |
Amino acids regulate mTORC1 | 51 | 2.66e-02 | -0.179000 | 4.34e-02 |
Pre-NOTCH Expression and Processing | 71 | 9.00e-03 | -0.179000 | 1.68e-02 |
Cellular Senescence | 153 | 1.30e-04 | -0.179000 | 4.01e-04 |
HATs acetylate histones | 100 | 1.99e-03 | -0.179000 | 4.47e-03 |
Extracellular matrix organization | 263 | 7.17e-07 | -0.177000 | 3.68e-06 |
APC-Cdc20 mediated degradation of Nek2A | 26 | 1.18e-01 | -0.177000 | 1.60e-01 |
ADORA2B mediated anti-inflammatory cytokines production | 85 | 4.78e-03 | -0.177000 | 9.72e-03 |
NRIF signals cell death from the nucleus | 16 | 2.23e-01 | -0.176000 | 2.79e-01 |
Neurotransmitter release cycle | 48 | 3.50e-02 | -0.176000 | 5.51e-02 |
Amine ligand-binding receptors | 23 | 1.44e-01 | -0.176000 | 1.90e-01 |
Sema4D induced cell migration and growth-cone collapse | 20 | 1.76e-01 | -0.175000 | 2.28e-01 |
RIP-mediated NFkB activation via ZBP1 | 16 | 2.26e-01 | -0.175000 | 2.82e-01 |
Anti-inflammatory response favouring Leishmania parasite infection | 112 | 1.42e-03 | -0.174000 | 3.42e-03 |
Leishmania parasite growth and survival | 112 | 1.42e-03 | -0.174000 | 3.42e-03 |
Protein-protein interactions at synapses | 80 | 7.04e-03 | -0.174000 | 1.36e-02 |
FGFR2c ligand binding and activation | 10 | 3.41e-01 | 0.174000 | 3.99e-01 |
Downstream signaling of activated FGFR3 | 23 | 1.49e-01 | -0.174000 | 1.95e-01 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 3.18e-01 | -0.174000 | 3.75e-01 |
Aspartate and asparagine metabolism | 10 | 3.42e-01 | 0.173000 | 4.00e-01 |
G2/M Checkpoints | 140 | 3.95e-04 | -0.173000 | 1.10e-03 |
Interferon alpha/beta signaling | 58 | 2.25e-02 | -0.173000 | 3.75e-02 |
Activation of Matrix Metalloproteinases | 28 | 1.13e-01 | -0.173000 | 1.54e-01 |
Diseases of metabolism | 218 | 1.12e-05 | -0.172000 | 4.33e-05 |
ZBP1(DAI) mediated induction of type I IFNs | 19 | 1.93e-01 | -0.172000 | 2.47e-01 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 6.59e-02 | -0.172000 | 9.59e-02 |
Negative regulation of NOTCH4 signaling | 54 | 2.86e-02 | -0.172000 | 4.63e-02 |
Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 2.08e-01 | -0.172000 | 2.62e-01 |
Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 3.80e-02 | -0.171000 | 5.95e-02 |
Phosphorylation of CD3 and TCR zeta chains | 17 | 2.24e-01 | -0.170000 | 2.80e-01 |
Nucleotide-like (purinergic) receptors | 11 | 3.31e-01 | 0.169000 | 3.88e-01 |
Prostacyclin signalling through prostacyclin receptor | 17 | 2.27e-01 | -0.169000 | 2.82e-01 |
ABC-family proteins mediated transport | 98 | 3.79e-03 | -0.169000 | 7.89e-03 |
Vif-mediated degradation of APOBEC3G | 52 | 3.49e-02 | -0.169000 | 5.51e-02 |
Processing of Intronless Pre-mRNAs | 19 | 2.05e-01 | -0.168000 | 2.59e-01 |
TICAM1-dependent activation of IRF3/IRF7 | 12 | 3.14e-01 | -0.168000 | 3.70e-01 |
Nuclear signaling by ERBB4 | 29 | 1.18e-01 | -0.168000 | 1.60e-01 |
Interconversion of nucleotide di- and triphosphates | 29 | 1.18e-01 | -0.168000 | 1.60e-01 |
Stabilization of p53 | 53 | 3.60e-02 | -0.166000 | 5.65e-02 |
CDK-mediated phosphorylation and removal of Cdc6 | 71 | 1.55e-02 | -0.166000 | 2.70e-02 |
Metabolism of Angiotensinogen to Angiotensins | 12 | 3.19e-01 | 0.166000 | 3.76e-01 |
Plasma lipoprotein assembly, remodeling, and clearance | 60 | 2.62e-02 | -0.166000 | 4.28e-02 |
Regulation of innate immune responses to cytosolic DNA | 14 | 2.83e-01 | -0.166000 | 3.40e-01 |
Signaling by FGFR2 IIIa TM | 19 | 2.12e-01 | -0.165000 | 2.67e-01 |
p38MAPK events | 13 | 3.05e-01 | -0.164000 | 3.62e-01 |
Post-translational protein phosphorylation | 88 | 7.71e-03 | -0.164000 | 1.47e-02 |
Diseases of programmed cell death | 62 | 2.54e-02 | -0.164000 | 4.17e-02 |
Intrinsic Pathway of Fibrin Clot Formation | 18 | 2.29e-01 | -0.164000 | 2.84e-01 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 1.09e-01 | 0.164000 | 1.49e-01 |
Smooth Muscle Contraction | 31 | 1.15e-01 | -0.163000 | 1.57e-01 |
Dual Incision in GG-NER | 41 | 7.05e-02 | -0.163000 | 1.02e-01 |
Unblocking of NMDA receptors, glutamate binding and activation | 20 | 2.07e-01 | -0.163000 | 2.61e-01 |
Nitric oxide stimulates guanylate cyclase | 18 | 2.31e-01 | -0.163000 | 2.86e-01 |
Collagen degradation | 37 | 8.99e-02 | -0.161000 | 1.26e-01 |
The canonical retinoid cycle in rods (twilight vision) | 20 | 2.15e-01 | 0.160000 | 2.70e-01 |
Post-chaperonin tubulin folding pathway | 20 | 2.16e-01 | -0.160000 | 2.71e-01 |
Neuronal System | 339 | 4.40e-07 | -0.159000 | 2.32e-06 |
Striated Muscle Contraction | 26 | 1.61e-01 | 0.159000 | 2.09e-01 |
AURKA Activation by TPX2 | 72 | 1.99e-02 | -0.159000 | 3.37e-02 |
RMTs methylate histone arginines | 43 | 7.20e-02 | -0.159000 | 1.04e-01 |
Degradation of the extracellular matrix | 97 | 7.10e-03 | -0.158000 | 1.37e-02 |
Plasma lipoprotein clearance | 30 | 1.35e-01 | -0.158000 | 1.79e-01 |
Metabolism of vitamins and cofactors | 171 | 3.71e-04 | -0.158000 | 1.04e-03 |
FGFR3 mutant receptor activation | 10 | 3.89e-01 | 0.157000 | 4.45e-01 |
Signaling by activated point mutants of FGFR3 | 10 | 3.89e-01 | 0.157000 | 4.45e-01 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 72 | 2.13e-02 | -0.157000 | 3.57e-02 |
Glycosphingolipid metabolism | 41 | 8.38e-02 | -0.156000 | 1.18e-01 |
Ras activation upon Ca2+ influx through NMDA receptor | 20 | 2.27e-01 | -0.156000 | 2.82e-01 |
The phototransduction cascade | 26 | 1.69e-01 | -0.156000 | 2.19e-01 |
Cross-presentation of soluble exogenous antigens (endosomes) | 47 | 6.46e-02 | -0.156000 | 9.42e-02 |
Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 13 | 3.35e-01 | 0.154000 | 3.93e-01 |
Sensory processing of sound by inner hair cells of the cochlea | 57 | 4.46e-02 | -0.154000 | 6.82e-02 |
Processing of DNA double-strand break ends | 72 | 2.43e-02 | -0.153000 | 3.99e-02 |
Signaling by Hedgehog | 133 | 2.31e-03 | -0.153000 | 5.12e-03 |
Signaling by FGFR3 in disease | 20 | 2.43e-01 | -0.151000 | 2.97e-01 |
Signaling by FGFR3 point mutants in cancer | 20 | 2.43e-01 | -0.151000 | 2.97e-01 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 89 | 1.40e-02 | -0.151000 | 2.49e-02 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 36 | 1.18e-01 | -0.151000 | 1.60e-01 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 3.32e-01 | -0.150000 | 3.89e-01 |
Senescence-Associated Secretory Phenotype (SASP) | 72 | 2.83e-02 | -0.149000 | 4.59e-02 |
Cellular response to starvation | 150 | 1.71e-03 | 0.148000 | 3.99e-03 |
DNA Repair | 298 | 1.06e-05 | -0.148000 | 4.15e-05 |
Defective GALNT3 causes HFTC | 10 | 4.18e-01 | 0.148000 | 4.74e-01 |
DNA Double-Strand Break Repair | 140 | 2.49e-03 | -0.148000 | 5.47e-03 |
TNFR2 non-canonical NF-kB pathway | 92 | 1.44e-02 | -0.148000 | 2.54e-02 |
Trafficking of GluR2-containing AMPA receptors | 16 | 3.07e-01 | -0.147000 | 3.64e-01 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 2.04e-01 | -0.147000 | 2.58e-01 |
Platelet Adhesion to exposed collagen | 12 | 3.79e-01 | -0.147000 | 4.37e-01 |
Activation of kainate receptors upon glutamate binding | 28 | 1.79e-01 | -0.147000 | 2.31e-01 |
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 4.22e-01 | -0.147000 | 4.77e-01 |
SLC-mediated transmembrane transport | 207 | 3.02e-04 | -0.146000 | 8.73e-04 |
Switching of origins to a post-replicative state | 89 | 1.76e-02 | -0.146000 | 3.02e-02 |
Degradation of cysteine and homocysteine | 12 | 3.85e-01 | 0.145000 | 4.42e-01 |
APC/C:Cdc20 mediated degradation of Securin | 66 | 4.21e-02 | -0.145000 | 6.52e-02 |
Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 4.55e-02 | -0.145000 | 6.94e-02 |
Sensory processing of sound | 62 | 4.96e-02 | -0.144000 | 7.43e-02 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 3.51e-01 | -0.144000 | 4.08e-01 |
Hedgehog ‘off’ state | 96 | 1.50e-02 | -0.144000 | 2.64e-02 |
Termination of O-glycan biosynthesis | 17 | 3.05e-01 | -0.144000 | 3.62e-01 |
Peroxisomal lipid metabolism | 28 | 1.89e-01 | -0.143000 | 2.42e-01 |
Insulin receptor recycling | 24 | 2.24e-01 | -0.143000 | 2.80e-01 |
TP53 Regulates Transcription of DNA Repair Genes | 61 | 5.30e-02 | -0.143000 | 7.89e-02 |
RNA Polymerase III Chain Elongation | 18 | 2.94e-01 | -0.143000 | 3.52e-01 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 2.61e-01 | -0.142000 | 3.16e-01 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 2.61e-01 | -0.142000 | 3.16e-01 |
Pregnenolone biosynthesis | 11 | 4.18e-01 | -0.141000 | 4.74e-01 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 99 | 1.56e-02 | -0.141000 | 2.71e-02 |
Basigin interactions | 23 | 2.44e-01 | -0.140000 | 2.98e-01 |
Inactivation, recovery and regulation of the phototransduction cascade | 25 | 2.25e-01 | -0.140000 | 2.81e-01 |
NR1H2 and NR1H3-mediated signaling | 44 | 1.10e-01 | -0.139000 | 1.50e-01 |
Dectin-2 family | 16 | 3.36e-01 | 0.139000 | 3.93e-01 |
Recycling of bile acids and salts | 13 | 3.86e-01 | 0.139000 | 4.42e-01 |
Downstream signaling of activated FGFR1 | 28 | 2.04e-01 | -0.139000 | 2.58e-01 |
Fatty acid metabolism | 153 | 3.25e-03 | -0.138000 | 6.88e-03 |
Packaging Of Telomere Ends | 25 | 2.34e-01 | -0.138000 | 2.88e-01 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 2.75e-01 | -0.137000 | 3.32e-01 |
Detoxification of Reactive Oxygen Species | 31 | 1.86e-01 | -0.137000 | 2.39e-01 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 4.13e-01 | -0.137000 | 4.69e-01 |
Diseases of hemostasis | 12 | 4.13e-01 | -0.137000 | 4.69e-01 |
Endogenous sterols | 23 | 2.57e-01 | -0.136000 | 3.14e-01 |
Carboxyterminal post-translational modifications of tubulin | 37 | 1.52e-01 | -0.136000 | 1.98e-01 |
PI-3K cascade:FGFR2 | 19 | 3.05e-01 | -0.136000 | 3.62e-01 |
PI-3K cascade:FGFR4 | 17 | 3.32e-01 | -0.136000 | 3.89e-01 |
Dopamine Neurotransmitter Release Cycle | 23 | 2.60e-01 | -0.136000 | 3.16e-01 |
Diseases of mitotic cell cycle | 38 | 1.48e-01 | -0.136000 | 1.94e-01 |
Cell death signalling via NRAGE, NRIF and NADE | 76 | 4.09e-02 | -0.136000 | 6.36e-02 |
Repression of WNT target genes | 14 | 3.80e-01 | -0.135000 | 4.39e-01 |
Methylation | 14 | 3.81e-01 | 0.135000 | 4.39e-01 |
Synthesis of IP2, IP, and Ins in the cytosol | 14 | 3.82e-01 | -0.135000 | 4.40e-01 |
Transcriptional Regulation by E2F6 | 34 | 1.74e-01 | -0.135000 | 2.25e-01 |
Neurexins and neuroligins | 51 | 9.61e-02 | -0.135000 | 1.33e-01 |
Pre-NOTCH Transcription and Translation | 55 | 8.51e-02 | -0.134000 | 1.19e-01 |
Hedgehog ‘on’ state | 84 | 3.35e-02 | -0.134000 | 5.33e-02 |
Complement cascade | 36 | 1.65e-01 | 0.134000 | 2.14e-01 |
TP53 Regulates Transcription of Cell Death Genes | 43 | 1.29e-01 | -0.134000 | 1.73e-01 |
TRP channels | 20 | 3.01e-01 | 0.134000 | 3.58e-01 |
Chromosome Maintenance | 110 | 1.58e-02 | -0.133000 | 2.74e-02 |
Oxidative Stress Induced Senescence | 83 | 3.65e-02 | -0.133000 | 5.72e-02 |
Loss of Nlp from mitotic centrosomes | 69 | 5.68e-02 | -0.133000 | 8.42e-02 |
Loss of proteins required for interphase microtubule organization from the centrosome | 69 | 5.68e-02 | -0.133000 | 8.42e-02 |
GPCR downstream signalling | 434 | 2.23e-06 | -0.132000 | 1.01e-05 |
Base Excision Repair | 64 | 6.75e-02 | -0.132000 | 9.79e-02 |
Organelle biogenesis and maintenance | 272 | 1.96e-04 | -0.131000 | 5.87e-04 |
FGFR2 alternative splicing | 26 | 2.49e-01 | -0.131000 | 3.03e-01 |
Regulation of TLR by endogenous ligand | 15 | 3.83e-01 | 0.130000 | 4.41e-01 |
Gluconeogenesis | 29 | 2.28e-01 | -0.129000 | 2.83e-01 |
Regulation of TNFR1 signaling | 35 | 1.87e-01 | -0.129000 | 2.40e-01 |
G alpha (s) signalling events | 96 | 2.92e-02 | -0.129000 | 4.70e-02 |
Signaling by GPCR | 490 | 1.11e-06 | -0.128000 | 5.43e-06 |
DSCAM interactions | 10 | 4.84e-01 | -0.128000 | 5.37e-01 |
Meiotic synapsis | 50 | 1.18e-01 | -0.128000 | 1.60e-01 |
Fanconi Anemia Pathway | 36 | 1.85e-01 | 0.128000 | 2.38e-01 |
DNA Damage/Telomere Stress Induced Senescence | 52 | 1.12e-01 | -0.127000 | 1.53e-01 |
Early Phase of HIV Life Cycle | 13 | 4.29e-01 | -0.127000 | 4.83e-01 |
Transcriptional regulation of pluripotent stem cells | 31 | 2.24e-01 | -0.126000 | 2.80e-01 |
Acyl chain remodelling of PS | 17 | 3.69e-01 | -0.126000 | 4.26e-01 |
Visual phototransduction | 74 | 6.10e-02 | -0.126000 | 9.00e-02 |
NCAM signaling for neurite out-growth | 56 | 1.04e-01 | -0.126000 | 1.43e-01 |
Epigenetic regulation of gene expression | 110 | 2.28e-02 | -0.126000 | 3.79e-02 |
G alpha (i) signalling events | 204 | 2.06e-03 | -0.125000 | 4.62e-03 |
The citric acid (TCA) cycle and respiratory electron transport | 174 | 4.52e-03 | 0.125000 | 9.21e-03 |
Signaling by FGFR2 in disease | 39 | 1.79e-01 | -0.124000 | 2.31e-01 |
Transport of Mature Transcript to Cytoplasm | 82 | 5.30e-02 | -0.124000 | 7.89e-02 |
RNA Polymerase I Transcription Initiation | 47 | 1.43e-01 | -0.123000 | 1.89e-01 |
Surfactant metabolism | 21 | 3.28e-01 | -0.123000 | 3.86e-01 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 38 | 1.93e-01 | -0.122000 | 2.46e-01 |
Mitochondrial translation initiation | 90 | 4.80e-02 | 0.121000 | 7.20e-02 |
Condensation of Prophase Chromosomes | 35 | 2.18e-01 | -0.120000 | 2.73e-01 |
Metabolism | 1899 | 2.72e-18 | -0.120000 | 8.42e-17 |
Synthesis, secretion, and deacylation of Ghrelin | 13 | 4.55e-01 | -0.120000 | 5.10e-01 |
rRNA processing | 214 | 2.54e-03 | 0.120000 | 5.55e-03 |
Heme degradation | 11 | 4.93e-01 | -0.119000 | 5.45e-01 |
Downstream signaling of activated FGFR2 | 26 | 2.92e-01 | -0.119000 | 3.50e-01 |
Olfactory Signaling Pathway | 24 | 3.13e-01 | 0.119000 | 3.70e-01 |
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 13 | 4.59e-01 | 0.119000 | 5.14e-01 |
Resolution of Abasic Sites (AP sites) | 38 | 2.06e-01 | -0.119000 | 2.61e-01 |
Downstream signaling of activated FGFR4 | 24 | 3.17e-01 | -0.118000 | 3.74e-01 |
FCGR activation | 10 | 5.20e-01 | -0.117000 | 5.70e-01 |
Glucagon-type ligand receptors | 25 | 3.10e-01 | -0.117000 | 3.66e-01 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 73 | 8.37e-02 | -0.117000 | 1.18e-01 |
MicroRNA (miRNA) biogenesis | 24 | 3.22e-01 | -0.117000 | 3.79e-01 |
PD-1 signaling | 18 | 3.91e-01 | -0.117000 | 4.47e-01 |
Cleavage of the damaged pyrimidine | 34 | 2.40e-01 | -0.116000 | 2.94e-01 |
Depyrimidination | 34 | 2.40e-01 | -0.116000 | 2.94e-01 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 34 | 2.40e-01 | -0.116000 | 2.94e-01 |
Mitochondrial iron-sulfur cluster biogenesis | 13 | 4.68e-01 | -0.116000 | 5.21e-01 |
Interleukin-2 signaling | 10 | 5.28e-01 | -0.115000 | 5.78e-01 |
Interleukin-37 signaling | 21 | 3.62e-01 | -0.115000 | 4.19e-01 |
Intraflagellar transport | 39 | 2.15e-01 | 0.115000 | 2.70e-01 |
Synthesis of DNA | 118 | 3.12e-02 | -0.115000 | 4.98e-02 |
Metabolism of water-soluble vitamins and cofactors | 117 | 3.23e-02 | -0.115000 | 5.15e-02 |
Mitochondrial translation termination | 90 | 6.18e-02 | 0.114000 | 9.08e-02 |
Processing of Capped Intron-Containing Pre-mRNA | 239 | 2.47e-03 | -0.114000 | 5.45e-03 |
Recruitment of NuMA to mitotic centrosomes | 80 | 7.95e-02 | -0.113000 | 1.13e-01 |
ATF4 activates genes in response to endoplasmic reticulum stress | 27 | 3.08e-01 | 0.113000 | 3.65e-01 |
Regulation of expression of SLITs and ROBOs | 166 | 1.18e-02 | 0.113000 | 2.13e-02 |
Phase II - Conjugation of compounds | 78 | 8.46e-02 | 0.113000 | 1.19e-01 |
FRS-mediated FGFR3 signaling | 18 | 4.08e-01 | -0.113000 | 4.65e-01 |
FRS-mediated FGFR1 signaling | 20 | 3.85e-01 | -0.112000 | 4.42e-01 |
Cleavage of the damaged purine | 29 | 2.97e-01 | -0.112000 | 3.54e-01 |
Depurination | 29 | 2.97e-01 | -0.112000 | 3.54e-01 |
Recognition and association of DNA glycosylase with site containing an affected purine | 29 | 2.97e-01 | -0.112000 | 3.54e-01 |
Metabolism of nucleotides | 90 | 6.71e-02 | -0.112000 | 9.73e-02 |
Biotin transport and metabolism | 11 | 5.22e-01 | -0.112000 | 5.72e-01 |
Deposition of new CENPA-containing nucleosomes at the centromere | 45 | 1.97e-01 | -0.111000 | 2.51e-01 |
Nucleosome assembly | 45 | 1.97e-01 | -0.111000 | 2.51e-01 |
Glutamate Neurotransmitter Release Cycle | 24 | 3.47e-01 | -0.111000 | 4.05e-01 |
Activation of HOX genes during differentiation | 82 | 8.31e-02 | -0.111000 | 1.18e-01 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 82 | 8.31e-02 | -0.111000 | 1.18e-01 |
Leading Strand Synthesis | 14 | 4.74e-01 | -0.111000 | 5.26e-01 |
Polymerase switching | 14 | 4.74e-01 | -0.111000 | 5.26e-01 |
Mitochondrial translation elongation | 90 | 6.98e-02 | 0.111000 | 1.01e-01 |
APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 3.50e-01 | -0.110000 | 4.08e-01 |
Transferrin endocytosis and recycling | 30 | 3.01e-01 | -0.109000 | 3.58e-01 |
Influenza Viral RNA Transcription and Replication | 134 | 2.94e-02 | 0.109000 | 4.73e-02 |
Telomere Maintenance | 85 | 8.26e-02 | -0.109000 | 1.17e-01 |
MyD88 deficiency (TLR2/4) | 15 | 4.73e-01 | 0.107000 | 5.26e-01 |
Lagging Strand Synthesis | 20 | 4.09e-01 | -0.107000 | 4.66e-01 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 2.70e-01 | -0.106000 | 3.27e-01 |
G alpha (12/13) signalling events | 77 | 1.08e-01 | -0.106000 | 1.48e-01 |
CS/DS degradation | 14 | 4.96e-01 | -0.105000 | 5.48e-01 |
HDR through Single Strand Annealing (SSA) | 37 | 2.69e-01 | -0.105000 | 3.25e-01 |
Regulation of TP53 Activity through Association with Co-factors | 13 | 5.12e-01 | -0.105000 | 5.63e-01 |
IRAK4 deficiency (TLR2/4) | 16 | 4.67e-01 | 0.105000 | 5.21e-01 |
Fertilization | 18 | 4.41e-01 | 0.105000 | 4.96e-01 |
SUMOylation of DNA methylation proteins | 16 | 4.69e-01 | -0.105000 | 5.22e-01 |
Assembly of the pre-replicative complex | 91 | 8.46e-02 | -0.105000 | 1.19e-01 |
Positive epigenetic regulation of rRNA expression | 68 | 1.37e-01 | -0.104000 | 1.82e-01 |
Synthesis of PE | 12 | 5.36e-01 | -0.103000 | 5.85e-01 |
TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 5.54e-01 | -0.103000 | 6.01e-01 |
Hyaluronan uptake and degradation | 10 | 5.73e-01 | -0.103000 | 6.19e-01 |
Phosphorylation of the APC/C | 20 | 4.28e-01 | -0.102000 | 4.83e-01 |
RNA Polymerase I Promoter Opening | 25 | 3.76e-01 | 0.102000 | 4.34e-01 |
Phase 4 - resting membrane potential | 16 | 4.79e-01 | -0.102000 | 5.32e-01 |
LGI-ADAM interactions | 12 | 5.44e-01 | 0.101000 | 5.93e-01 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 4.48e-01 | -0.100000 | 5.04e-01 |
DNA Replication Pre-Initiation | 108 | 7.13e-02 | -0.100000 | 1.03e-01 |
RNA Polymerase I Transcription Termination | 30 | 3.41e-01 | -0.100000 | 3.99e-01 |
Class B/2 (Secretin family receptors) | 73 | 1.40e-01 | -0.099800 | 1.85e-01 |
Response of EIF2AK1 (HRI) to heme deficiency | 15 | 5.04e-01 | -0.099700 | 5.55e-01 |
mRNA 3’-end processing | 57 | 1.97e-01 | 0.098700 | 2.51e-01 |
Biosynthesis of DHA-derived SPMs | 14 | 5.23e-01 | 0.098700 | 5.72e-01 |
Mitochondrial translation | 96 | 9.66e-02 | 0.098100 | 1.34e-01 |
Plasma lipoprotein remodeling | 26 | 3.88e-01 | -0.097800 | 4.45e-01 |
Signaling by Retinoic Acid | 38 | 2.98e-01 | -0.097600 | 3.55e-01 |
Formation of the ternary complex, and subsequently, the 43S complex | 50 | 2.33e-01 | 0.097500 | 2.88e-01 |
Removal of the Flap Intermediate | 14 | 5.29e-01 | -0.097300 | 5.78e-01 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 57 | 2.09e-01 | -0.096200 | 2.63e-01 |
Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 2.62e-02 | 0.096000 | 4.28e-02 |
Ion channel transport | 156 | 3.88e-02 | -0.095800 | 6.06e-02 |
RNA Polymerase II Transcription Termination | 66 | 1.78e-01 | 0.095700 | 2.30e-01 |
Centrosome maturation | 81 | 1.38e-01 | -0.095300 | 1.83e-01 |
Recruitment of mitotic centrosome proteins and complexes | 81 | 1.38e-01 | -0.095300 | 1.83e-01 |
Keratinization | 64 | 1.90e-01 | -0.094700 | 2.43e-01 |
Adrenaline,noradrenaline inhibits insulin secretion | 26 | 4.06e-01 | -0.094100 | 4.63e-01 |
Nucleotide salvage | 21 | 4.56e-01 | -0.094000 | 5.11e-01 |
Meiosis | 76 | 1.60e-01 | -0.093300 | 2.08e-01 |
Metabolism of RNA | 678 | 3.35e-05 | -0.093200 | 1.20e-04 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 5.47e-01 | -0.093000 | 5.95e-01 |
Inhibition of DNA recombination at telomere | 40 | 3.14e-01 | -0.092000 | 3.70e-01 |
NRAGE signals death through JNK | 59 | 2.25e-01 | -0.091300 | 2.80e-01 |
Plasma lipoprotein assembly | 13 | 5.69e-01 | 0.091300 | 6.15e-01 |
Mucopolysaccharidoses | 11 | 6.01e-01 | 0.091200 | 6.48e-01 |
Biological oxidations | 161 | 4.67e-02 | 0.090800 | 7.08e-02 |
Synthesis of bile acids and bile salts | 31 | 3.82e-01 | -0.090700 | 4.40e-01 |
SHC-mediated cascade:FGFR1 | 18 | 5.07e-01 | -0.090300 | 5.59e-01 |
Base-Excision Repair, AP Site Formation | 36 | 3.51e-01 | -0.089800 | 4.08e-01 |
Processing of Capped Intronless Pre-mRNA | 28 | 4.13e-01 | -0.089400 | 4.69e-01 |
DNA methylation | 27 | 4.25e-01 | 0.088700 | 4.79e-01 |
SHC-mediated cascade:FGFR3 | 16 | 5.42e-01 | -0.088000 | 5.91e-01 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 6.15e-01 | -0.087600 | 6.61e-01 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 4.98e-01 | -0.087500 | 5.50e-01 |
KSRP (KHSRP) binds and destabilizes mRNA | 17 | 5.35e-01 | 0.086800 | 5.85e-01 |
Regulation of Complement cascade | 29 | 4.18e-01 | 0.086800 | 4.74e-01 |
HDACs deacetylate histones | 53 | 2.77e-01 | -0.086400 | 3.33e-01 |
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | 10 | 6.37e-01 | -0.086100 | 6.83e-01 |
Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 3.54e-01 | -0.085800 | 4.10e-01 |
Lysine catabolism | 12 | 6.08e-01 | 0.085600 | 6.55e-01 |
Cilium Assembly | 181 | 4.68e-02 | -0.085600 | 7.08e-02 |
Assembly of collagen fibrils and other multimeric structures | 53 | 2.82e-01 | 0.085300 | 3.40e-01 |
Chemokine receptors bind chemokines | 28 | 4.35e-01 | 0.085200 | 4.90e-01 |
Assembly of the ORC complex at the origin of replication | 31 | 4.14e-01 | -0.084700 | 4.70e-01 |
Post-translational modification: synthesis of GPI-anchored proteins | 67 | 2.31e-01 | -0.084600 | 2.86e-01 |
Defective C1GALT1C1 causes TNPS | 11 | 6.27e-01 | 0.084600 | 6.73e-01 |
Activation of G protein gated Potassium channels | 25 | 4.66e-01 | -0.084300 | 5.20e-01 |
G protein gated Potassium channels | 25 | 4.66e-01 | -0.084300 | 5.20e-01 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 25 | 4.66e-01 | -0.084300 | 5.20e-01 |
Pyrimidine salvage | 10 | 6.46e-01 | 0.084000 | 6.91e-01 |
Collagen biosynthesis and modifying enzymes | 64 | 2.46e-01 | 0.083900 | 3.00e-01 |
Cardiac conduction | 113 | 1.26e-01 | -0.083400 | 1.69e-01 |
Activation of the pre-replicative complex | 33 | 4.09e-01 | -0.083100 | 4.66e-01 |
Activation of ATR in response to replication stress | 37 | 3.86e-01 | -0.082400 | 4.42e-01 |
ROS and RNS production in phagocytes | 32 | 4.20e-01 | -0.082400 | 4.75e-01 |
Metabolism of steroid hormones | 29 | 4.50e-01 | -0.080900 | 5.06e-01 |
Serotonin Neurotransmitter Release Cycle | 18 | 5.57e-01 | -0.079900 | 6.04e-01 |
Other interleukin signaling | 23 | 5.10e-01 | -0.079400 | 5.61e-01 |
Homologous DNA Pairing and Strand Exchange | 42 | 3.77e-01 | -0.078800 | 4.35e-01 |
Mitochondrial protein import | 64 | 2.76e-01 | -0.078700 | 3.33e-01 |
Amyloid fiber formation | 60 | 2.92e-01 | -0.078600 | 3.50e-01 |
Sulfur amino acid metabolism | 26 | 4.89e-01 | 0.078300 | 5.41e-01 |
mitochondrial fatty acid beta-oxidation of saturated fatty acids | 10 | 6.68e-01 | -0.078300 | 7.14e-01 |
Metabolism of cofactors | 19 | 5.55e-01 | -0.078200 | 6.02e-01 |
DNA Replication | 151 | 1.01e-01 | -0.077300 | 1.39e-01 |
Glycogen breakdown (glycogenolysis) | 15 | 6.11e-01 | -0.075800 | 6.57e-01 |
rRNA processing in the nucleus and cytosol | 190 | 7.42e-02 | 0.075000 | 1.06e-01 |
FGFR1c ligand binding and activation | 10 | 6.82e-01 | 0.074700 | 7.26e-01 |
Maturation of nucleoprotein | 11 | 6.75e-01 | -0.073100 | 7.20e-01 |
mRNA Splicing - Major Pathway | 179 | 9.23e-02 | -0.072900 | 1.29e-01 |
Metabolism of porphyrins | 22 | 5.67e-01 | -0.070500 | 6.13e-01 |
Integrin cell surface interactions | 59 | 3.51e-01 | -0.070200 | 4.08e-01 |
NCAM1 interactions | 36 | 4.67e-01 | 0.070000 | 5.21e-01 |
Synthesis of IP3 and IP4 in the cytosol | 25 | 5.46e-01 | -0.069700 | 5.94e-01 |
Homology Directed Repair | 111 | 2.06e-01 | -0.069400 | 2.61e-01 |
Anchoring of the basal body to the plasma membrane | 97 | 2.46e-01 | -0.068200 | 3.00e-01 |
Nucleotide catabolism | 31 | 5.15e-01 | 0.067500 | 5.66e-01 |
Diseases of carbohydrate metabolism | 31 | 5.17e-01 | -0.067300 | 5.67e-01 |
B-WICH complex positively regulates rRNA expression | 53 | 3.98e-01 | -0.067100 | 4.54e-01 |
Termination of translesion DNA synthesis | 32 | 5.13e-01 | -0.066800 | 5.64e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 6.35e-01 | -0.066500 | 6.81e-01 |
Generation of second messenger molecules | 28 | 5.45e-01 | -0.066000 | 5.94e-01 |
CDC6 association with the ORC:origin complex | 11 | 7.08e-01 | 0.065300 | 7.48e-01 |
FGFR3 ligand binding and activation | 11 | 7.10e-01 | 0.064700 | 7.49e-01 |
FGFR3c ligand binding and activation | 11 | 7.10e-01 | 0.064700 | 7.49e-01 |
mRNA Splicing - Minor Pathway | 52 | 4.23e-01 | 0.064300 | 4.77e-01 |
Muscle contraction | 164 | 1.58e-01 | -0.063900 | 2.05e-01 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 94 | 2.84e-01 | -0.063800 | 3.42e-01 |
RNA Polymerase I Promoter Clearance | 72 | 3.50e-01 | -0.063700 | 4.08e-01 |
RNA Polymerase I Transcription | 72 | 3.50e-01 | -0.063700 | 4.08e-01 |
FGFR1 ligand binding and activation | 13 | 6.93e-01 | 0.063200 | 7.35e-01 |
Metabolism of amino acids and derivatives | 344 | 4.42e-02 | 0.063000 | 6.78e-02 |
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 6.53e-01 | -0.063000 | 6.99e-01 |
Negative epigenetic regulation of rRNA expression | 71 | 3.68e-01 | -0.061700 | 4.26e-01 |
TNFs bind their physiological receptors | 23 | 6.11e-01 | 0.061300 | 6.57e-01 |
Mitochondrial Fatty Acid Beta-Oxidation | 35 | 5.37e-01 | 0.060200 | 5.86e-01 |
mRNA Splicing | 187 | 1.56e-01 | -0.060100 | 2.04e-01 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 15 | 6.91e-01 | 0.059400 | 7.33e-01 |
Purine catabolism | 17 | 6.75e-01 | 0.058700 | 7.20e-01 |
Nicotinamide salvaging | 18 | 6.76e-01 | 0.057000 | 7.20e-01 |
Transcriptional Regulation by VENTX | 38 | 5.52e-01 | -0.055700 | 6.00e-01 |
Reproduction | 94 | 3.54e-01 | -0.055300 | 4.10e-01 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 38 | 5.59e-01 | -0.054800 | 6.05e-01 |
Biosynthesis of specialized proresolving mediators (SPMs) | 15 | 7.13e-01 | 0.054800 | 7.52e-01 |
Acetylcholine binding and downstream events | 10 | 7.66e-01 | 0.054400 | 8.01e-01 |
Postsynaptic nicotinic acetylcholine receptors | 10 | 7.66e-01 | 0.054400 | 8.01e-01 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 105 | 3.39e-01 | -0.054000 | 3.96e-01 |
FRS-mediated FGFR2 signaling | 21 | 6.69e-01 | -0.053900 | 7.15e-01 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 6.86e-01 | -0.052100 | 7.30e-01 |
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 21 | 6.97e-01 | -0.049100 | 7.38e-01 |
Defective B3GALTL causes PpS | 37 | 6.10e-01 | 0.048500 | 6.57e-01 |
Phase I - Functionalization of compounds | 79 | 4.56e-01 | 0.048500 | 5.11e-01 |
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 7.63e-01 | -0.048400 | 7.99e-01 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 7.31e-01 | -0.048200 | 7.68e-01 |
Potassium Channels | 86 | 4.46e-01 | -0.047500 | 5.02e-01 |
Caspase activation via Death Receptors in the presence of ligand | 15 | 7.52e-01 | -0.047100 | 7.89e-01 |
Sensory Perception | 182 | 2.75e-01 | -0.046800 | 3.32e-01 |
FRS-mediated FGFR4 signaling | 19 | 7.33e-01 | -0.045200 | 7.70e-01 |
Xenobiotics | 14 | 7.71e-01 | 0.044900 | 8.06e-01 |
SIRT1 negatively regulates rRNA expression | 30 | 6.73e-01 | -0.044500 | 7.19e-01 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 87 | 4.86e-01 | -0.043200 | 5.39e-01 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 7.04e-01 | 0.043100 | 7.44e-01 |
Phenylalanine and tyrosine metabolism | 10 | 8.16e-01 | 0.042400 | 8.42e-01 |
PERK regulates gene expression | 32 | 6.87e-01 | -0.041200 | 7.30e-01 |
Norepinephrine Neurotransmitter Release Cycle | 17 | 7.71e-01 | -0.040800 | 8.06e-01 |
Beta-oxidation of very long chain fatty acids | 11 | 8.15e-01 | 0.040800 | 8.42e-01 |
Activation of Ca-permeable Kainate Receptor | 10 | 8.26e-01 | -0.040100 | 8.51e-01 |
Ionotropic activity of kainate receptors | 10 | 8.26e-01 | -0.040100 | 8.51e-01 |
Binding and Uptake of Ligands by Scavenger Receptors | 33 | 6.92e-01 | -0.039900 | 7.34e-01 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 27 | 7.23e-01 | -0.039400 | 7.61e-01 |
Diseases of DNA repair | 34 | 6.95e-01 | -0.038900 | 7.36e-01 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 16 | 7.90e-01 | -0.038400 | 8.21e-01 |
Apoptosis induced DNA fragmentation | 12 | 8.18e-01 | -0.038300 | 8.44e-01 |
NoRC negatively regulates rRNA expression | 68 | 5.87e-01 | -0.038000 | 6.34e-01 |
Stimuli-sensing channels | 86 | 5.64e-01 | -0.036000 | 6.10e-01 |
O-glycosylation of TSR domain-containing proteins | 38 | 7.19e-01 | 0.033700 | 7.57e-01 |
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function | 24 | 7.80e-01 | -0.032900 | 8.12e-01 |
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function | 24 | 7.80e-01 | -0.032900 | 8.12e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 24 | 7.80e-01 | -0.032900 | 8.12e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 24 | 7.80e-01 | -0.032900 | 8.12e-01 |
Diseases of DNA Double-Strand Break Repair | 24 | 7.80e-01 | -0.032900 | 8.12e-01 |
Voltage gated Potassium channels | 34 | 7.40e-01 | -0.032900 | 7.77e-01 |
RNA Polymerase I Promoter Escape | 53 | 6.82e-01 | -0.032500 | 7.26e-01 |
PIWI-interacting RNA (piRNA) biogenesis | 26 | 7.83e-01 | 0.031200 | 8.14e-01 |
Acyl chain remodelling of PC | 21 | 8.06e-01 | 0.030900 | 8.35e-01 |
Nicotinate metabolism | 29 | 7.80e-01 | 0.030000 | 8.12e-01 |
Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 13 | 8.62e-01 | -0.027900 | 8.83e-01 |
Signaling by ROBO receptors | 211 | 4.86e-01 | -0.027800 | 5.39e-01 |
Processive synthesis on the lagging strand | 15 | 8.54e-01 | -0.027400 | 8.76e-01 |
SHC-mediated cascade:FGFR2 | 19 | 8.38e-01 | -0.027000 | 8.62e-01 |
Diseases associated with the TLR signaling cascade | 28 | 8.10e-01 | -0.026300 | 8.37e-01 |
Diseases of Immune System | 28 | 8.10e-01 | -0.026300 | 8.37e-01 |
DNA strand elongation | 32 | 8.02e-01 | 0.025500 | 8.32e-01 |
Defective pyroptosis | 35 | 8.02e-01 | -0.024500 | 8.32e-01 |
GPCR ligand binding | 276 | 4.88e-01 | -0.024200 | 5.40e-01 |
Antimicrobial peptides | 26 | 8.34e-01 | 0.023700 | 8.58e-01 |
Interaction between L1 and Ankyrins | 26 | 8.37e-01 | 0.023300 | 8.61e-01 |
Influenza Infection | 154 | 6.24e-01 | 0.022800 | 6.71e-01 |
Cytochrome P450 - arranged by substrate type | 47 | 8.04e-01 | -0.020900 | 8.33e-01 |
Translation initiation complex formation | 57 | 7.87e-01 | -0.020700 | 8.18e-01 |
Metabolism of folate and pterines | 16 | 8.89e-01 | 0.020100 | 9.09e-01 |
Eicosanoid ligand-binding receptors | 13 | 9.00e-01 | 0.020100 | 9.19e-01 |
PRC2 methylates histones and DNA | 35 | 8.40e-01 | -0.019800 | 8.62e-01 |
tRNA processing | 124 | 7.05e-01 | -0.019700 | 7.45e-01 |
Ribosomal scanning and start codon recognition | 57 | 8.04e-01 | -0.019000 | 8.33e-01 |
Trafficking and processing of endosomal TLR | 11 | 9.15e-01 | 0.018600 | 9.32e-01 |
tRNA modification in the nucleus and cytosol | 43 | 8.40e-01 | -0.017800 | 8.62e-01 |
Cytosolic sulfonation of small molecules | 22 | 8.90e-01 | -0.017000 | 9.10e-01 |
Translocation of ZAP-70 to Immunological synapse | 14 | 9.18e-01 | 0.015900 | 9.33e-01 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 14 | 9.21e-01 | -0.015400 | 9.35e-01 |
Vitamin B5 (pantothenate) metabolism | 16 | 9.16e-01 | -0.015200 | 9.32e-01 |
Class A/1 (Rhodopsin-like receptors) | 189 | 7.20e-01 | -0.015100 | 7.58e-01 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 9.36e-01 | -0.014600 | 9.47e-01 |
Scavenging by Class A Receptors | 18 | 9.16e-01 | -0.014400 | 9.32e-01 |
SHC-mediated cascade:FGFR4 | 17 | 9.19e-01 | -0.014200 | 9.34e-01 |
Amino acid transport across the plasma membrane | 30 | 9.02e-01 | 0.013000 | 9.20e-01 |
Meiotic recombination | 46 | 8.85e-01 | 0.012300 | 9.06e-01 |
Cellular hexose transport | 18 | 9.31e-01 | -0.011800 | 9.44e-01 |
Heme biosynthesis | 13 | 9.43e-01 | 0.011400 | 9.53e-01 |
RA biosynthesis pathway | 18 | 9.35e-01 | -0.011100 | 9.46e-01 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 13 | 9.50e-01 | -0.010100 | 9.59e-01 |
Acyl chain remodelling of PI | 12 | 9.55e-01 | 0.009380 | 9.62e-01 |
Peptide ligand-binding receptors | 108 | 8.71e-01 | 0.009020 | 8.92e-01 |
FGFR2 mutant receptor activation | 29 | 9.35e-01 | -0.008810 | 9.46e-01 |
HDR through Homologous Recombination (HRR) | 66 | 9.02e-01 | 0.008790 | 9.20e-01 |
Diseases associated with O-glycosylation of proteins | 61 | 9.15e-01 | -0.007930 | 9.32e-01 |
Inwardly rectifying K+ channels | 31 | 9.40e-01 | -0.007820 | 9.50e-01 |
Acyl chain remodelling of PE | 21 | 9.56e-01 | -0.006990 | 9.62e-01 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 58 | 9.29e-01 | -0.006810 | 9.42e-01 |
Metabolic disorders of biological oxidation enzymes | 29 | 9.53e-01 | 0.006320 | 9.61e-01 |
Killing mechanisms | 12 | 9.81e-01 | -0.004030 | 9.83e-01 |
WNT5:FZD7-mediated leishmania damping | 12 | 9.81e-01 | -0.004030 | 9.83e-01 |
Collagen formation | 85 | 9.50e-01 | 0.003920 | 9.59e-01 |
Regulation of TP53 Activity through Methylation | 19 | 9.77e-01 | 0.003860 | 9.82e-01 |
Acetylcholine Neurotransmitter Release Cycle | 16 | 9.80e-01 | -0.003610 | 9.83e-01 |
Activation of SMO | 18 | 9.80e-01 | -0.003450 | 9.83e-01 |
GABA synthesis, release, reuptake and degradation | 18 | 9.84e-01 | -0.002730 | 9.85e-01 |
Arachidonic acid metabolism | 42 | 9.79e-01 | -0.002380 | 9.83e-01 |
Translation | 293 | 9.54e-01 | 0.001960 | 9.61e-01 |
Bile acid and bile salt metabolism | 38 | 9.92e-01 | -0.000927 | 9.93e-01 |
Na+/Cl- dependent neurotransmitter transporters | 11 | 9.99e-01 | -0.000231 | 9.99e-01 |
CLEC7A (Dectin-1) induces NFAT activation
137 | |
---|---|
set | CLEC7A (Dectin-1) induces NFAT activation |
setSize | 11 |
pANOVA | 1.73e-06 |
s.dist | -0.833 |
p.adjustANOVA | 8.11e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ITPR1 | -11274 |
NFATC3 | -10658 |
PPP3R1 | -10428 |
NFATC1 | -10216 |
AHCYL1 | -10203 |
CALM1 | -9971 |
ITPR2 | -9789 |
PPP3CB | -8357 |
NFATC2 | -6641 |
ITPR3 | -6102 |
PPP3CA | -5776 |
GeneID | Gene Rank |
---|---|
ITPR1 | -11274 |
NFATC3 | -10658 |
PPP3R1 | -10428 |
NFATC1 | -10216 |
AHCYL1 | -10203 |
CALM1 | -9971 |
ITPR2 | -9789 |
PPP3CB | -8357 |
NFATC2 | -6641 |
ITPR3 | -6102 |
PPP3CA | -5776 |
Establishment of Sister Chromatid Cohesion
375 | |
---|---|
set | Establishment of Sister Chromatid Cohesion |
setSize | 11 |
pANOVA | 2.26e-06 |
s.dist | -0.823 |
p.adjustANOVA | 1.02e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
WAPL | -10923 |
SMC1A | -10584 |
ESCO1 | -10444 |
RAD21 | -10425 |
PDS5A | -10262 |
STAG2 | -10205 |
PDS5B | -8616 |
CDCA5 | -7392 |
SMC3 | -7292 |
ESCO2 | -6117 |
STAG1 | -5772 |
GeneID | Gene Rank |
---|---|
WAPL | -10923 |
SMC1A | -10584 |
ESCO1 | -10444 |
RAD21 | -10425 |
PDS5A | -10262 |
STAG2 | -10205 |
PDS5B | -8616 |
CDCA5 | -7392 |
SMC3 | -7292 |
ESCO2 | -6117 |
STAG1 | -5772 |
Cohesin Loading onto Chromatin
207 | |
---|---|
set | Cohesin Loading onto Chromatin |
setSize | 10 |
pANOVA | 7.27e-06 |
s.dist | -0.819 |
p.adjustANOVA | 2.94e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
WAPL | -10923 |
SMC1A | -10584 |
RAD21 | -10425 |
PDS5A | -10262 |
STAG2 | -10205 |
PDS5B | -8616 |
NIPBL | -8564 |
SMC3 | -7292 |
MAU2 | -5931 |
STAG1 | -5772 |
GeneID | Gene Rank |
---|---|
WAPL | -10923 |
SMC1A | -10584 |
RAD21 | -10425 |
PDS5A | -10262 |
STAG2 | -10205 |
PDS5B | -8616 |
NIPBL | -8564 |
SMC3 | -7292 |
MAU2 | -5931 |
STAG1 | -5772 |
ERKs are inactivated
360 | |
---|---|
set | ERKs are inactivated |
setSize | 13 |
pANOVA | 4.28e-07 |
s.dist | -0.81 |
p.adjustANOVA | 2.27e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
MAPK1 | -10995 |
PPP2CB | -10791 |
DUSP7 | -10486 |
DUSP6 | -10231 |
DUSP4 | -9894 |
PPP2CA | -9827 |
MAPK3 | -8949 |
VRK3 | -8340 |
DUSP3 | -8063 |
PPP2R1A | -6397 |
PPP2R1B | -4990 |
MAPK7 | -3522 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
MAPK1 | -10995 |
PPP2CB | -10791 |
DUSP7 | -10486 |
DUSP6 | -10231 |
DUSP4 | -9894 |
PPP2CA | -9827 |
MAPK3 | -8949 |
VRK3 | -8340 |
DUSP3 | -8063 |
PPP2R1A | -6397 |
PPP2R1B | -4990 |
MAPK7 | -3522 |
S33 mutants of beta-catenin aren’t phosphorylated
1108 | |
---|---|
set | S33 mutants of beta-catenin aren’t phosphorylated |
setSize | 15 |
pANOVA | 5.89e-08 |
s.dist | -0.808 |
p.adjustANOVA | 3.91e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
S37 mutants of beta-catenin aren’t phosphorylated
1109 | |
---|---|
set | S37 mutants of beta-catenin aren’t phosphorylated |
setSize | 15 |
pANOVA | 5.89e-08 |
s.dist | -0.808 |
p.adjustANOVA | 3.91e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
S45 mutants of beta-catenin aren’t phosphorylated
1110 | |
---|---|
set | S45 mutants of beta-catenin aren’t phosphorylated |
setSize | 15 |
pANOVA | 5.89e-08 |
s.dist | -0.808 |
p.adjustANOVA | 3.91e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
Signaling by CTNNB1 phospho-site mutants
1180 | |
---|---|
set | Signaling by CTNNB1 phospho-site mutants |
setSize | 15 |
pANOVA | 5.89e-08 |
s.dist | -0.808 |
p.adjustANOVA | 3.91e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
Signaling by GSK3beta mutants
1207 | |
---|---|
set | Signaling by GSK3beta mutants |
setSize | 15 |
pANOVA | 5.89e-08 |
s.dist | -0.808 |
p.adjustANOVA | 3.91e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
T41 mutants of beta-catenin aren’t phosphorylated
1298 | |
---|---|
set | T41 mutants of beta-catenin aren’t phosphorylated |
setSize | 15 |
pANOVA | 5.89e-08 |
s.dist | -0.808 |
p.adjustANOVA | 3.91e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
Golgi Cisternae Pericentriolar Stack Reorganization
506 | |
---|---|
set | Golgi Cisternae Pericentriolar Stack Reorganization |
setSize | 14 |
pANOVA | 1.76e-07 |
s.dist | -0.806 |
p.adjustANOVA | 1.07e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GORASP2 | -11171 |
USO1 | -11125 |
RAB1A | -11091 |
MAPK1 | -10995 |
RAB1B | -10519 |
PLK1 | -10443 |
RAB2A | -9543 |
GOLGA2 | -8961 |
MAPK3 | -8949 |
CCNB2 | -7266 |
BLZF1 | -7214 |
CDK1 | -5951 |
GORASP1 | -4207 |
CCNB1 | -4104 |
GeneID | Gene Rank |
---|---|
GORASP2 | -11171 |
USO1 | -11125 |
RAB1A | -11091 |
MAPK1 | -10995 |
RAB1B | -10519 |
PLK1 | -10443 |
RAB2A | -9543 |
GOLGA2 | -8961 |
MAPK3 | -8949 |
CCNB2 | -7266 |
BLZF1 | -7214 |
CDK1 | -5951 |
GORASP1 | -4207 |
CCNB1 | -4104 |
APC truncation mutants have impaired AXIN binding
11 | |
---|---|
set | APC truncation mutants have impaired AXIN binding |
setSize | 14 |
pANOVA | 2.29e-07 |
s.dist | -0.798 |
p.adjustANOVA | 1.33e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
AXIN missense mutants destabilize the destruction complex
24 | |
---|---|
set | AXIN missense mutants destabilize the destruction complex |
setSize | 14 |
pANOVA | 2.29e-07 |
s.dist | -0.798 |
p.adjustANOVA | 1.33e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
Signaling by AMER1 mutants
1173 | |
---|---|
set | Signaling by AMER1 mutants |
setSize | 14 |
pANOVA | 2.29e-07 |
s.dist | -0.798 |
p.adjustANOVA | 1.33e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
Signaling by APC mutants
1174 | |
---|---|
set | Signaling by APC mutants |
setSize | 14 |
pANOVA | 2.29e-07 |
s.dist | -0.798 |
p.adjustANOVA | 1.33e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
Signaling by AXIN mutants
1175 | |
---|---|
set | Signaling by AXIN mutants |
setSize | 14 |
pANOVA | 2.29e-07 |
s.dist | -0.798 |
p.adjustANOVA | 1.33e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
Truncations of AMER1 destabilize the destruction complex
1414 | |
---|---|
set | Truncations of AMER1 destabilize the destruction complex |
setSize | 14 |
pANOVA | 2.29e-07 |
s.dist | -0.798 |
p.adjustANOVA | 1.33e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
Signaling by Hippo
1209 | |
---|---|
set | Signaling by Hippo |
setSize | 20 |
pANOVA | 7.94e-10 |
s.dist | -0.794 |
p.adjustANOVA | 7.32e-09 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AMOTL2 | -11160 |
AMOTL1 | -10851 |
STK4 | -10164 |
LATS1 | -9809 |
AMOT | -9698 |
LATS2 | -9601 |
WWTR1 | -9598 |
CASP3 | -9502 |
SAV1 | -9277 |
MOB1A | -9188 |
YAP1 | -8955 |
TJP1 | -8832 |
STK3 | -8208 |
MOB1B | -7938 |
YWHAE | -7771 |
TJP2 | -7640 |
DVL2 | -7613 |
YWHAB | -5335 |
WWC1 | -5329 |
NPHP4 | -3783 |
GeneID | Gene Rank |
---|---|
AMOTL2 | -11160 |
AMOTL1 | -10851 |
STK4 | -10164 |
LATS1 | -9809 |
AMOT | -9698 |
LATS2 | -9601 |
WWTR1 | -9598 |
CASP3 | -9502 |
SAV1 | -9277 |
MOB1A | -9188 |
YAP1 | -8955 |
TJP1 | -8832 |
STK3 | -8208 |
MOB1B | -7938 |
YWHAE | -7771 |
TJP2 | -7640 |
DVL2 | -7613 |
YWHAB | -5335 |
WWC1 | -5329 |
NPHP4 | -3783 |
MET activates RAP1 and RAC1
664 | |
---|---|
set | MET activates RAP1 and RAC1 |
setSize | 11 |
pANOVA | 5.41e-06 |
s.dist | -0.792 |
p.adjustANOVA | 2.27e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CRKL | -11034 |
CRK | -10952 |
GRB2 | -10928 |
RAP1B | -10417 |
MET | -9674 |
RAC1 | -8358 |
DOCK7 | -8330 |
RAPGEF1 | -7763 |
RAP1A | -7117 |
GAB1 | -6967 |
HGF | -1883 |
GeneID | Gene Rank |
---|---|
CRKL | -11034 |
CRK | -10952 |
GRB2 | -10928 |
RAP1B | -10417 |
MET | -9674 |
RAC1 | -8358 |
DOCK7 | -8330 |
RAPGEF1 | -7763 |
RAP1A | -7117 |
GAB1 | -6967 |
HGF | -1883 |
MAPK3 (ERK1) activation
659 | |
---|---|
set | MAPK3 (ERK1) activation |
setSize | 10 |
pANOVA | 2.78e-05 |
s.dist | -0.765 |
p.adjustANOVA | 1e-04 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MAP2K1 | -11084 |
IL6ST | -10145 |
JAK1 | -9989 |
IL6R | -9783 |
PTPN11 | -9660 |
MAPK3 | -8949 |
IL6 | -6261 |
CDK1 | -5951 |
JAK2 | -4851 |
TYK2 | -4701 |
GeneID | Gene Rank |
---|---|
MAP2K1 | -11084 |
IL6ST | -10145 |
JAK1 | -9989 |
IL6R | -9783 |
PTPN11 | -9660 |
MAPK3 | -8949 |
IL6 | -6261 |
CDK1 | -5951 |
JAK2 | -4851 |
TYK2 | -4701 |
RAF-independent MAPK1/3 activation
943 | |
---|---|
set | RAF-independent MAPK1/3 activation |
setSize | 23 |
pANOVA | 2.16e-10 |
s.dist | -0.764 |
p.adjustANOVA | 2.17e-09 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DUSP5 | -11270 |
MAP2K1 | -11084 |
MAPK1 | -10995 |
DUSP16 | -10981 |
DUSP7 | -10486 |
DUSP6 | -10231 |
IL6ST | -10145 |
JAK1 | -9989 |
DUSP4 | -9894 |
IL6R | -9783 |
PTPN11 | -9660 |
MAPK3 | -8949 |
DUSP1 | -8928 |
DUSP9 | -8393 |
PEA15 | -8230 |
DUSP10 | -6617 |
DUSP8 | -6606 |
IL6 | -6261 |
CDK1 | -5951 |
JAK2 | -4851 |
GeneID | Gene Rank |
---|---|
DUSP5 | -11270 |
MAP2K1 | -11084 |
MAPK1 | -10995 |
DUSP16 | -10981 |
DUSP7 | -10486 |
DUSP6 | -10231 |
IL6ST | -10145 |
JAK1 | -9989 |
DUSP4 | -9894 |
IL6R | -9783 |
PTPN11 | -9660 |
MAPK3 | -8949 |
DUSP1 | -8928 |
DUSP9 | -8393 |
PEA15 | -8230 |
DUSP10 | -6617 |
DUSP8 | -6606 |
IL6 | -6261 |
CDK1 | -5951 |
JAK2 | -4851 |
TYK2 | -4701 |
MAP2K2 | -1778 |
DUSP2 | -1052 |
Interleukin-6 signaling
609 | |
---|---|
set | Interleukin-6 signaling |
setSize | 11 |
pANOVA | 1.18e-05 |
s.dist | -0.763 |
p.adjustANOVA | 4.54e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CBL | -10473 |
IL6ST | -10145 |
JAK1 | -9989 |
IL6R | -9783 |
PTPN11 | -9660 |
STAT1 | -9586 |
STAT3 | -8517 |
IL6 | -6261 |
SOCS3 | -5184 |
JAK2 | -4851 |
TYK2 | -4701 |
GeneID | Gene Rank |
---|---|
CBL | -10473 |
IL6ST | -10145 |
JAK1 | -9989 |
IL6R | -9783 |
PTPN11 | -9660 |
STAT1 | -9586 |
STAT3 | -8517 |
IL6 | -6261 |
SOCS3 | -5184 |
JAK2 | -4851 |
TYK2 | -4701 |
Beta-catenin phosphorylation cascade
114 | |
---|---|
set | Beta-catenin phosphorylation cascade |
setSize | 17 |
pANOVA | 5.52e-08 |
s.dist | -0.761 |
p.adjustANOVA | 3.83e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
FRAT2 | -6045 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
FRAT1 | -595 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
APC | -8408 |
AXIN1 | -8223 |
AMER1 | -8065 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
FRAT2 | -6045 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
FRAT1 | -595 |
Mitotic Telophase/Cytokinesis
725 | |
---|---|
set | Mitotic Telophase/Cytokinesis |
setSize | 13 |
pANOVA | 2.05e-06 |
s.dist | -0.76 |
p.adjustANOVA | 9.4e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
WAPL | -10923 |
SMC1A | -10584 |
PLK1 | -10443 |
RAD21 | -10425 |
PDS5A | -10262 |
STAG2 | -10205 |
PDS5B | -8616 |
NIPBL | -8564 |
SMC3 | -7292 |
MAU2 | -5931 |
STAG1 | -5772 |
KIF23 | -4475 |
KIF20A | -1447 |
GeneID | Gene Rank |
---|---|
WAPL | -10923 |
SMC1A | -10584 |
PLK1 | -10443 |
RAD21 | -10425 |
PDS5A | -10262 |
STAG2 | -10205 |
PDS5B | -8616 |
NIPBL | -8564 |
SMC3 | -7292 |
MAU2 | -5931 |
STAG1 | -5772 |
KIF23 | -4475 |
KIF20A | -1447 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC
78 | |
---|---|
set | Antigen Presentation: Folding, assembly and peptide loading of class I MHC |
setSize | 25 |
pANOVA | 5.85e-11 |
s.dist | -0.756 |
p.adjustANOVA | 6.52e-10 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SEC24D | -11280 |
SEC23A | -11227 |
CANX | -11208 |
SEC24A | -11144 |
HLA-E | -11119 |
SEC13 | -10720 |
SEC24B | -10646 |
PDIA3 | -10410 |
TAP1 | -10379 |
SEC24C | -10311 |
SEC31A | -9979 |
HSPA5 | -9966 |
ERAP1 | -9731 |
HLA-H | -9536 |
HLA-C | -9273 |
HLA-B | -8950 |
B2M | -7777 |
TAPBP | -7676 |
HLA-G | -7568 |
TAP2 | -7516 |
GeneID | Gene Rank |
---|---|
SEC24D | -11280 |
SEC23A | -11227 |
CANX | -11208 |
SEC24A | -11144 |
HLA-E | -11119 |
SEC13 | -10720 |
SEC24B | -10646 |
PDIA3 | -10410 |
TAP1 | -10379 |
SEC24C | -10311 |
SEC31A | -9979 |
HSPA5 | -9966 |
ERAP1 | -9731 |
HLA-H | -9536 |
HLA-C | -9273 |
HLA-B | -8950 |
B2M | -7777 |
TAPBP | -7676 |
HLA-G | -7568 |
TAP2 | -7516 |
CALR | -6927 |
SAR1B | -3725 |
HLA-F | -3567 |
HLA-A | -2888 |
ERAP2 | 13239 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS
273 | |
---|---|
set | Defective EXT1 causes exostoses 1, TRPS2 and CHDS |
setSize | 13 |
pANOVA | 7.2e-06 |
s.dist | -0.719 |
p.adjustANOVA | 2.92e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GPC6 | -10762 |
SDC4 | -10589 |
GPC4 | -10309 |
GPC1 | -9946 |
SDC2 | -8067 |
EXT2 | -8015 |
EXT1 | -7609 |
AGRN | -7222 |
SDC1 | -6782 |
SDC3 | -6073 |
HSPG2 | -5446 |
GPC5 | -4208 |
GPC2 | -2676 |
GeneID | Gene Rank |
---|---|
GPC6 | -10762 |
SDC4 | -10589 |
GPC4 | -10309 |
GPC1 | -9946 |
SDC2 | -8067 |
EXT2 | -8015 |
EXT1 | -7609 |
AGRN | -7222 |
SDC1 | -6782 |
SDC3 | -6073 |
HSPG2 | -5446 |
GPC5 | -4208 |
GPC2 | -2676 |
Defective EXT2 causes exostoses 2
274 | |
---|---|
set | Defective EXT2 causes exostoses 2 |
setSize | 13 |
pANOVA | 7.2e-06 |
s.dist | -0.719 |
p.adjustANOVA | 2.92e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GPC6 | -10762 |
SDC4 | -10589 |
GPC4 | -10309 |
GPC1 | -9946 |
SDC2 | -8067 |
EXT2 | -8015 |
EXT1 | -7609 |
AGRN | -7222 |
SDC1 | -6782 |
SDC3 | -6073 |
HSPG2 | -5446 |
GPC5 | -4208 |
GPC2 | -2676 |
GeneID | Gene Rank |
---|---|
GPC6 | -10762 |
SDC4 | -10589 |
GPC4 | -10309 |
GPC1 | -9946 |
SDC2 | -8067 |
EXT2 | -8015 |
EXT1 | -7609 |
AGRN | -7222 |
SDC1 | -6782 |
SDC3 | -6073 |
HSPG2 | -5446 |
GPC5 | -4208 |
GPC2 | -2676 |
Synthesis of PIPs at the early endosome membrane
1283 | |
---|---|
set | Synthesis of PIPs at the early endosome membrane |
setSize | 16 |
pANOVA | 1.38e-06 |
s.dist | -0.697 |
p.adjustANOVA | 6.58e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MTMR12 | -11203 |
PIKFYVE | -9788 |
PIK3R4 | -9423 |
VAC14 | -9302 |
MTMR2 | -9253 |
PI4K2A | -8161 |
PIK3C3 | -8086 |
MTMR4 | -8019 |
INPP5F | -7989 |
PIK3C2A | -7978 |
INPP4A | -7786 |
PI4K2B | -7232 |
MTM1 | -6304 |
MTMR10 | -5507 |
FIG4 | -4129 |
INPP4B | 4559 |
GeneID | Gene Rank |
---|---|
MTMR12 | -11203 |
PIKFYVE | -9788 |
PIK3R4 | -9423 |
VAC14 | -9302 |
MTMR2 | -9253 |
PI4K2A | -8161 |
PIK3C3 | -8086 |
MTMR4 | -8019 |
INPP5F | -7989 |
PIK3C2A | -7978 |
INPP4A | -7786 |
PI4K2B | -7232 |
MTM1 | -6304 |
MTMR10 | -5507 |
FIG4 | -4129 |
INPP4B | 4559 |
Signaling by PDGFRA extracellular domain mutants
1234 | |
---|---|
set | Signaling by PDGFRA extracellular domain mutants |
setSize | 12 |
pANOVA | 3.55e-05 |
s.dist | -0.689 |
p.adjustANOVA | 0.000124 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PDGFRA | -11218 |
PIK3CB | -10967 |
GRB2 | -10928 |
STAT1 | -9586 |
PIK3R1 | -9444 |
NRAS | -9293 |
PIK3CA | -8881 |
SOS1 | -8846 |
STAT3 | -8517 |
KRAS | -7194 |
PIK3R2 | -5467 |
HRAS | 14873 |
GeneID | Gene Rank |
---|---|
PDGFRA | -11218 |
PIK3CB | -10967 |
GRB2 | -10928 |
STAT1 | -9586 |
PIK3R1 | -9444 |
NRAS | -9293 |
PIK3CA | -8881 |
SOS1 | -8846 |
STAT3 | -8517 |
KRAS | -7194 |
PIK3R2 | -5467 |
HRAS | 14873 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
1235 | |
---|---|
set | Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants |
setSize | 12 |
pANOVA | 3.55e-05 |
s.dist | -0.689 |
p.adjustANOVA | 0.000124 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PDGFRA | -11218 |
PIK3CB | -10967 |
GRB2 | -10928 |
STAT1 | -9586 |
PIK3R1 | -9444 |
NRAS | -9293 |
PIK3CA | -8881 |
SOS1 | -8846 |
STAT3 | -8517 |
KRAS | -7194 |
PIK3R2 | -5467 |
HRAS | 14873 |
GeneID | Gene Rank |
---|---|
PDGFRA | -11218 |
PIK3CB | -10967 |
GRB2 | -10928 |
STAT1 | -9586 |
PIK3R1 | -9444 |
NRAS | -9293 |
PIK3CA | -8881 |
SOS1 | -8846 |
STAT3 | -8517 |
KRAS | -7194 |
PIK3R2 | -5467 |
HRAS | 14873 |
Activation of RAC1
48 | |
---|---|
set | Activation of RAC1 |
setSize | 13 |
pANOVA | 1.72e-05 |
s.dist | -0.688 |
p.adjustANOVA | 6.43e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NCK1 | -11135 |
SLIT2 | -10674 |
PAK1 | -10640 |
PAK2 | -10191 |
PAK4 | -9314 |
NCK2 | -8988 |
SOS1 | -8846 |
RAC1 | -8358 |
SOS2 | -7183 |
ROBO1 | -7141 |
PAK3 | -4574 |
PAK5 | -1369 |
PAK6 | 5967 |
GeneID | Gene Rank |
---|---|
NCK1 | -11135 |
SLIT2 | -10674 |
PAK1 | -10640 |
PAK2 | -10191 |
PAK4 | -9314 |
NCK2 | -8988 |
SOS1 | -8846 |
RAC1 | -8358 |
SOS2 | -7183 |
ROBO1 | -7141 |
PAK3 | -4574 |
PAK5 | -1369 |
PAK6 | 5967 |
Synthesis of PIPs at the late endosome membrane
1284 | |
---|---|
set | Synthesis of PIPs at the late endosome membrane |
setSize | 11 |
pANOVA | 8.35e-05 |
s.dist | -0.685 |
p.adjustANOVA | 0.000269 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PIKFYVE | -9788 |
PIK3R4 | -9423 |
VAC14 | -9302 |
MTMR2 | -9253 |
PIK3C3 | -8086 |
MTMR4 | -8019 |
PIK3C2A | -7978 |
MTMR9 | -7864 |
MTM1 | -6304 |
FIG4 | -4129 |
MTMR7 | 2433 |
GeneID | Gene Rank |
---|---|
PIKFYVE | -9788 |
PIK3R4 | -9423 |
VAC14 | -9302 |
MTMR2 | -9253 |
PIK3C3 | -8086 |
MTMR4 | -8019 |
PIK3C2A | -7978 |
MTMR9 | -7864 |
MTM1 | -6304 |
FIG4 | -4129 |
MTMR7 | 2433 |
Signal transduction by L1
1169 | |
---|---|
set | Signal transduction by L1 |
setSize | 21 |
pANOVA | 5.62e-08 |
s.dist | -0.684 |
p.adjustANOVA | 3.86e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ITGB3 | -11255 |
ITGA5 | -11230 |
ITGB1 | -11155 |
MAP2K1 | -11084 |
MAPK1 | -10995 |
CSNK2A1 | -10886 |
L1CAM | -10775 |
PAK1 | -10640 |
EGFR | -10531 |
CSNK2A2 | -10253 |
ITGAV | -10173 |
MAPK3 | -8949 |
NRP1 | -8764 |
RAC1 | -8358 |
VAV2 | -7167 |
ITGA9 | -6351 |
FGFR1 | -2958 |
NCAM1 | -2110 |
MAP2K2 | -1778 |
CSNK2B | 7911 |
GeneID | Gene Rank |
---|---|
ITGB3 | -11255 |
ITGA5 | -11230 |
ITGB1 | -11155 |
MAP2K1 | -11084 |
MAPK1 | -10995 |
CSNK2A1 | -10886 |
L1CAM | -10775 |
PAK1 | -10640 |
EGFR | -10531 |
CSNK2A2 | -10253 |
ITGAV | -10173 |
MAPK3 | -8949 |
NRP1 | -8764 |
RAC1 | -8358 |
VAV2 | -7167 |
ITGA9 | -6351 |
FGFR1 | -2958 |
NCAM1 | -2110 |
MAP2K2 | -1778 |
CSNK2B | 7911 |
ITGA2B | 9389 |
ALK mutants bind TKIs
10 | |
---|---|
set | ALK mutants bind TKIs |
setSize | 12 |
pANOVA | 4.26e-05 |
s.dist | -0.682 |
p.adjustANOVA | 0.000146 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CLTC | -11168 |
EIF2AK3 | -10957 |
FN1 | -10893 |
PPM1B | -10633 |
STRN | -9764 |
PRKAR1A | -9591 |
ALK | -7854 |
HIP1 | -7803 |
BIRC6 | -7359 |
EML4 | -3335 |
NPM1 | -2560 |
BCL11A | 7576 |
GeneID | Gene Rank |
---|---|
CLTC | -11168 |
EIF2AK3 | -10957 |
FN1 | -10893 |
PPM1B | -10633 |
STRN | -9764 |
PRKAR1A | -9591 |
ALK | -7854 |
HIP1 | -7803 |
BIRC6 | -7359 |
EML4 | -3335 |
NPM1 | -2560 |
BCL11A | 7576 |
FOXO-mediated transcription of cell cycle genes
407 | |
---|---|
set | FOXO-mediated transcription of cell cycle genes |
setSize | 16 |
pANOVA | 5.18e-06 |
s.dist | -0.658 |
p.adjustANOVA | 2.18e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CDKN1A | -11243 |
FOXO3 | -10755 |
SMAD4 | -10603 |
CAV1 | -10469 |
GADD45A | -10202 |
CDKN1B | -10176 |
SMAD2 | -10052 |
BTG1 | -9297 |
FOXO1 | -9262 |
RBL2 | -9205 |
CCNG2 | -8156 |
SMAD3 | -7704 |
KLF4 | -6673 |
FOXO4 | -5667 |
MSTN | 8126 |
PCBP4 | 14098 |
GeneID | Gene Rank |
---|---|
CDKN1A | -11243 |
FOXO3 | -10755 |
SMAD4 | -10603 |
CAV1 | -10469 |
GADD45A | -10202 |
CDKN1B | -10176 |
SMAD2 | -10052 |
BTG1 | -9297 |
FOXO1 | -9262 |
RBL2 | -9205 |
CCNG2 | -8156 |
SMAD3 | -7704 |
KLF4 | -6673 |
FOXO4 | -5667 |
MSTN | 8126 |
PCBP4 | 14098 |
Syndecan interactions
1273 | |
---|---|
set | Syndecan interactions |
setSize | 20 |
pANOVA | 5.15e-07 |
s.dist | -0.648 |
p.adjustANOVA | 2.7e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ITGB3 | -11255 |
ITGA6 | -11210 |
ITGB1 | -11155 |
ACTN1 | -11138 |
ITGA2 | -10877 |
TNC | -10814 |
SDC4 | -10589 |
ITGAV | -10173 |
TGFB1 | -9334 |
TRAPPC4 | -8603 |
SDC2 | -8067 |
ITGB5 | -8045 |
CASK | -7112 |
SDC1 | -6782 |
SDC3 | -6073 |
PRKCA | -5486 |
FGF2 | -5236 |
THBS1 | 6048 |
VTN | 6412 |
ITGB4 | 8038 |
GeneID | Gene Rank |
---|---|
ITGB3 | -11255 |
ITGA6 | -11210 |
ITGB1 | -11155 |
ACTN1 | -11138 |
ITGA2 | -10877 |
TNC | -10814 |
SDC4 | -10589 |
ITGAV | -10173 |
TGFB1 | -9334 |
TRAPPC4 | -8603 |
SDC2 | -8067 |
ITGB5 | -8045 |
CASK | -7112 |
SDC1 | -6782 |
SDC3 | -6073 |
PRKCA | -5486 |
FGF2 | -5236 |
THBS1 | 6048 |
VTN | 6412 |
ITGB4 | 8038 |
Prolonged ERK activation events
922 | |
---|---|
set | Prolonged ERK activation events |
setSize | 14 |
pANOVA | 2.87e-05 |
s.dist | -0.646 |
p.adjustANOVA | 0.000103 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MAP2K1 | -11084 |
CRKL | -11034 |
MAPK1 | -10995 |
CRK | -10952 |
FRS2 | -9097 |
MAPK3 | -8949 |
BRAF | -7961 |
RAPGEF1 | -7763 |
RAP1A | -7117 |
YWHAB | -5335 |
KIDINS220 | -4716 |
NTRK1 | -3485 |
MAP2K2 | -1778 |
NGF | 8729 |
GeneID | Gene Rank |
---|---|
MAP2K1 | -11084 |
CRKL | -11034 |
MAPK1 | -10995 |
CRK | -10952 |
FRS2 | -9097 |
MAPK3 | -8949 |
BRAF | -7961 |
RAPGEF1 | -7763 |
RAP1A | -7117 |
YWHAB | -5335 |
KIDINS220 | -4716 |
NTRK1 | -3485 |
MAP2K2 | -1778 |
NGF | 8729 |
CTLA4 inhibitory signaling
147 | |
---|---|
set | CTLA4 inhibitory signaling |
setSize | 17 |
pANOVA | 4.47e-06 |
s.dist | -0.643 |
p.adjustANOVA | 1.92e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
YES1 | -10514 |
AKT3 | -10477 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
PTPN11 | -9660 |
SRC | -7851 |
FYN | -7099 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
AKT1 | -2579 |
LYN | -2496 |
AKT2 | 14457 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
YES1 | -10514 |
AKT3 | -10477 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
PTPN11 | -9660 |
SRC | -7851 |
FYN | -7099 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
AKT1 | -2579 |
LYN | -2496 |
AKT2 | 14457 |
Gastrin-CREB signalling pathway via PKC and MAPK
479 | |
---|---|
set | Gastrin-CREB signalling pathway via PKC and MAPK |
setSize | 17 |
pANOVA | 4.75e-06 |
s.dist | -0.641 |
p.adjustANOVA | 2.02e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
HBEGF | -11003 |
MAPK1 | -10995 |
GRB2 | -10928 |
EGFR | -10531 |
RPS6KA3 | -10363 |
NRAS | -9293 |
MAPK3 | -8949 |
SOS1 | -8846 |
CREB1 | -8171 |
KRAS | -7194 |
RPS6KA2 | -6326 |
RPS6KA1 | -6227 |
MMP3 | -5706 |
PRKCA | -5486 |
MAPK7 | -3522 |
CCKBR | -1384 |
HRAS | 14873 |
GeneID | Gene Rank |
---|---|
HBEGF | -11003 |
MAPK1 | -10995 |
GRB2 | -10928 |
EGFR | -10531 |
RPS6KA3 | -10363 |
NRAS | -9293 |
MAPK3 | -8949 |
SOS1 | -8846 |
CREB1 | -8171 |
KRAS | -7194 |
RPS6KA2 | -6326 |
RPS6KA1 | -6227 |
MMP3 | -5706 |
PRKCA | -5486 |
MAPK7 | -3522 |
CCKBR | -1384 |
HRAS | 14873 |
Cell-extracellular matrix interactions
175 | |
---|---|
set | Cell-extracellular matrix interactions |
setSize | 16 |
pANOVA | 9.64e-06 |
s.dist | -0.639 |
p.adjustANOVA | 3.82e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FLNC | -11249 |
FLNA | -11232 |
ITGB1 | -11155 |
ACTN1 | -11138 |
FERMT2 | -11109 |
LIMS1 | -9445 |
PARVB | -8827 |
PXN | -7403 |
VASP | -7162 |
ILK | -6739 |
RSU1 | -6419 |
PARVA | -6330 |
ARHGEF6 | -3564 |
LIMS2 | -1547 |
FBLIM1 | -682 |
TESK1 | 10849 |
GeneID | Gene Rank |
---|---|
FLNC | -11249 |
FLNA | -11232 |
ITGB1 | -11155 |
ACTN1 | -11138 |
FERMT2 | -11109 |
LIMS1 | -9445 |
PARVB | -8827 |
PXN | -7403 |
VASP | -7162 |
ILK | -6739 |
RSU1 | -6419 |
PARVA | -6330 |
ARHGEF6 | -3564 |
LIMS2 | -1547 |
FBLIM1 | -682 |
TESK1 | 10849 |
Regulation of gene expression by Hypoxia-inducible Factor
1068 | |
---|---|
set | Regulation of gene expression by Hypoxia-inducible Factor |
setSize | 11 |
pANOVA | 0.000244 |
s.dist | -0.639 |
p.adjustANOVA | 0.000714 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EPAS1 | -11157 |
HIF1A | -11032 |
CITED2 | -10905 |
ARNT | -10656 |
CREBBP | -9655 |
EP300 | -9548 |
CA9 | -9179 |
HIGD1A | -6950 |
VEGFA | 1235 |
HIF3A | 1620 |
EPO | 5297 |
GeneID | Gene Rank |
---|---|
EPAS1 | -11157 |
HIF1A | -11032 |
CITED2 | -10905 |
ARNT | -10656 |
CREBBP | -9655 |
EP300 | -9548 |
CA9 | -9179 |
HIGD1A | -6950 |
VEGFA | 1235 |
HIF3A | 1620 |
EPO | 5297 |
Regulation of cholesterol biosynthesis by SREBP (SREBF)
1065 | |
---|---|
set | Regulation of cholesterol biosynthesis by SREBP (SREBF) |
setSize | 55 |
pANOVA | 3.95e-16 |
s.dist | -0.634 |
p.adjustANOVA | 9.46e-15 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SEC24D | -11280 |
INSIG1 | -11275 |
HMGCR | -11253 |
SQLE | -11242 |
SEC23A | -11227 |
HMGCS1 | -11180 |
CYP51A1 | -11166 |
SEC24A | -11144 |
IDI1 | -11106 |
SREBF2 | -11089 |
MED1 | -11049 |
FDFT1 | -11018 |
HELZ2 | -10991 |
SC5D | -10873 |
DHCR7 | -10855 |
PPARA | -10816 |
NFYA | -10704 |
SEC24B | -10646 |
SEC24C | -10311 |
NCOA2 | -10279 |
GeneID | Gene Rank |
---|---|
SEC24D | -11280 |
INSIG1 | -11275 |
HMGCR | -11253 |
SQLE | -11242 |
SEC23A | -11227 |
HMGCS1 | -11180 |
CYP51A1 | -11166 |
SEC24A | -11144 |
IDI1 | -11106 |
SREBF2 | -11089 |
MED1 | -11049 |
FDFT1 | -11018 |
HELZ2 | -10991 |
SC5D | -10873 |
DHCR7 | -10855 |
PPARA | -10816 |
NFYA | -10704 |
SEC24B | -10646 |
SEC24C | -10311 |
NCOA2 | -10279 |
SCD | -10199 |
MTF1 | -10117 |
SP1 | -9960 |
KPNB1 | -9790 |
CREBBP | -9655 |
FASN | -9635 |
MBTPS2 | -9157 |
TBL1XR1 | -8937 |
TGS1 | -8714 |
MVD | -8259 |
INSIG2 | -7996 |
TBL1X | -7506 |
GPAM | -7211 |
NCOA6 | -6993 |
RAN | -6907 |
ACACA | -6705 |
CHD9 | -6687 |
NCOA1 | -6430 |
MBTPS1 | -6159 |
RXRA | -6096 |
CARM1 | -6020 |
FDPS | -5771 |
LSS | -5697 |
GGPS1 | -5677 |
MVK | -5111 |
SCAP | -4798 |
SAR1B | -3725 |
NFYB | -1906 |
PMVK | 64 |
ELOVL6 | 1965 |
ACACB | 11796 |
NFYC | 12639 |
TM7SF2 | 14698 |
SMARCD3 | 14895 |
SREBF1 | 14902 |
Signaling by WNT in cancer
1250 | |
---|---|
set | Signaling by WNT in cancer |
setSize | 32 |
pANOVA | 5.49e-10 |
s.dist | -0.633 |
p.adjustANOVA | 5.19e-09 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
LRP6 | -10666 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
TNKS | -10471 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
FZD5 | -9793 |
TNKS2 | -9338 |
KREMEN1 | -9123 |
APC | -8408 |
AXIN1 | -8223 |
FZD8 | -8140 |
AMER1 | -8065 |
CTBP2 | -7543 |
FZD6 | -7097 |
PPP2R1A | -6397 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
PPP2CB | -10791 |
LRP6 | -10666 |
GSK3B | -10632 |
CTNNB1 | -10568 |
CSNK1A1 | -10561 |
TNKS | -10471 |
PPP2R5A | -10349 |
PPP2R5E | -10222 |
PPP2CA | -9827 |
FZD5 | -9793 |
TNKS2 | -9338 |
KREMEN1 | -9123 |
APC | -8408 |
AXIN1 | -8223 |
FZD8 | -8140 |
AMER1 | -8065 |
CTBP2 | -7543 |
FZD6 | -7097 |
PPP2R1A | -6397 |
PPP2R5C | -6296 |
PORCN | -6161 |
KREMEN2 | -6104 |
FZD4 | -6015 |
DKK2 | -5215 |
PPP2R1B | -4990 |
PPP2R5B | -4338 |
LRP5 | -3923 |
DKK1 | -3745 |
RNF43 | 5449 |
TCF7L2 | 11251 |
CTBP1 | 13492 |
Processing and activation of SUMO
912 | |
---|---|
set | Processing and activation of SUMO |
setSize | 10 |
pANOVA | 0.000534 |
s.dist | -0.632 |
p.adjustANOVA | 0.00143 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UBA2 | -10392 |
SENP2 | -10330 |
SENP1 | -9567 |
SUMO3 | -9159 |
SENP5 | -8296 |
SAE1 | -7953 |
SUMO2 | -7239 |
UBE2I | -5331 |
SUMO1 | -4980 |
RWDD3 | 9620 |
GeneID | Gene Rank |
---|---|
UBA2 | -10392 |
SENP2 | -10330 |
SENP1 | -9567 |
SUMO3 | -9159 |
SENP5 | -8296 |
SAE1 | -7953 |
SUMO2 | -7239 |
UBE2I | -5331 |
SUMO1 | -4980 |
RWDD3 | 9620 |
ERK/MAPK targets
359 | |
---|---|
set | ERK/MAPK targets |
setSize | 22 |
pANOVA | 2.85e-07 |
s.dist | -0.632 |
p.adjustANOVA | 1.59e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
MAPK1 | -10995 |
PPP2CB | -10791 |
DUSP7 | -10486 |
RPS6KA3 | -10363 |
DUSP6 | -10231 |
DUSP4 | -9894 |
PPP2CA | -9827 |
MAPK14 | -9054 |
MAPK3 | -8949 |
VRK3 | -8340 |
ELK1 | -8163 |
DUSP3 | -8063 |
RPS6KA5 | -6900 |
PPP2R1A | -6397 |
RPS6KA2 | -6326 |
RPS6KA1 | -6227 |
PPP2R1B | -4990 |
MAPK7 | -3522 |
MEF2C | 2785 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11026 |
MAPK1 | -10995 |
PPP2CB | -10791 |
DUSP7 | -10486 |
RPS6KA3 | -10363 |
DUSP6 | -10231 |
DUSP4 | -9894 |
PPP2CA | -9827 |
MAPK14 | -9054 |
MAPK3 | -8949 |
VRK3 | -8340 |
ELK1 | -8163 |
DUSP3 | -8063 |
RPS6KA5 | -6900 |
PPP2R1A | -6397 |
RPS6KA2 | -6326 |
RPS6KA1 | -6227 |
PPP2R1B | -4990 |
MAPK7 | -3522 |
MEF2C | 2785 |
MEF2A | 5395 |
MAPK11 | 12572 |
Frs2-mediated activation
439 | |
---|---|
set | Frs2-mediated activation |
setSize | 12 |
pANOVA | 0.00016 |
s.dist | -0.629 |
p.adjustANOVA | 0.000486 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MAP2K1 | -11084 |
CRKL | -11034 |
MAPK1 | -10995 |
FRS2 | -9097 |
MAPK3 | -8949 |
BRAF | -7961 |
RAPGEF1 | -7763 |
RAP1A | -7117 |
YWHAB | -5335 |
NTRK1 | -3485 |
MAP2K2 | -1778 |
NGF | 8729 |
GeneID | Gene Rank |
---|---|
MAP2K1 | -11084 |
CRKL | -11034 |
MAPK1 | -10995 |
FRS2 | -9097 |
MAPK3 | -8949 |
BRAF | -7961 |
RAPGEF1 | -7763 |
RAP1A | -7117 |
YWHAB | -5335 |
NTRK1 | -3485 |
MAP2K2 | -1778 |
NGF | 8729 |
STAT5 activation downstream of FLT3 ITD mutants
1132 | |
---|---|
set | STAT5 activation downstream of FLT3 ITD mutants |
setSize | 10 |
pANOVA | 0.000578 |
s.dist | -0.628 |
p.adjustANOVA | 0.00153 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CDKN1A | -11243 |
GRB2 | -10928 |
PTPN11 | -9660 |
GAB2 | -9072 |
PIM1 | -8519 |
BCL2L1 | -7142 |
STAT5B | -4295 |
STAT5A | -3099 |
NOX4 | -1405 |
FLT3 | 2252 |
GeneID | Gene Rank |
---|---|
CDKN1A | -11243 |
GRB2 | -10928 |
PTPN11 | -9660 |
GAB2 | -9072 |
PIM1 | -8519 |
BCL2L1 | -7142 |
STAT5B | -4295 |
STAT5A | -3099 |
NOX4 | -1405 |
FLT3 | 2252 |
Signaling by PDGFR in disease
1233 | |
---|---|
set | Signaling by PDGFR in disease |
setSize | 20 |
pANOVA | 1.17e-06 |
s.dist | -0.628 |
p.adjustANOVA | 5.65e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PDGFRA | -11218 |
PIK3CB | -10967 |
GRB2 | -10928 |
GOLGA4 | -10758 |
STRN | -9764 |
FIP1L1 | -9616 |
STAT1 | -9586 |
PIK3R1 | -9444 |
NRAS | -9293 |
PIK3CA | -8881 |
SOS1 | -8846 |
STAT3 | -8517 |
KRAS | -7194 |
WDR48 | -5606 |
PIK3R2 | -5467 |
KANK1 | -5112 |
KDR | -4501 |
ETV6 | 2077 |
BIN2 | 2795 |
HRAS | 14873 |
GeneID | Gene Rank |
---|---|
PDGFRA | -11218 |
PIK3CB | -10967 |
GRB2 | -10928 |
GOLGA4 | -10758 |
STRN | -9764 |
FIP1L1 | -9616 |
STAT1 | -9586 |
PIK3R1 | -9444 |
NRAS | -9293 |
PIK3CA | -8881 |
SOS1 | -8846 |
STAT3 | -8517 |
KRAS | -7194 |
WDR48 | -5606 |
PIK3R2 | -5467 |
KANK1 | -5112 |
KDR | -4501 |
ETV6 | 2077 |
BIN2 | 2795 |
HRAS | 14873 |
Citric acid cycle (TCA cycle)
197 | |
---|---|
set | Citric acid cycle (TCA cycle) |
setSize | 22 |
pANOVA | 3.63e-07 |
s.dist | -0.626 |
p.adjustANOVA | 1.96e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IDH2 | -11079 |
ME2 | -10846 |
CS | -10604 |
SDHA | -10529 |
SUCLG2 | -10244 |
MDH2 | -9964 |
OGDH | -9550 |
DLD | -9398 |
DLST | -9257 |
SUCLA2 | -8074 |
SDHB | -7529 |
NNT | -7468 |
SDHC | -7321 |
SDHD | -7213 |
IDH3A | -6427 |
IDH3B | -5545 |
FH | -4807 |
SUCLG1 | -3607 |
IDH3G | -1805 |
ME3 | 504 |
GeneID | Gene Rank |
---|---|
IDH2 | -11079 |
ME2 | -10846 |
CS | -10604 |
SDHA | -10529 |
SUCLG2 | -10244 |
MDH2 | -9964 |
OGDH | -9550 |
DLD | -9398 |
DLST | -9257 |
SUCLA2 | -8074 |
SDHB | -7529 |
NNT | -7468 |
SDHC | -7321 |
SDHD | -7213 |
IDH3A | -6427 |
IDH3B | -5545 |
FH | -4807 |
SUCLG1 | -3607 |
IDH3G | -1805 |
ME3 | 504 |
FAHD1 | 5378 |
ACO2 | 7258 |
Signaling by Activin
1176 | |
---|---|
set | Signaling by Activin |
setSize | 15 |
pANOVA | 2.67e-05 |
s.dist | -0.626 |
p.adjustANOVA | 9.65e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MAPK1 | -10995 |
SMAD4 | -10603 |
INHBA | -10467 |
SMAD2 | -10052 |
ACVR2B | -9533 |
MAPK3 | -8949 |
SMAD3 | -7704 |
FST | -6486 |
ACVR1B | -5927 |
ACVR1C | -5440 |
FSTL3 | -5320 |
INHBB | -4752 |
ACVR2A | -4320 |
DRAP1 | -4214 |
FOXH1 | 10577 |
GeneID | Gene Rank |
---|---|
MAPK1 | -10995 |
SMAD4 | -10603 |
INHBA | -10467 |
SMAD2 | -10052 |
ACVR2B | -9533 |
MAPK3 | -8949 |
SMAD3 | -7704 |
FST | -6486 |
ACVR1B | -5927 |
ACVR1C | -5440 |
FSTL3 | -5320 |
INHBB | -4752 |
ACVR2A | -4320 |
DRAP1 | -4214 |
FOXH1 | 10577 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.2.0 (2022-04-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats4 stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.2.4 GGally_2.1.2
## [3] gtools_3.9.2 echarts4r_0.4.3
## [5] beeswarm_0.4.0 vioplot_0.3.7
## [7] sm_2.2-5.7 kableExtra_1.3.4
## [9] topconfects_1.8.0 limma_3.48.3
## [11] eulerr_6.1.1 mitch_1.4.1
## [13] MASS_7.3-56 fgsea_1.18.0
## [15] gplots_3.1.1 DESeq2_1.32.0
## [17] SummarizedExperiment_1.22.0 Biobase_2.52.0
## [19] MatrixGenerics_1.4.3 matrixStats_0.61.0
## [21] GenomicRanges_1.44.0 GenomeInfoDb_1.28.4
## [23] IRanges_2.26.0 S4Vectors_0.30.2
## [25] BiocGenerics_0.38.0 reshape2_1.4.4
## [27] forcats_0.5.1 stringr_1.4.0
## [29] dplyr_1.0.8 purrr_0.3.4
## [31] readr_2.1.2 tidyr_1.2.0
## [33] tibble_3.1.6 ggplot2_3.3.5
## [35] tidyverse_1.3.1 zoo_1.8-9
##
## loaded via a namespace (and not attached):
## [1] readxl_1.3.1 backports_1.4.1 fastmatch_1.1-3
## [4] systemfonts_1.0.4 plyr_1.8.6 polylabelr_0.2.0
## [7] splines_4.2.0 BiocParallel_1.26.2 digest_0.6.29
## [10] htmltools_0.5.2 fansi_1.0.2 magrittr_2.0.2
## [13] memoise_2.0.1 tzdb_0.2.0 Biostrings_2.60.2
## [16] annotate_1.70.0 modelr_0.1.8 svglite_2.1.0
## [19] colorspace_2.0-3 blob_1.2.2 rvest_1.0.2
## [22] haven_2.4.3 xfun_0.30 crayon_1.5.0
## [25] RCurl_1.98-1.6 jsonlite_1.8.0 genefilter_1.74.1
## [28] survival_3.3-1 glue_1.6.2 polyclip_1.10-0
## [31] gtable_0.3.0 zlibbioc_1.38.0 XVector_0.32.0
## [34] webshot_0.5.2 DelayedArray_0.18.0 scales_1.1.1
## [37] DBI_1.1.2 Rcpp_1.0.8.2 viridisLite_0.4.0
## [40] xtable_1.8-4 bit_4.0.4 htmlwidgets_1.5.4
## [43] httr_1.4.2 RColorBrewer_1.1-2 ellipsis_0.3.2
## [46] pkgconfig_2.0.3 reshape_0.8.8 XML_3.99-0.9
## [49] sass_0.4.0 dbplyr_2.1.1 locfit_1.5-9.5
## [52] utf8_1.2.2 tidyselect_1.1.2 rlang_1.0.2
## [55] later_1.3.0 AnnotationDbi_1.54.1 munsell_0.5.0
## [58] cellranger_1.1.0 tools_4.2.0 cachem_1.0.6
## [61] cli_3.2.0 generics_0.1.2 RSQLite_2.2.10
## [64] broom_0.7.12 evaluate_0.15 fastmap_1.1.0
## [67] yaml_2.3.5 knitr_1.37 bit64_4.0.5
## [70] fs_1.5.2 caTools_1.18.2 KEGGREST_1.32.0
## [73] mime_0.12 xml2_1.3.3 compiler_4.2.0
## [76] rstudioapi_0.13 png_0.1-7 reprex_2.0.1
## [79] geneplotter_1.70.0 bslib_0.3.1 stringi_1.7.6
## [82] highr_0.9 desc_1.4.1 lattice_0.20-45
## [85] Matrix_1.4-1 vctrs_0.3.8 pillar_1.7.0
## [88] lifecycle_1.0.1 jquerylib_0.1.4 data.table_1.14.2
## [91] bitops_1.0-7 httpuv_1.6.5 R6_2.5.1
## [94] promises_1.2.0.1 KernSmooth_2.23-20 gridExtra_2.3
## [97] assertthat_0.2.1 rprojroot_2.0.2 withr_2.5.0
## [100] GenomeInfoDbData_1.2.6 hms_1.1.1 grid_4.2.0
## [103] rmarkdown_2.13 shiny_1.7.1 lubridate_1.8.0
END of report